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THESIS	SUMMARY
Systemic inflammation has been recognized as a risk factor for a number of diseases, 
including type 2 diabetes. There is a growing awareness that inflammatory diseases have an 
oxidative pathology, which can result in specific oxidation of amino acids within proteins. 
Patients with inflammatory disease have higher levels of plasma protein 3-nitrotyrosine than 
healthy controls. Fibrinogen is an abundant plasma protein, and has been shown to be 
highly susceptible to such oxidative modifications, and is therefore a potential marker. 
Oxidative damage and modifications to fibrinogen offer potential as biomarkers of disease, 
and for diagnosis and a greater understanding of the pathology. The aim of this study was to 
map the in-vitro locations of oxidatively-modified fibrinogen, and test the possibility of 
producing antibodies that show increased binding to protein-specific modification sites. 
Fibrinogen was nitrated using the peroxynitrite generator SIN-1, and analyzed by liquid 
chromatography tandem mass spectrometry. Several modified peptides that consistently 
occurred were identified with the Mascot© search engine and manually validated. Based on 
literature or mass spectrometry results, peptides with the core amino acid sequence 
STSYGTGC or DYEDDQQKQLC, either unmodified, or containing 3-chlorotyrosine or 3-
nitrotyrosine were synthesized and subsequently antibodies were produced. Each 
subsequently produced sheep anti-serum was tested against various native and modified 
peptides containing a variety of different amino acid sequences. Anti-STSY-(NO2)-GTGC 
serum showed modification site specificity, whereas anti-DY-(Cl)-EDDQQKQLC serum 
showed sequence specificity but was unable to distinguish between 3-chlorotyrosine and 3-
nitrotyrosine. This cross-reactivity between chlorinated and nitrated modification sites might 
allow broader detection of modified fibrinogen in inflammation. The anti-STSY-(NO2)-GTGC 
serum was also tested against plasma from healthy control volunteers and type 2 diabetic 
patients, but showed limited binding and ability to discriminate the disease state. In 
conclusion, it has been shown that antibodies can be produced to differentiate between 
native and modified proteins; however, further work is required to understand sequence-
specificity better and monoclonal antibodies might be better suited to achieving sequence-
specificity.    
Key words: Mass Spectrometry (MS), Oxidative Post-Translational Modifications 
(OxPTMs), Inflammation, Antibodies, Proteins  
3	
ACKNOWLEDGMENTS
My journey to date has been an unconventional one, I started university with no 
relevant academic qualifications, and faced my fair share of naysayers and 
adversity along the way. I hope my success encourages others to stay true to their 
dreams regardless.  
“Nothing in this world can take the place of persistence. Talent will not: nothing is 
more common than unsuccessful men with talent.  
Genius will not; unrewarded genius is almost a proverb. Education will not: the world 
is full of educated derelicts.  
Persistence and determination alone are omnipotent.” - Calvin Coolidge. 
I would like to start by thanking my supervisors at Aston University, Professor 
Corinne Spickett and Professor Helen Griffiths for providing me with the opportunity 
to do a Ph.D., welcoming me into their research groups, and moulding me into a 
research scientist.  
With particular thanks to Professor Corinne Spickett. The guidance, skills and 
mindset that she has provided me with are invaluable.  
The Oxidative Stress team at Aston, Dr Karina Tveen-Jensen, Dr Sabah Pasha and 
Dr Ivan Verrastro have been supportive colleagues, great friends, and from who I 
have learnt a lot about the field of analytical biochemistry. The first-class mass 
spectrometry training I received from Professor Andy Pitt is unrivalled, thank you.  
I would like to take this opportunity to acknowledge research placement student 
Aneesa Ali for the hard work and dedication she showed in performing many ELISA 
assays throughout her placement year, never deterred by the challenging workload I 
provided her with. 
I acknowledge Arian Mustafa for his help testing the reproducibility of anti-sera, in a 
parallel study used to produce an averaged data set (figures 4.16, 4.18 and 4.20).  
Thank you to Professor Paul Davis and the friendly professional staff at Mologic who 
welcomed me into their team, helped to train me in various scientific techniques, 
and have always been generally very supportive throughout my research project, 
thank you.  
Finally, I would like to thank Jasmine Foley and my father Jeffrey Meredith for being 
staunch supporters, spending multiple hours proof-reading my thesis in the stressful 
final stages. Thank you all.     
4	
List of Abbreviations 
AD Alzheimer’s disease  
ALS Amyotrophic lateral sclerosis 
AP Affinity purification   
ARD Acute respiratory disease 
BCA Bicinchoninic acid  
BSA Bovine serum albumin 
CID Collision induced dissociation  
COPD Chronic obstructive pulmonary disease 
CRP C-reactive protein
CV Coefficient of variance  
CVD Cardiovascular disease  
DCM Dichloromethane 
DMF Dimethylformamide 
DNP Dinitrophenylhydrazone 
DNPH 2,4-Dinitrophenylhydrazine 
ELISA Enzyme-linked immunosorbent assay 
ESI Electrospray ionisation  
ETC Electron transport chain 
ETD Electron transfer dissociation 
Exp. Experiment 
GSH Glutathione  
GSSG Glutathione disulphide 
HCD Higher-energy collisional dissociation 
HOBT Hydroxybenzotriazole 
HPLC High performance liquid chromatography  
HRP Horseradish peroxidase 
HSA Human serum albumin 
ICC Immunocytochemistry 
IHC Immunohistochemistry 
KLH Keyhole limpet haemocyanin 
MALDI Matrix-assisted laser desorption ionisation 
MDA Malondialdehyde 
MRM Multiple reaction monitoring  
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MS Mass spectrometry 
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Chapter 1 
General Introduction	
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1.1 Research Overview 
Systemic inflammation has been recognized as a risk factor for a number of 
diseases, including type 2 diabetes, atherosclerosis and chronic obstructive 
pulmonary disease (COPD) (Gan et al., 2004). Diseases that involve systemic 
inflammation, such as COPD, have been shown to cost the national health service 
£1 billion a year in indirect costs, illustrating the importance of techniques to detect 
inflammation (Gani et al., 2010). There is a growing awareness that inflammatory 
diseases have an oxidative pathology, which can result in specific oxidation of 
amino acids within proteins. Patients with inflammatory disease have higher levels 
of plasma protein 3-nitrotyrosine than healthy controls. Fibrinogen is an abundant 
plasma protein, and has been shown to be highly susceptible to such oxidative 
modifications, and therefore a potential marker (Weigandt et al., 2012, and Shacter 
et al., 1994). Oxidative damage and modifications to fibrinogen offer potential as 
biomarkers of disease, providing potential for diagnosis and a greater understanding 
of the pathology. Identification of these susceptible peptides will allow design of 
sequence-specific biomarkers of oxidative, chlorinative and nitrative damage to 
plasma protein in inflammatory conditions. The aim of this project was to develop 
diagnostic tools for detecting oxidative markers of inflammatory disease. Antibody-
based techniques for detecting oxidative post-translational modifications (oxPTMs) 
are often used to measure protein oxidation. There are many commercially available 
antibodies but some uncertainty regarding the cross reactivity they exhibit; moreover 
little information regarding the specific target epitopes is available. The specific 
objectives were to map tyrosine nitration and chlorination in fibrinogen under 
oxidative conditions to identify susceptible residues, and to investigate the potential 
of antibodies to distinguish between specific peptides with and without oxPTMs. 
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1.2 Inflammation in the Pathology of Disease 
The fundamental principles of inflammation are well established. Inflammation is 
traditionally defined by heat, pain, redness and swelling, of which the latter three are 
explained by the dilation and increased permeability of blood vessels, which causes 
greater local blood and fluid flow. The pain present during inflammation is explained 
by the migration and action of cells into the tissue (Murphy, Travers and Walport, 
2008). The skin, mucosal and epithelia lining of the gut and lungs make up the first 
point of defence of the immune system. Pathogens that breach this initial line of 
defence are met by molecules and cells of the innate immune system. Macrophages 
are abundant phagocytes in the tissue, and are the next line of defence, recognising 
pathogens by cell surface proteins known as pattern recognition receptors (PRR) 
such as toll like receptor (Beutler et al., 2006). Once the macrophage’s receptors 
are triggered by invading pathogens, it then becomes activated, and the invading 
species is phagocytosed. The macrophages also secrete chemokines and 
cytokines. Tumour necrosis factor α (TNF-α), affects the behaviour of nearby cells 
with TNF-α receptors, more specifically, TNF-α is a potent chemoattractant for 
neutrophils and stimulant for macrophage phagocytosis. Chemokines, such as 
CCL2, CCL3 and CCL5, CXCL1, CXCL2 and CXCL8, also attract cells that have 
chemokine receptors; for example, CXCL8 attracts neutrophils and monocytes into 
infected tissue (Graham et al., 2013). These released macrophage, chemokines and 
cytokines initiate the process of inflammation. During inflammation, cells of the 
innate immune system are recruited into the area of infection. Macrophages and 
neutrophils are considered the primary responders. Neutrophils, much like 
macrophages, have surface receptors that recognise pathogens and as such are 
recruited in large numbers during inflammation, in fact neutrophils are the most 
abundant, and principal, phagocytising cells of the immune system (Ermert et al., 
2013). In the next stages, at a slower rate, eosinophils migrate to the site of 
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inflammation and destroy pathogens. In addition to destroying the invading 
pathogens the inflammatory immune response also increases the flow of antigen-
presenting cells to nearby lymphoid tissues, where they activate lymphocytes, 
initiating the adaptive immune response (Murphy, Travers and Walport, 2008). Many 
diseases are defined as inflammatory disorders; there are also many more diseases 
whereby Inflammation is part of the pathology. Diseases such as type 2 diabetes 
(Kadiiska, et al., 2012), COPD, atherosclerosis (Gan et al., 2004) and rheumatoid 
arthritis (Tetik, et al., 2010) are all defined as inflammatory. The mechanisms 
between diseases however, are different. Inflammation in type 2 diabetes involves 
hyperglycaemic dependant b-cell dysfunction and the subsequent induction of pro-
inflammatory mediators and oxidative stress (Akash et al., 2013). In patients with 
COPD the inflammation is similar to that seen in healthy patients, but amplified, 
whereby inhaled irritants activate surface macrophages of the respiratory tract, and 
subsequently a cascade of pro-inflammatory chemokines and oxidative insult follow. 
This inflammation persists after the initial response, suggesting a self-perpetuating 
mechanism, which is yet to be elucidated (Barnes, 2016). The inflammation in 
Atherosclerosis is caused by atherosclerotic plaques, and alteration of the 
phenotypes of vascular cells, more specifically, arterial endothelial cells express 
vascular cell adhesion molecule-1 (VCAM-1) which binds to leukocytes, and 
promote inflammation (Galkina and Ley, 2009, and Libby, 2002). The mechanisms 
of RA pathogenesis are not fully understood; however, it is thought to involve 
synovial inflammation, hyperplasia and autoantibody production (McInnes and 
Schett, 2011).  
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A study performed by Ichinose (2009) showed high levels of 3-nitrotyrosine in 
COPD patients, supporting the involvement of the modification in the pathogenesis 
of the disease (Ichinose, 2009). More specifically, throughout the inflammatory 
response macrophages and neutrophils respond to chemo-attractants, and 
subsequently produce superoxide and nitric oxide, shown to form peroxynitrite (Wall 
et al., 2012 and Pacher et al., 2007). Peroxynitrite is highly reactive, and has been 
shown to oxidatively modify tyrosine residues to form 3-nitrotyrosine. A number of 
biological oxidants can be produced during an inflammatory response, these include 
hypochlorous acid (HOCl), hydrogen peroxide (H2O2), hydroxyl radical and 
peroxynitrite (ONOO-) (Dalle-Donne et al., 2003). 
16	
1.3 Sources of Biological Oxidants 
 1.3 .1 Reactive Oxygen Species 
There are many types of biological oxidants involved in maintaining cellular 
homeostasis, such as those seen during inflammation. Amongst these biological 
oxidants and reactive species are the radicals, superoxide (O2•-), hydroxyl (OH•), 
peroxyl (RO2•), alkoxyl (RO•), hydroperoxyl (HO2•); and non-radical species such as 
hydrogen peroxide (H2O2), hypochlorous acid (HOCl), singlet oxygen (O2), and 
peroxynitrite (ONOO-) (Dalle-Donne et al., 2003).  
The radicals derived from oxygen represent the most important class of radical 
species generated in living systems (Valko et al., 2007). Molecular oxygen 
(dioxygen) is ubiquitous, and is itself a radical forming species, the addition of one 
electron to which forms the reactive species superoxide (O2•-). Superoxide is 
produced in a number of ways physiologically, and is considered a primary ROS. 
One example of which is the production of adenosine triphosphate (ATP) via the 
mitochondrial electron transport chain. During the electron transport chain, a small 
number of electrons leak to oxygen prematurely, forming superoxide (Valko et al., 
2007). In eukaryotic organisms, it was calculated that more than 90% of the ROS 
produced were by the mitochondrial electron transport chain (Lushchak, 2014). The 
inflammatory phagocytic cells of the immune system, such as neutrophils, also 
utilise superoxide and hydrogen peroxide to destroy pathogens. This reaction is 
catalysed by the membrane bound enzyme nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase, assembling on the membrane and generating 
superoxide by donating electrons from NADPH in the cell across the membrane to 
molecular oxygen (Clark, 1999). The overall process is termed respiratory or 
oxidative burst (Guzik, 2003, Inoguchi, 2003 and Shacter, 2000). The enzymatic 
antioxidant superoxide dismutase keeps superoxide within safe levels, by converting 
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it to the less reactive molecular oxygen (O2) AND hydrogen peroxide (H2O2) 
(Hayyan et al., 2016).   
The hydroxyl radical (OH•) is one of the most reactive ROS; it has a half-life of 10-9 
seconds in vivo, and hence when produced it reacts at its site of formation (Fiser et 
al., 2013 and Valko et al., 2007). Under normal physiological conditions hydroxyl 
radicals are produced via transition metal catalysed cleavage of hydrogen peroxide 
(H2O2), known as the Fenton reaction (Stadtman, 1998).  Under conditions of 
oxidative stress, such as those during respiratory burst, superoxide excess 
promotes the release of free iron from iron containing proteins, such as iron-sulphur 
proteins (4Fe-4S). The released divalent iron (Fe2+) can participate in the metal 
catalysed, Fenton reaction, producing highly reactive radicals (Fe2+ + H2O2  Fe3+ + 
•OH + OH-) (Valko et al., 2007 and Stadtman, 1998).  
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1.3.2 Reactive Nitrogen Species 
The production of nitric oxide (NO•) is catalysed by nitric oxide synthases; it is used 
to regulate vasodilation, modulate mitochondrial respiration, and for immunity based 
defence (Wall et al., 2012). Nitric oxide is not particularly problematic in-vivo, as 
there are sufficient means of preventing its accumulation. Nitric oxide is less 
reactive than molecular oxygen and diffuses from the cell via the cell membrane into 
the red blood cells. Once in the red blood cells it becomes nitrate via a reaction with 
oxyhaemoglobin, this limits its half-life to half a second (Pacher et al., 2007 and 
Butler et al., 1998). Nitric oxide in μM concentrations inhibits catalase cytochrome 
P-450, involved in oxidative metabolism	 and cytochrome P-450, which is involved in
oxidative metabolism. Similarly, it can also inhibit cytochrome c oxidase, which 
transiently increases the leakage of superoxide from the electron transport chain 
(ETC) of the mitochondria. Superoxide exists as an anion, which is more likely to 
donate an electron than accept one from another molecule.  
When both superoxide (O2•-) and nitric oxide (NO•) are synthesised in close 
proximity, peroxynitrite (ONOO-) is formed. Nitric oxide reacts with superoxide so 
quickly that it out-competes dismutation catalysed by superoxide dismutase (Pacher 
et al., 2007). A 10-fold increase of both superoxide and nitric oxide can result in an 
overall increase in peroxynitrite formation by 100-fold. Under inflammatory 
conditions there is often an increased level of both superoxide and nitric oxide in the 
region of 1,000-fold, this results in a 1,000,000-fold increase in the formation of 
peroxynitrite (Wall et al., 2012 and Pacher et al., 2007).  
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There is an inverse relationship between reactivity and specificity, in that highly 
reactive species are less specific to what they will react with (Wall et al., 2012). For 
example, hydroxyl radicals are shown to be so reactive that they are only able to 
diffuse approximately the diameter of a protein away from their production site. In 
contrast, peroxynitrite reacts more slowly than hydroxyl radicals so that its 
dispersion area is greater and more selective with regard to what it will react with 
(Pacher et al., 2007).	 Consequently, peroxynitrite can influence biological 
processes. Peroxynitrite has been shown to be more efficient at producing hydroxyl 
ions than the Fenton reaction. The hydroxyl radical reacts with aromatic amino acids 
such as tyrosine, abstracting the hydrogen, and the remaining nitrogen dioxide 
(NO2•) of peroxynitrite then reacts with the aromatic ring to produce 3-nitrotyrosine 
via the intermediate tyrosyl radical (Figure 1.1) (Radi, 2013, Pacher et al., 2007 and 
Hipkiss, 2006).  
Figure 1.1: Reaction Mechanism of Tyrosine Forming 3-Nitrotyrosine After 
Peroxynitrite Treatment. Reaction pathway of peroxynitrite-treated tyrosine, showing the 
formation of the intermediate tyrosyl radical before forming the 3-nitrotyrosine product.  
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1.3.3 Reactive Chlorine Species 
Neutrophils contain the haem enzyme myeloperoxidase (MPO), which converts 
hydrogen peroxide (H2O2) and the chloride anion (Cl-) into hypochlorous acid (HOCl) 
(Figure 1.2). 
Figure 1.2: Reaction Mechanism of Hypochlorous Acid Formation Catalyzed by the 
Enzyme Myeloperoxidase.  
Hypochlorous acid is a strong oxidant produced by neutrophils (Winterbourn, 2002). 
In addition to oxidizing biomolecules, hypochlorous acid also reacts with the 
superoxide radical, to generate the hydroxyl radical. The hydroxyl radical is known 
to react with a number of aromatic and aliphatic side chains (Valko et al., 2007, 
Stadtman and Levine, 2003 and Gutteridge, 1984). A study performed by Kettle et 
al. (1996) reported the presence of chlorinated amino acids in proteins exposed to 
myeloperoxidase directly, and also indirectly via stimulated neutrophils. The same 
study also showed that 3-chlorotyrosine and 3, 5-dichlorotyrosine were formed when 
peptides and proteins containing tyrosine residues were exposed to hypochlorous 
acid. These 3-chlorotyrosine and 3, 5-dichlorotyrosine modifications were shown to 
be minor products of hypochlorous acid reactions, and for this reason sensitive 
procedures are required to detect tyrosine chlorination (Kettle et al., 1996).   
MyeloperoxidaseH2O2 + HCl H2O + HOCl
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In addition to the chlorination reactions, MPO catalyses the oxidation of tyrosine, 
producing a tyrosyl radical, in a similar way that during 3-nitrotyrosine formation 
there is an intermediate tyrosyl radical step during formation. HOCl reacts 
preferentially with sulfur-containing residues, followed by amines (Winterbourn, 
2002 and Prütz et al., 1996). The main reaction products of hypochlorous acid with 
proteins are protein carbonyl groups, formed via breakdown of chloramines to 
aldehydes (Winterbourn, 2002). The amino acids that can form carbonyl groups 
include proline, arginine, lysine and threonine (Owen and Butterfield, 2010). At a 
cellular level, high concentrations of hypochlorous acid have been shown to be 
cytotoxic, whereas low concentrations have been shown to induce apoptotic 
pathways (Winterbourn, 2002)
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1.4 Overview of Oxidative Stress 
The production of biological oxidants is required to maintain cellular homeostasis, 
and has been shown to be crucial to physiological processes. More specifically, 
reactive species superoxide (O2•-) and nitric oxide (NO•) are products of normal 
cellular function, and are used in a number of physiological processes. This 
includes, cell signalling, mitochondrial respiration, vasodilation and cellular defence 
during phagocytosis by immune cells such as neutrophils (Wall et al., 2012, Karve 
and Cheema et al., 2011, Valko et al., 2007 and Pacher et al., 2007).  
An antioxidant is defined as any substance that delays or inhibits oxidation of a 
substrate (Sies, 1993). Enzymatic and non-enzymatic anti-oxidants act 
cooperatively; for example, the reduction of vitamin C, a non-enzymatic antioxidant, 
by the tri-peptide antioxidant glutathione is supported by glutathione reductase, the 
enzyme that regenerates reduced glutathione (GSH) using NADPH as a reductant. 
Another good example of how antioxidants act cooperatively is the antioxidant α-
tocopherol (Vitamin E), a non-enzymatic antioxidant, α-tocopherol was shown to be 
one of the most efficient antioxidants in neutralising lipids by reduction.  The 
resulting tocopheroxyl radical produced is then reduced back to its original form by 
the aqueous soluble anion ascorbate (Vitamin C). These non-enzymatic 
antioxidants require enzymatic reduction to return to their former state. In most cells 
the three most abundant enzymatic antioxidants are superoxide dismutase, catalase 
and glutathione peroxidase (Sies, 1997 and Sies, 1993).  
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When reactive species occur in excess, and are not balanced by antioxidant 
capacity, oxidative stress and associated adverse effects can follow. Oxidative 
stress has been defined as an imbalance between the homeostatic levels of 
biological oxidants and their corresponding antioxidants, in favour of the oxidant 
(Sies, 1997). Some reactive oxygen species (ROS) are free radicals, with one or 
more unpaired electrons, which are very reactive, and often have short half-lives 
due to this reactive nature (Toshinori and Heinemann, 2001). The harmful effects of 
biological oxidants occur when there is an overproduction, and or, a deficiency of 
enzymatic and non-enzymatic antioxidants used to maintain the balance. In times of 
oxidative stress these biological oxidants can react with the lipids, proteins and or 
DNA, altering their normal function, which have various implications in disease 
(Karve and Cheema, 2011 and Valko et al., 2007). 
The regulation of oxidative balance is termed ‘redox regulation’, meaning the 
protection of an organism by maintaining redox homeostasis (Valko et al., 2007). 
Under normal healthy biological conditions >90% of glutathione is in its reduced 
form, GSH, and <10% in the oxidised form, GSSG. When the ratio of oxidised to 
reduced glutathione increases beyond this, the system may enter oxidative stress, 
and harmful effects of radicals may ensue (Owen and Butterfield, 2010). The extent 
and consequences of oxidative stress are dependent on both the intensity and 
duration of the condition (Karve and Cheema, 2011). Redox balance may fluctuate 
over a healthy range under normal biological conditions; beyond this the system 
enters acute or chronic oxidative stress, and may even stabilise at a new, more 
oxidative level. This is illustrated in Figure 1.3, taken from a review by Lushchak 
(2014).     
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Figure 1.3: How the Dynamic Levels of Biological Oxidants Effect the Degree of 
Oxidative Stress Over Time.  The basic steady-state (stationary) level of biological 
oxidants fluctuates over a certain range under normal conditions. However, under stress 
biological oxidants levels may increase beyond the normal range resulting in acute or 
chronic oxidative stress. Under some conditions, biological oxidants levels may not return to 
their initial range, and instead stabilize at a new quasi- stationary level (Lushchak, 2014). 
25	
1.5 Oxidative Post-Translational Modifications to Proteins  
Biological oxidants such as reactive oxygen, nitrogen and chlorine species can 
modify the biomolecules including DNA, lipids and protein. The main reasons for an 
increased level of oxidatively modified proteins can be broken down into four main 
factors: an increase in the rate of production of an oxidising species, a decrease in 
the scavenging of oxidants by antioxidants, increased susceptibility of proteins (for 
example, due to altered structure) and finally, a decrease in the rate of removal of 
modified proteins by proteases including proteasomes (Raynes et al., 2016 and 
Levine, 2002).  
Proteins can become oxidised in a number of different ways, all of which are 
considered post-translational modifications. These modifications can occur in a 
multitude of ways, mostly distinguishable by mass spectrometry. The first type of 
modification involves the oxidative cleavage of either the protein backbone or amino 
acid side chain.  The residues that are most susceptible to these backbone oxidative 
cleavage type modifications are proline, arginine, lysine, threonine, glutamic acid 
and aspartic acid (Levine, 2002). The mechanism involves the radical abstraction of 
the α-hydrogen atom, causing the cleavage of the backbone at the peptide bond; 
this leaves a carbon-centred radical, which reacts with molecular oxygen (O2) to 
form an alkylperoxyl radical intermediate, followed by alkyl peroxide, and finally, an 
alkoxyl radical. With regard to the alkoxyl radical formed during oxidative peptide 
fragmentation, in the absence of oxygen the carbon radical may also form a carbon-
carbon cross linkage to another protein (Levine, 2002 and Berlett and Stadtman, 
1997).  
Another type of oxidative modification that can occur is to amino acid side chains, 
which differ in how easily they can be oxidatively modified (Hoshi and Heinemann, 
2001). These modifications can have different effects, some of which alter 
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physiological cellular homeostasis, and others are a consequence of oxidative 
stress. For example, phosphorylation is involved in cell signalling pathways, 
methylation and acetylation in the regulation of gene transcription and protein 
function, and hydroxylation in the excretion pathways of drug metabolism (Karve 
and Cheema et al., 2011). 
Some of these modifications are a chemical consequence of oxidative stress; for 
example, carbonyl formation on the amino acids lysine, proline, threonine and 
arginine are well-established hallmarks and measures of general oxidative damage.  
The sulphur side chain containing amino acids, cysteine and methionine, are 
particularly noteworthy as they are amongst the most sensitive residues to oxidation 
by almost all forms of biological oxidants. Oxidative modifications to cysteine side 
chains include mono, di and tri oxidation, respectively called sulfenic, sulfinic and 
sulfonic acids (Poole and Nelson, 2008). Under even mild conditions of oxidative 
stress, cysteine residues can be modified to disulphides and, methionine, to 
methionine sulphoxide (MeSOX) (Berlett and Stadtman, 1997). Oxidative 
modifications of these amino acids are reversible, and could be considered the only 
truly reversible modifications to amino acid residues.  Physiologically, disulphide 
formation is the most common consequence of cysteine oxidation, and is reversible 
by reduction back to the thiol state, by thioredoxin system. Methionine also has a 
side chain containing sulphur, which can be oxidised by a range of biological 
oxidants. The oxidised form of methionine, methionine sulphoxide (MetO), much like 
cysteine, can be reduced back to its original state. This reduction is catalysed 
enzymatically by methionine sulphoxide reductases (MSRs), and consequently MSR 
is considered an antioxidant and protein repair enzyme (Kim and Gladyshev, 2007; 
Hoshi and Heinemann, 2001). The oxidation of methionine residues usually has little 
biological effect, and the cyclic reduction of methionine sulphoxide acts as an innate 
scavenger of biological oxidants to protect proteins from extensive irreversible 
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oxidative modifications (Berlett and Stadtman, 1997). Histidine has also been 
reported to be one of the more susceptible amino acids to oxidation type reactions. 
A common modification of histidine is 2-oxo-histidine, occurring after exposure to 
hydrogen peroxide (Uchida, 2003). Another residue susceptible to oxPTMs is 
tryptophan, which can be modified to N-formylkynureine; kynureine, 5-
hydroxytryptophan and 7-hydroxytryptophan. As previously described, modifications 
to tyrosine residues after exposure to nitrating and chlorinating species can form 3-
nitrotyrosine and 3-chlorotyrosine, which are considered potential markers of 
inflammation (Mann and Jensen 2011, Dalle-Donne et al., 2003, and Karve and 
Cheema et al., Levine, 2002). The final type of modification to proteins is the indirect 
addition of bimolecular oxidative products, for example the addition of lipid 
peroxidation product malondialehyde (Levine, 2002). Because proteins have many 
different unique functions, such oxidative modifications can have diverse functional 
consequences. For example, oxidative structural modifications to enzymes can 
inhibit their normal activity. Enzymes with metal near their active site are particularly 
susceptible to metal catalysed oxidation, and a subsequent inhibition of function. 
These types of modifications can have mild or severe effects on the cellular system, 
depending on the percentage, and location of the oxidative modification (Shacter, 
2000).  The cellular function of biological organisms relies on the functionality of 
proteins, which provide multiple levels of structure, allow intra and extra cellular 
movement, carry out enzymatic reactions, and conduct cell signalling to manage 
biological pathways (Raynes et al., 2016). The modifications described can 
therefore have various implications for biological systems and in the pathology of 
various diseases. Table 1.1 provides an overview of the most common types of side 
chain oxidative modifications that can occur. 
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Table 1.1: The Commonly Occurring OxPTMs to Amino Acids by Biological Oxidants. 
Amino	Acid	 Reaction	 Modification	
Arginine	 Oxidation	 Glutamic	semialdehyde	
Lysine	 Oxidation	 α-aminoadipic	semialdehyde	
Proline	 Oxidation	 Glutamic	semialdehyde	and	5-oxoProline	
Threonine	 Oxidation	 2-amino-3-butyric	acid
Histidine	 Oxidation	 2-oxohistidine
Cysteine	 Oxidation	 Cysteine	sulfenic	acid,	Cysteine	sulfonic	acid,	Cysteine	sulfinic
acid	and	Cystine	(disulfide	bonds)
Tyrosine	 Oxidation	 Dityrosine	and	3-hydroxytyrosine
Tryptophan	 Oxidation	 5-hydroxy-tryptophan
Phenylalanine	 Oxidation	 2,3-dihydroxyphenylalanine,	2-,	3-,	and	4-hydroxyphenylalanine
Methionine	 Oxidation	 Methionine	sulfoxide	and	methionine	sulfone
Tyrosine	 Nitration	 3-nitrotyrosine
Cysteine	 S-nitrosylation	 S-nitrosocysteine
Tyrosine	 Chlorination	 3-chlorotyrosine
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1.6 Oxidative Modifications to Proteins in Disease 
As previously discussed, proteins have a diverse range of cellular functions, and 
post-translational modifications of these proteins can impair their normal function. 
And for these reasons, OxPTMs to proteins play a role in the pathology of many 
diseases (Karve and Cheema, 2011). Carbonyl formation is considered a well-
established hallmark of oxidative stress and is currently the commonly used 
indicator of oxidative stress (Karve and Cheema, 2011). Protein carbonyls have 
been identified in Alzheimer's disease (Carney et al., 1994), amyotrophic lateral 
sclerosis (Bowling et al., 1994), cataractogenesis (Garland et al., 1988), systemic 
amyloidosis (Ando et al., 1997), muscular dystrophy (Murphy and Kehrer, 1989), 
Parkinson's disease (Yoritaka et al., 1996), progeria, Werner's syndrome (Oliver et 
al., 1987), rheumatoid arthritis (Tetik et al., 2010), and respiratory distress syndrome 
(Gladstone and Levine, 1994). The measurement of increased oxidative stress by 
carbonyl formation in these diseases, further confirms the oxidative inflammatory 
aspect of their pathology.   
More specific modifications include, amongst others, oxidation of tryptophan, 
histidine and cysteine residues. Cysteine modifications, including sulfenic, sulfinic 
and sulfonic acids, have been observed in diseases with an oxidative pathology. 
And serve as both markers of cell signalling, and diseases with an oxidative 
pathology, such as cancer and cardiovascular disease (Pan and Carroll, 2013). 
Oxidative modifications of tryptophan include, N-formylkynureine; kynureine, 5-
hydroxytryptophan and 7-hydroxytryptophan (Dalle-Donne et al., 2003). These 
modifications have been reported to have implications in infectious and autoimmune 
diseases, neurological diseases such as Alzheimer's disease (AD), Huntington's 
disease (HD) and Amyotrophic Lateral Sclerosis (ALS) (Chen and Guillemin, 2009).  
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The 2-oxo-histidine modification can be produced after exposure to hydrogen 
peroxide, and has been observed in the enzyme superoxide dismutase, inactivating 
its active site. This 2-oxo-histidine modification of superoxide dismutase  has been 
linked to the pathology of familial Amyotrophic Lateral Sclerosis disease, and, β-
amyloid, a peptide implicated in Alzheimer’s disease (Lee and Helmann, 2006 and 
Uchida, 2003).  
The aging process is another good example that illustrates how modifications to 
proteins can have observable biological effects. One of the first, and most well-
established theories of aging was proposed originally by Denham Harman in 1956, 
where he proposed aging and the associated degenerative diseases to be attributed 
to excessive production of radicals and the consequent damage to biomolecules 
(Harman, 1956). This theory was later updated by the rate of living theory, which 
stated that an increased rate of mitochondrial respiration would lead to an increased 
production of oxygen radicals and therefore speed up ageing as a consequence 
(Beckman and Ames, 1998). Several studies have shown specific enzymes to be 
oxidatively modified during aging e.g. glutamine synthetase. Carbonyl group 
formation is considered a hallmark of oxidative stress, based on Harman’s theory of 
aging, modifications to biomolecules such as the enyzme glutamine synthetase are 
indicative of aging. More specifically, a significant increase in the general number of 
protein carbonyl groups was seen after glutamine synthetase was modified (Hipkiss, 
2006 and Shacter, 2000).  
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1. 7 Susceptibility of the Fibrinogen Protein to Modification
William Hewson was the first to describe the clot formation protein fibrinogen in 
1770. Before this the clot formation process was thought to be determined by the 
activity of red blood cells. Subsequently, this work paved the way for the future work 
that provided a better understanding of thrombin, prothrombin and the coagulation 
cascade (Doyle, 2006).
Fibrinogen is a 340 kDa glycoprotein, made up of two pairs of three non-identical 
chains (hexamer). It is synthesized in the hepatocytes and is one of the most 
abundant plasma proteins, constituting 4% of the total plasma protein. It is a positive 
acute phase protein, which means that during inflammation its plasma concentration 
increases.	 Epidemiological studies have indicated that increased levels of circulating 
fibrinogen is a predictor of coronary heart disease (Vadseth et al., 2003). Fibrinogen 
is used biologically in the blood to allow clot formation, essentially, plugging blood 
vessels and wounds to prevent fatal loss of blood. The mechanisms of this reaction 
involve the addition of thrombin, which acts as a serine protease, to cleave 
fibrinopeptides A (FpA) and B (FpB) to expose knob A and knob B. These knobs 
then go on to associate with each other, and form fibrin type fibers used in the clot 
formation process (Martinez et al., 2013, Anderson and Anderson, 2002, Castell et 
al., 1989, and Laki, 1953). 
A study performed by Shacter et al., 1994 showed fibrinogen as the most 
susceptible plasma protein to oxidation with Western blotting for carbonyl formation 
with anti-DNP antibodies. The study showed albumin, being the most abundant 
plasma protein, as having the greatest absolute oxidation levels. However, as a ratio 
of protein to oxidation, fibrinogen showed 20 times more oxidation than albumin. 
The respective study concluded fibrinogen to be the most susceptible plasma 
protein to oxidation (Shacter et al., 1994). The levels of 3-nitrotyrosine were shown 
to be higher in patients with coronary artery disease when compared to healthy 
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controls, respectively, 9.1 µmol/mol tyrosine and 5.2 µmol/mol tyrosine. (Shishehbor 
et al., 2003). A study by Vadseth et al., in 2003 showed more specific protein 
nitration with 3-nitrotyosine formation in fibrinogen, and, functional alterations in 
fibrinogen/fibrins physical properties that could lead to a pro-thrombotic state. The 
data indicates that tyrosine nitration selectively alters fibrinogens function and 
physical properties, promoting clot acceleration, which may account for the 
association between nitration of fibrinogen and coronary artery disease (Vadseth et 
al., in 2003). 
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1.8 Overview of Methods for Detecting Modifications to Proteins  
Measuring carbonyl group formation is a well-established method for quantifying 
general oxidation. One of the most common methods of detecting carbonyl group 
formation involves the derivatisation of carbonyl groups with 2,4-
dinitrophenylhyrdrazine (DNPH) to 2,4-dinitrophenylhyrdrazone (DNP), followed by 
either spectrophotometric measurement, or immunodetection with DNP specific 
antibodies, either in gels or in ELISA type immunoassays (Shacter, 2000).  
However, such assays lack specificity, and are unable to identify the precise 
residues modified. The use of MS allows a more precise analysis of carbonylation, 
identifying and quantifying specific amino acids and their locations within a given 
protein. Even though these types of techniques are considered the standard 
methods of detecting protein carbonyls, they are not without limitations. The focus of 
the limitations resides with the use of DNPH. Where DNPH was shown to rapidly 
degrade, form further carbonyl groups, react with oxidized thiols, and 
spectrophotometric measurements in the presence of any other chromophores with 
an absorbance of 370 nm can provide false positives (Rogowska-Wrzesinska et al., 
2014).  
There are a number of chromatographic methods for detecting 3-nitrotyrosine, each 
of which displaying disadvantages as a result of sample preparation intended to 
overcome either selectivity or sensitivity limitations. Gas chromatography (GC) 
provides the best sensitivity but requires pre-analysis derivitisation, whereas HPLC 
does not, but is also less accurate.  Coupling HPLC to MS can overcome such 
limitations, allowing robust unambiguous identification of modifications without 
producing artefacts during the chromatography derivitisation steps, and for this 
reason MS is considered the gold standard technique for identifying modifications to 
proteins (Teixeira et al., 2016, and Pitt and Spickett, 2008). The process involved in 
MS analysis is, however, both time consuming and complex. Immunological assays 
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are a quick and cheap means of identifying such modifications. Many antibodies and 
ELISA type techniques exist for identifying and quantifying 3-nitrotyrosine (Tsuneki 
et al., 2015, Ashraf et al., 2014, Satoh et al., 2008, Zhang et al., 2014, Nagai et al., 
2002). A study performed by Safinowski et al., 2009 compared different 
immunoassays for 3-nitrotyrosine. The study concluded inconsistencies in the 
reliability of the results. The observed discrepancies were thought to relate to the 
low abundance of 3-nitrotyrosine (Safinowski et al., 2009). There are a few critical 
limitations with the ELISA, including: (i) antibodies may display some non-specific 
binding, and (ii) 3-nitrotyrosine may not be accessible to the antibody in some 
protein sites due to tertiary and quaternary structure (Teixeira et al., 2016). Similarly 
to 3-nitrotyrosine, chromatographic and MS techniques to detect and quantify 3-
chlorotyrosine exist, along with their limitations (Hazen and Heinecke, 1997). With 
regard to antibody-based techniques, detecting 3-chlorotyrosine is limited by the 
availability of specific antibodies. Several cited studies that have successfully 
utilized the polyclonal anti-chlorotyrosine antibody from Hycult Biotech (Zhou et al., 
2015, Nishikawa et al., 2012, Robaszkiewicz et al., 2011, Rudolph et al., 2010, 
Siwak et al., 2013). A study by Lu et al., 2015 successfully used the anti-3-
chlorotyrosine antibody (Hycult, Biotech) in Western blotting and immuno-
precipitation experiments (Lu et al., 2015). The reliability of immunoassay 
techniques is largely dependent on the specificity and avidity of the antibodies used; 
currently available commercial antibodies are known to show variance in avidity 
(Khan et al., 1998).  
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1.9 Fundamentals of Mass Spectrometry for Analysing Proteins 
1.9.1 Introduction to Mass Spectrometry 
Mass Spectrometry (MS) characterises molecular ions based on their mass-to-
charge ratio, and using their response to electrical or magnetic fields (Fenn et al., 
1989).  It can also be used to characterise and confirm oxidative modifications to 
amino acid residues, as these alter the mass of the molecular ion. The resulting 
data output, or spectrum is presented as intensity, y-axis, versus m/z on the x-axis. 
The mass to charge ratio is the relationship of the ions molecular mass and the 
number of charges that the ion carries, and intensity is the relative abundance of the 
molecular ion (Verrastro et al., 2015). Mass spectrometers contain an ionisation 
source, at least one mass analyser (depending on whether it is single or tandem) 
and a mass detector.  The technique relies on the generation of gas phase ions of 
the analyte in the ionisation source, followed by separation according to the mass-
to-charge ratio of the produced ionised fragments. This involves the use of one of 
many multiple types of mass analysers, and detection by a micro-channel plate 
detector. There are a number of different types of MS ionisation sources, mass 
analysers and detectors, some of which will be discussed further throughout.  
1.9.2 High Performance Liquid Chromatography for MS 
Samples are first separated before injection into the MS. In order to achieve this the 
MS is connected to a chromatography system known as high performance liquid 
chromatography (HPLC). Chromatography relies on different mobile and stationary 
phases to separate molecules by their affinities. This chromatography system 
operates at high pressure to achieve good separation resolution. Most HPLC 
configurations for proteomics utilise reverse phase HPLC, whereby analytes elute 
into the ionisation source based on their retention time, in reversed HPLC, to a 
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hydrophobic non-polar stationary phase and an aqueous polar mobile phase. 
Protein or peptide analytes are eluted off the column using a gradient of non-polar 
organic solvent introduction. The respective eluents are separated as mentioned by 
their retention time to a non-polar stationary phase, such as an 18-carbon chain (C-
18) silica column. Reverse-phase columns are well suited to MS analysis, as they
offer varied analysis, compatibility with ionization systems, and most importantly 
high reproducibility and separation efficiency (Regalado et al., 2013).  
1.9.3 Electrospray Ionisation 
Solvent is passed into the source through a fine capillary needle, held at high 
potential (2-4kV) (figure 1.4), resulting in a fine spray of droplets. These gas phase 
ions are produced as a result of four main processes: the formation of highly 
charged spray droplets due to the potential provided by the capillary needle, 
evaporation of the carrier solvent is enhanced by heating the ion source and the 
introduction of a flow of warm nitrogen gas known as drying gas, which causes the 
droplet size to decrease and the charge density to increase. During the final stage 
the droplet reaches its Raleigh limit, and undergoes coulomb fission, whereby the 
droplet explodes into smaller more stable droplets. This process continues until gas 
phase ions of individual molecules are formed. Any remaining solvent vapour, or 
uncharged material, is swept away by nitrogen gas, known as the curtain gas. 
Electrospray can produce both positive and negatively charged ions by the addition 
of volatile acids or bases to the solvents, either providing or removing protons. As a 
soft ionization technique, producing ionized intact proteins, electrospray is well 
suited to analysis of biomolecules such as proteins (Pitt, 1998 and Fenn et al., 
1989).  Other soft ionization techniques suited to biomolecules such as proteins also 
exist, of which the best known is matrix-assisted laser desorption ionisation (MALDI) 
(Mitchell Wells and McLuckey, 2005).  
37	
Figure 1.4: Electrospray Ionization Technique Diagram. The electrospray ionization 
technique is a soft ionization method that is well suited to analysis of biomolecules, due to its 
ability to produce ions without fragmentation.  
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1.9.4 Collision Induced Disassociation and Peptide Fragmentation Patterns  
Soft ionisation techniques allow the molecular ions, such as peptides, to be 
analysed without fragmentation. However, structural elucidation of biomolecules 
requires subsequent fragmentation of the precursor or parent ion. A few different 
techniques are available for fragmentation of proteins or peptides for further analysis 
with MS2; the most common are electron transfer dissociation (ETD), collision 
induced dissociation (CID) and high-energy collisional dissociation (HCD). The non-
targeted mass spectrometry approaches in this study utilised quadrupole-TOF with 
collision-induced disassociation (CID) fragmentation (figure 1.5). The peptide or 
protein molecules enter the collision cell (Q2) and collide with inert gas, such as 
nitrogen or argon, the produced kinetic energy is converted into internal energy, 
which results in the bonds vibrating and breaking, and the fragmentation of the 
molecular ion into smaller fragment ions (Mitchell Wells and McLuckey, 2005). 
There are a number of fragment ions that can be produced from peptides: a, b and c 
ions correspond to peptide fragments whereby the charge resides on the N-
terminus, whereas, x, y and z ions, the charge resides on the C-terminus (Figure 
1.5A). Typically, CID generates predominately b and y series fragment ions, 
whereby the peptides break around the peptide bond, and b and y ions are 
produced (Ross et al., 2004) (Figure 1.5B and 1.5C).     
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Figure 1.5: Peptide Fragmentation Pattern. (A) Peptide fragment ion nomenclature, a1, b1 
and c1 ions represent fragment ions of the first amino acid with the charge residing on the N-
terminus, and x1, y1 and z1, fragment ions of the first amino acid with the charge residing on 
the C-terminus (B) and (C) shows an example of a b and y ion fragment, with the charges 
residing on the N and C-terminus respectively.  
B	 C	
A 
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1.9.5 Quadrupole and Time-of-Flight MS Mass Analysers in MS 
A quadrupole mass analyser uses four parallel rod electrodes in a square formation 
around a central axis (figure 1.6). A negative direct current (DC) is applied to all four 
rods, and a superimposed alternating (AC) radio frequency (RF) positive current is 
applied to two of the rods at any given time, moving around the rods from x to y-axis 
in a clockwise direction. The combination of alternating RF and fixed DC are varied 
in magnitude, and allows the quadrupole to operate as an ion filter. When ions are 
injected along the central z-axis, if the ratio of the destabilising RF potential applied 
is not too great or little for the corresponding ions, they will spiral with a clear 
trajectory through the quadrupole to the detector. The balance of applied potential 
allows precise mass selectivity, and ions with masses that are not stable with the 
applied potential will disperse away from the space and not be detected. Thus, the 
sample ions are separated by the stability of their trajectories in the oscillating 
electrical field (Hoffmann and Stroobant, 2007). This balance of applied potential 
can be alternated, and used in a scanning mode, allowing all possible masses in a 
given range to be selected for detection (Misek, 1993).  
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Figure 1.6: Quadrupole Mass Analyser. The electrospray ionization technique is a soft 
ionization method that is well suited to analysis of biomolecules, due to its ability to produce 
ions without fragmentation. Ions travel from the ion source through the quadrupole across 
the z-axis towards the detector. The trajectory of ions to the detector is dependent on the 
amount of DC and RF potential applied to the rods, acting as an ion filter. Ions move along 
the z axis. More specifically, the red line illustrates ions moving along the z-axis, which do 
not have the correct corresponding mass for the applied field, and as such are deflected 
away from the quadrupole. Whereas, the green line illustrates the ions that have a stable 
trajectory based on the applied field, and therefore travel through the centre of the 
quadrupole to the detector.  
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1.9.6 Quadrupole Multiple and Single Reaction Monitoring Programmes 
Multiple (MRM), and single (SRM) reaction monitoring modes are similar MS modes 
of analysis, whereby MRM analyses multiple precursor and product ions, and SRM 
just one. In order to understand the procedure, the MRM mode is described. It 
utilises three quadrupoles, of which 2 are mass analysers and the other is a collision 
cell. The first quadrupole (Q1) selects the desired precursor ion by mass; the 
second quadrupole (Q2) generates the fragment ions of this precursor ion via 
collisional induced disassociation. Finally, the third quadrupole (Q3) is configured to 
specific fragment ion masses, of the precursor ion. This method provides increased 
sensitivity. This is because only the ions of interest pass through the first and third 
quadrupoles and reach the detector (Anderson and Hunter, 2006). In these modes 
triple quadrupole systems have some advantages over quadrupole-time-of-flight 
systems. The normal use of the quadrupole system is limited by its scanning nature, 
scanning through the mass range limits the acquisition rate and as such the 
sensitivity. However, in MRM and SRM modes this problem is overcome, and triple 
quadrupoles are more sensitive than quadrupole-time-of-flight systems, relating to 
the dead time required by the respective system to calculate the TOF.  For these 
reasons triple quadrupole systems are well suited to quantifying known mass ions to 
high sensitivity. Triple quadrupole mass analysers are however limited by mass 
resolution and to mass ranges of 1 – 4000 m/z, when compared to a quadrupole–
time–of– flight system, with a working mass analysis range of 20 – 20,000 m/z 
(Harris, 2010 and, Domon and Aebersold, 2006).  
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The time-of-flight mass analyser works by applying a high voltage of 5,000 V to the 
back plate, accelerating ions, expelling them from the ion source and into a drift 
region. Here there is no electrical or magnetic field and as such, no further 
acceleration. If all ions have the same kinetic energy, but differ in mass, the lighter 
ions will travel to the detector faster than the ions with a larger mass. The sample 
ions are separated by the time it takes them to reach the detector, relative to 
velocity, which is relative to their mass (Hoffmann and Stroobant, 2007). 
Unfortunately, not all ions leave the ion source and begin the path to the detector 
with the same kinetic energy. In order to equalise the kinetic energy of the ions, they 
enter the reflectron. Which is made up of hollow, increasing gradient, of positively 
charged rings used to stop and redirect the ions. The reflectron is terminated by the 
grid at the point whereby the potential becomes greater than the original 
accelerating potential. The more kinetic energy the ion has, the further into the 
reflectron it will travel, and as such the more it will slow down. This process 
equalises the kinetic energy of the ions before they begin their measured time-of-
flight journey to the detector, meaning all ions of the same mass reach the detector 
at the same time, improving resolution (Harris, 2010). Time-flight-systems as 
mentioned show less sensitivity than triple quadrupole based systems in MRM or 
SRM modes, however, when identifying unknown analytes, the TOF system is 
better suited. A non-scanning instrument such as a TOF system offers many 
advantages including fast acquisition rates, spectral continuity, and exceptional 
dynamic range. But most importantly, under normal conditions, greater mass 
resolution than triple quadrupole based systems, making it well suited to identifying 
modifications to amino acids (Domon and Aebersold, 2006). 
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1.9.7 Mass Spectrometry as a Technique for Analysing Modified Proteins  
Tandem mass spectrometry (ESI-MS2) can be used in protein analysis to confirm 
peptide sequences that contain oxidative amino acid modifications (Pitt and 
Spickett, 2008).  MS measures the mass-to-charge ratio (m/z) of ionized analytes, 
and subsequently, oxidative modifications to proteins change the m/z ratio of the 
intact protein, and of the residues where the oxidative modification occurred, 
allowing identification of the site of oxidative post-translational modification (oxPTM). 
The current accepted method of identifying oxidative modifications involves isolating 
the modified amino acid within the protein sequence (Abello et al., 2009). Two main 
approaches exist for identifying modifications to proteins, top-down and bottom-up. 
The former involves analysis of intact proteins and their fragmentation products in 
the MS, while the latter involves proteolyic digestion of proteins into peptides by 
proteases such as trypsin before analysis. The latter is the most common approach 
for proteomics and for identifying modifications to proteins in biology. In order to 
facilitate data analysis, a number of statistical search engines are available, such as 
Mascot©, PEAKS©, Sequest©, ProteinPilot©, Tandem©, Ommsa© and Phenyx©, each 
of which has advantages and disadvantages. In most cases, peptide sequences are 
searched against a protein database (in-silico data), and any sequence in the 
database that partially matches the experimental sequence was investigated for a fit 
to the data. The search engines are susceptible to false positive identifications due 
to the error tolerant nature of the search engines, and for this reason, manual 
validation by de-novo sequencing was critical for confidence in the assignments. A 
study performed by Stevens et al. (2008) illustrates the importance of high mass 
resolving accuracy when identifying nitrated tyrosine residues using tandem mass 
spectrometry (MS2), and the need to manually validate data by de novo sequencing 
modification sites, in order to avoid problems with isobaric molecules (peptides of 
the same mass, constituted of different amino acids). The same study suggested 
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manually validating all MS2 spectra peaks with a relative abundance of ~20% and 
higher (Stevens et al., 2008). A study performed by Peterson et al. (2001) highlights 
that precursor ion scanning with a quadrupole mass analyser can be used for 
selective detection of nitrated peptides, based on a tryptic digest of nitrated blood 
serum albumin (BSA) (Peterson et al., 2001).  
There are several specific data analysis techniques and MS modes that can be 
utilised to identity and quantify modifications to proteins. These include neutral loss, 
precursor ion scanning and targeted SRM and MRM methods, as mentioned earlier. 
In precursor ion scanning the second mass analyser (Q3) is fixed to detect a 
specific fragment ion mass and scans for precursor ions that generate this product 
ion upon fragmentation in the collision cell. Commonly, immonium ions of oxidised 
amino acids are detected and quantified as product ions. In neutral loss scanning, 
the reporter fragment is uncharged and is monitored by scanning with both mass 
analysers (Q1 and Q3) with a mass offset corresponding to the mass removed. 
Searching, or mining, of high-resolution data sets of untargeted experiments can 
also be achieved by narrow-window extracted ion chromatograms. Narrow window 
extracted ion chromatograms (XIC) utilise high mass resolution to allow the data to 
be searched for reporter ions, with a very narrow mass window, providing a 
significant reduction in false positive isobaric molecules (Verrastro et al., 2015).  
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1.10 Fundamentals of Immunoassays 
While mass spectrometry approaches are capable of providing very detailed 
information on oxidized proteins, they are complex and time-consuming to perform, 
and for these reasons antibody-based approaches to measure protein oxidation is 
far more popular. The enzyme-linked immunosorbent assay (ELISA) is a well-
established type of immunoassay that has many applications, including the 
detection of oxidised proteins. The assay relies on antibodies conjugated to an 
enzyme binding electrostatically by Coulomb forces to an antigen, and the 
quantification of the respective enzyme-substrate reaction is often achieved 
spectrophotometrically. The addition of the substrate causes a measurable reaction, 
the extent of which is proportional to the amount of plate bound antigen (Janeway, 
2001, Hennion and Barcelo, 1998 Voller et al., 1978 and Wisdom, 1976), as shown 
in figure 1.7.  
A number of variations of the ELISA type immunoassays exist (Figure 1.7). The 
simplest ELISA, ‘Antigen capture’, requires only one antibody. In contrast, in the 
direct ELISA antigens such as proteins and peptides adsorb onto the plate wells 
electrostatically, and are then quantified by enzyme-conjugated antibodies 
(MacBeath, 2002). The Sandwich ELISA is a slightly modified ELISA, in that a 
capture antibody is bound to the plate, the sample containing the analyte is added 
and binds the capture antibody, and finally the primary antibody is added and binds 
the epitope of the antigen, more specifically via the antibody paratope amino acids 
hydrogen bonds and Van Der Waals forces to those of the antigen epitope. The 
competitive inhibition assay is considered relatively quantitative. One example of a 
competition based ELISA is as follows: biotinylated antigen is added and binds to 
the plate via the antibody, the sample of unknown concentration is added and 
competes with the biotinylated antigen for binding to the capture antibody. Enzyme-
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bound streptavidin is then added, binding specifically to the biotinylated antigen. The 
substrate of the enzyme is then added, and after colour development the reaction 
measured. The level of inhibition is relative to the amount of the non-biotinylated 
unknown antigen (Owen 2012, Janeway 2001, Voller et al., 1978, and Wisdom, 
1976).  
Figure 1.7: A diagram showing the fundamental components of an ELISA type 
immuno-assay. An in-direct ELISA is comprised of the antigen (peptide) electrostatically 
bound to the microtitre plate; the complementary antibody, which is bound with an enzyme, 
is added. Upon binding the substrate is added and the reactions measured. The capture 
ELISA involves binding the primary antibody to the plate, adding the antigen, followed by the 
secondary antibody-conjugated to an enzyme, and finally adding the substrate and 
measuring the reaction. In the direct ELISA, the primary antibody is conjugated with an 
enzyme; the substrate is added after binding and the reaction measured.  
Microtitre Plate
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+	
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Substrate	
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In addition to ELISA type immunoassays, various other antibody techniques exist, 
such as Western blotting whereby protein binding can be visualised on a 
membrane. Following gel electrophoresis separation of protein solution, a sandwich 
including the produced gel and a polyvinylidene fluoride (PVDF) membrane are 
constructed, as can be seen in chapter 2 (figure 2.1). The proteins are then 
electrophoretically transferred onto the membrane. The membrane is then used for 
treatments, similar to other immunoassay techniques. More specifically, the 
membrane is blocked with a non-reactive protein solution, such as BSA, a specific 
primary antibody is then added, followed by a secondary enzyme conjugated 
antibody, such as horseradish peroxidase (HRP). This is often detected by 
chemiluminescence reagents, and the subsequent signal produced is captured 
under dark room conditions (Brunette, 1980).  
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1.10.2 Considerations of Immunoassays for Analysing Modified Proteins  
Immunoassays, like all assays, have some advantages and disadvantages, most of 
which are dependent on the specificity of the antibodies used. Antibodies to a 
variety of modification-containing residues are available. A few examples include 
anti-DNP, anti-3-nitrotyrosine and anti-3-chlorotyrosine. Antibodies are known for 
their cross-reactivity with compounds that are structurally similar to their target 
analyte /molecule. As the size of the target analyte/molecule decreases, the 
probability of cross reactivity increases. This is relevant when considering small 
peptides and modified amino acid residues, as they are considered small molecules. 
Molecules of low molecular weight (<1000 kDa), such as peptides and modified 
amino acids, are unable to evoke an immune response by themselves. They 
therefore require modification by binding them to larger carriers such as whole 
proteins. A common carrier is keyhole limpet hemocyanin (KLH), which is 
phylogenetically distant from mammalian proteins, and as such can be conjugated 
to a molecule of low molecular weight to increase its mass and immunogenicity 
(Harris and Markl, 1999, and Hennion and Barcelo, 1998). A study performed by 
Franze et al. (2004) produced 6 antibodies with strong affinity for 3-nitrotyrosine, all 
of which utilised a carrier protein to enhance immunogenicity, and were tested for 
their ability to detect nitrated proteins in immunoassays such as the ELISA (Franze 
et al., 2004). The 1A6 monoclonal antibody complementary to 3-nitrotyrosine is well 
characterised, and commercially available. However, it is not clear whether this 
antibody recognises all proteins containing nitrated tyrosine residues. The study by 
Franze et al. (2004) highlighted the effect of competitive adsorption of the native 
protein in direct immunoassays, where the proportion of native protein is usually 
greater than the modified, and the limited plate binding capacity means binding may 
become saturated before all protein is bound. Hence it is difficult to obtain a true 
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representation of the proportion of 3-nitrotyrosine in a sample.  One way to avoid 
this problem is to utilise the sandwich assay, which avoids this effect, and is thought 
to be able to detect trace amounts of nitrated protein in samples, in the presence of 
a high excess of native protein. The nature of the sandwich ELISA means the 
nitrated protein is exclusively captured from the sample onto the plate, before 
adding the detecting antibody. It appeared that the affinities of the antibodies for 
nitrated proteins are not only governed by the number of 3-nitrotyrosine residues per 
protein molecule, but also by their position in the structure, with more and less 
favourable binding sites (Franze et al, 2004).  
Another major consideration that highlights the cross-reactive nature of many 
commercially available antibodies is how immunoassay type techniques show 
variability between laboratory samples.  This is true of both antibody specificity and 
variations in antibody affinity (Onorato et al., 1998). Multiple other factors must also 
be considered when comparing results between laboratories; for example, the 
affinity between the antibody and the microtiter plate must also be considered, as 
significant variations between plate types exist (Matyas, Rao and Alving, 2002). 
When considering mixtures of proteins, the ELISA is at best semi-quantitative. This 
relates to protein conformation and the ability of a given antibody to access and bind 
the epitope of interest, which can be affected by the molecular environment, such as 
pH. (Khan et al, 1998). Both the study performed by Khan et al. (1998) and that by 
Duncan (2002) stated that poor antibody-antigen specificity results in poor data, and 
that antibodies complementary to 3-nitrotyrosine show variance in their specificity, 
depending on the amino acids adjacent to the 3-nitrotyrosine residue (Khan et al., 
1998). Importantly for this work, the study suggested that this sequence-specific 
discriminatory power might be useful in producing more specific antibodies (Khan et 
al., 1998). 
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1.11 Focus, Aims and Hypothesis of this Thesis 
Protein oxidation occurs in a variety of diseases with an inflammatory pathology, 
owing to immune cell activation and the release of reactive oxidants, offering 
potential for diagnostic or prognostic markers of disease. The most commonly used, 
simple and readily translatable methods are those involving antibody-based assays, 
such as ELISA and Western blotting, but they are often hampered by the availability 
of antibodies with suitable specificity, especially if oxidative modifications to a 
specific protein are of interest.  
Fibrinogen is one of the most abundant plasma proteins, and has been implicated in 
the pathology of various inflammatory diseases. Therefore, the overall aim of the 
research project was to develop new biomaterials for detecting inflammatory protein 
oxidative damage to fibrinogen. More specifically, in order to achieve this, the initial 
goal was to identify stable modifications to fibrinogen as good potential markers of 
oxidative damage by various oxidizing species, and to produce anti-sera that bind 
the modified peptides with sequence and modification site specificity. The 
hypothesis was that antibodies could be produced for human fibrinogen peptides 
with both sequence and modification site specificity, to a number of oxidative 
modifications, similar to those that might be expected during inflammation. 
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Chapter 2 
Materials and Methods 
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2.1 Reagents 
All reagents were obtained from Sigma-Aldrich or Fisher Scientific, UK, unless 
otherwise specified. Human fibrinogen with 70% purity was obtained, and used 
throughout. Instant blue Coomassie stain was acquired from Expedeon, Cambridge, 
UK. Skimmed milk powder was purchased from Tesco, UK. Protein marker (10 – 
250 kDa) was obtained from Thermo-Fisher (Part of Fisher Scientific). MS grade 
trypsin was sourced from Promega, Southampton, UK. Polyvinylidene fluoride 
(PVDF) membrane was obtained from Millipore, Watford, UK. Tween 20 was 
purchased from Fisher Scientific, Loughborough, UK. SuperSignal West Pico 
Chemiluminescent substrate (ECL reagent) was purchased from Thermo Scientific 
(Part of Fisher Scientific). The KLH (77600), maleimide (77164) and 
sulfosuccinimidyl-4 -[N-maleimidomethyl] cyclohexane-1-carboxylate (sulfo-SMCC) 
(22322) were also purchased from Thermo-Scientific. High binding Nunc immuno 
maxi sorp plates (M9410-1CS) were obtained from Thermo Fisher. All solvents were 
of LC-MS grade and all solution preparations were made using ultra-pure Milli-Q 
water, and all solutions where a solvent is not specified were prepared in Milli-Q 
water.  
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2.2 Synthesis of Novel Peptides with Solid Phase Synthesis 
A 70-mL fritted filtration column (Fisher Scientific, UK) was used. The resin used 
was 0.11 mM FMOC-Cys (Trt) (Novabiochem, UK) in 20% piperidine 
dimethylformamide (DMF), at a final volume of 20 mL. The 20% piperidine solution 
de-protected the resin by removing the FMOC group. The solution was vacuum 
dried. The sample was first washed with dichloromethane (DCM), followed by 
ethanol. This was repeated to ensure all of the piperidine solution was removed. 
Each amino acid was added in molar equivalence, based on a 20 mL final volume, 
to the resin (0.11 mM), followed by 0.55 mM benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) (CEM) (5:1), 0.55 mM 
hydroxybenzotriazole (HOBT) (5:1), DMF was added followed by 1.1 mM N,N-
diisopropylethylamine (Dipea) (10:1). The solution was left in the column for at least 
30 minutes. The column was then drained on a vacuum manifold, and washed with 
DCM and ethanol as before. This process was repeated sequentially according to 
the peptide sequence. Several different peptides were synthesised throughout, 
shown in Table 2.1.  
55	
Table 2.1: Synthesized Peptides List. The peptide DYEDQQKQLC was selected from a 
study performed by Bergt et al., 2004, and is further described in chapter 4. The peptides 
identified in this study by MS are further described in chapter 3. The peptide with the 
sequence YICENQDSISSKC were identified in Tveen-Jensen et al. (2013) as chlorinated, 
and as such synthesized (Further described in chapter 4) All other peptide variants were 
synthesised to allow binding specificity to be tested.      
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2.3 Standardisation of Hypochlorous Acid Concentration 
Because hypochlorous acid (HOCl) degrades during storage, the concentration was 
checked before making up molar dilutions for each use. HOCl was made up into 
dilutions of 1:100, 1:200, 1:1000 and 1:2000 in 0.1 mM sodium chloride. The 
absorbance was measured using 1 mL of dilutions in quartz cuvettes 
spectrophotometrically at 292 nm. Based on the absorbance values, the 
concentration of each was calculated using the Beer Lambert law, with a molar 
extinction coefficient (ε) of 350 and a path length of 1 cm.  
2.4 Protein Oxidative Treatments 
Several plasma proteins were oxidatively treated in preparation for immunoassay 
testing of developed antibodies, and both Western blot, and MS analysis to identify 
modifications.  Proteins treated include the plasma proteins, bovine serum albumin 
(BSA), fibrinogen, human serum albumin (HSA), transferrin and haemoglobin. 
Nitrated proteins were individually produced by producing to final concentrations of 
either 1mg/mL fibrinogen, HSA, transferrin or haemoglobin in PBS at pH 7.2, with 
final oxidant concentrations ranging from 0.10 mM -100 mM, but predominantly 0.25 
mM, 0.5 mM, 0.75 mM, 1 mM or 10 mM 3-morpholinosydnonimine (SIN-1), the 
peroxynitrite (ONOO-) generator was used. Samples were then incubated for 1 hour 
at 37°C to allow the reaction to proceed. Similarly, chlorinated proteins were 
individually produced by treating final concentrations of 1mg/mL fibrinogen, HSA, 
transferrin or haemoglobin in phosphate buffer (PB) at pH 6.6, with final oxidant 
concentrations ranging from 0.10 mM -100, but predominantly treated to 0.25 mM, 
0.5 mM, 0.75 mM, 1 mM or 10 mM with hypochlorous acid (HOCl), and incubated 
for 1 hour at 37°C.  
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2.5 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis  
Proteins were resolved with sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) in order to prepare for Western blot or MS analysis. 
The gels were made with acrylamide and bis-acrylamide (10%) according to the 
Laemmli method (Laemmli, 1970). Proteins were made into a 1:1 ratio of Laemmli 
buffer and incubated at 90°C for 5 minutes. The loaded protein concentration for 
each sample was 10 μg/ well.  The samples were then cooled to room temperature 
and electrophoresed at a constant 130 V, in parallel with a protein marker (10- 250 
kDa) (Product code: 26619). The gel was stained overnight in 45% methanol, 10% 
acetic acid, and 0.1% Coomassie blue. It was then de-stained in the same solution 
without Coomassie blue. Alternatively, the gel was stained with Expedeon Instant 
blue stain, and washed with multiple exchanges of distilled water (dH2O). Gels were 
captured using a Syngene G-box (Syngene, Cambridge, UK) by selecting automatic 
imaging and choosing the Coomassie stained protein gel option in the GeneSys 
software (Syngene, Cambridge, UK). 
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2.6 Bicinchoninic Acid Assay to Measure Protein Concentration 
In order to determine protein concentration for various assays described throughout, 
the bicinchoninic acid assay (BCA) was utilized. Briefly, a solution of bicinchoninic 
acid (BCA) and copper (II) sulphate was made. Standards were produced to allow 
the protein concentration of unknown samples to be calculated. Protein standards 
were made in triplicate (0 μL, 2 μL, 4 μL, 6 μL, 8 μL and 10 μL) corresponding to 
0.2, 0.4, 0.6, 0.8 and 1 mg / mL. The samples volumes were standardized to 10 μL 
with PBS. The unknown samples were made into dilutions of PBS, as for standards, 
based on their approximate concentration. The BCA and copper sulphate solution 
was then added to each well of the 96-well-plate that the samples were made up 
into.  The plate was then incubated at 37°C for 20 minutes. The absorbance of each 
sample was then read at 570 nm using spectrophotometry (ELx800 plate reader, 
Bio-Tek, USA).   
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2.7 Spectrophotometric Carbonyl Assay for Quantifying Oxidation 
The protein carbonyl group formation was determined according to Carty et al. 
(2000), in order to determine any changes in the level of general oxidation to 
proteins after treatments. The samples were derivatised with 10 mM 2, 4-
dinitrophenylhydrazine (DNPH) in 2 M HCl or 2M HCl as a blank. The samples were 
then incubated at room temperature for 1 hour with vortexing every 15 minutes. To 
precipitate the proteins 10 % trichloroacetic acid (TCA) (w/v) was added. Each 
sample was vortexed and centrifuged to ensure precipitation, and the supernatant 
discarded. The pellets were washed three times with 1:1 Ethanol: Ethyl Acetate 
(v/v). The pellets were re-dissolved in 6 M guanidine HCl in 20 mM potassium 
phosphate; pH adjusted to 2.3 with trifluoroacetic acid (TFA). Each of the samples 
were vortexed and incubated for 30 minutes at 37 °C to allow the pellets to re-
dissolve before centrifugation at 13g for 2 minutes to remove any insoluble material. 
The supernatants absorbance was measured at 360 nm. The carbonyl content was 
calculated based on the formation of dinitrophenylhydrazone (DNP) adducts and 
using the molar absorption coefficient of 22,000 for aliphatic hydrazones. The 
protein content was measured using the Bicinchoninic acid assay (BCA) and the 
carbonyl content recorded as nano moles of carbonyl groups / milligram of protein.  
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2.8 Oxidised Protein Standards for Determining Oxidation Level 
Oxidised protein standards were produced according to Carty et al. (2000). Bovine 
serum albumin (BSA) was made to 6 mg/mL in PBS and left to solubilise overnight. 
The negative control was made up of reduced BSA, produced using sodium 
borohydride in a 2:1 ratio with BSA by adding 240 mg of sodium borohydride to 20 
mL of 6 mg/mL BSA in PBS. The reduced BSA control sample was neutralised prior 
to dialysis with 1 M HCl.  All of the buffers used throughout this assay were de-
oxygenated by passing nitrogen gas through the solutions for 45 minutes under the 
fume hood.  In order to remove any unreacted sodium borohydride, dialysis was 
carried out at 4 oC for 2, 5 and 12-hour equilibration periods, in 2 litre volume 
exchanges of PBS. A range of ferrous sulphate treated (oxidised samples) were 
then produced, using the mentioned reduced BSA. The samples were oxidised with 
superoxide, by way of a solution of 100 mM ferrous sulphate in 100 mM sodium 
citrate (BDH, USA). The BSA protein samples oxidised to varying degrees by 
making them to final concentrations of 0.75 mM, 2.5 mM, 5 mM and 10 mM of 
ferrous sulphate. To remove excess unreacted iron, samples were chelated with a 
final concentration of 5 mM deferoxamine mesylate and again dialysed as 
previously described. The protein concentrations were measured using BCA assay.  
61	
2.9 Western Blot For DNP-derivatised Carbonyl groups (Oxyblot) 
This procedure is similar to Western blotting, with added DNPH derivitization steps. 
In order to confirm and compare the levels of general oxidation between treated 
proteins, carbonyl group formation was measured. Proteins were firstly resolved by 
SDS-PAGE, the loaded protein concentration for each sample was 15 μg/ well. The 
gel was then made into a Western sandwich (figure 2.1) and transferred onto a 
PVDF membrane (0.45 μm) (Immobilon -P, Millipore Ltd, Feltham UK) in 25 mM 
Tris, 192 mM glycine, 10% methanol pH 8.3 (Western transfer buffer) by applying 
30V overnight at 4°C.  
Figure 2.1: Western Blot Membrane Transfer Sandwich.  The Western blot cassette is 
colour coded with black and red to represent sides of the cathode and anode. Each of the 
components shown in figure 2.1 were soaked in transfer buffer, and layered in the following 
order: Western blot sponge, two pieces of filter paper, SDS-PAGE gel, PVDF membrane, an 
additional two filter papers, and finally, another Western blot sponge. The sandwich is 
carefully put together with tweezers, minimizing contact, and removing any air bubbles with 
careful placement and a roller. The cassette was then locked and placed into the transfer 
tank. The protein transfer proceeded, with the addition of current, from the gel onto the 
membrane. 
The membrane was then washed for 5 minutes in Tris buffered saline Tween 
(TBST) (20 mM Tris, 137 mM NaCl 0.05% Tween-20 pH 7.6), followed by 2 M HCl, 
and finally an incubation step with 10 mM DNPH for 5 minutes at room temperature. 
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The membrane was then washed with 100% methanol 7 times, and again with 
TBST 5 times to ensure any excess DNPH was removed. The membrane was 
blocked in TBST supplemented with 5% skimmed milk powder, or 5% BSA for 2 
hours. The membrane was then incubated with monoclonal rabbit anti-
dinitrophenylhydrazone (anti-dnp) (D9656) in blocking buffer at the working dilution 
of 1:1000, overnight at 4oC. The membrane was then washed extensively for 30 
minutes (3x 10 minutes) with TBST, and incubated with HRP-linked goat anti-mouse 
(6154) antibodies at a working dilution of 1:1000, for 2 hours at room temperature. 
The membrane was washed again as described above, and the HRP-linked anti-
mouse was detected by reacting with enhanced chemiluminescence (ECL kit - 
34078, Thermo Fisher Scientific, Hemel Hempstead, UK) for 4 minutes, according to 
the manufacturer's instructions. The membrane was then captured using a G:BOX 
system with GeneSys software. The results were analysed with densitometry 
analysis software, ImageJ, Version 1.48.  
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2.10 Western Blot For 3-Nitrotyrosine Formation on Fibrinogen 
In order to identify nitration of fibrinogen, a more specific 3-nitrotyrosine Western 
blot was performed. Proteins were firstly resolved by SDS-PAGE. The loaded 
protein concentration for each sample was 15 μg/well. The gel was then made into a 
Western sandwich and transferred onto a PVDF membrane (0.45 μm) (Immobilon-
P, Millipore Ltd, Feltham UK) in Western transfer buffer, by applying 30 V overnight 
at 4oC. The membrane was washed for 5 minutes in tris-buffered saline, 0.1% 
Tween 20 (TBST) with 5% BSA or 5% milk powder. The membrane was blocked in 
TBST supplemented with 5% skimmed milk powder or 5% BSA for 2 hours. The 
membrane was then washed with TBST, and incubated in monoclonal rabbit anti-3-
nitrotyrosine (Product code: N0409) made into blocking solution at a working dilution 
of 1:1000, overnight at 4oC. The membrane was then washed extensively for 30 
minutes (3 washes of 10 minutes each) with TBST and incubated with a HRP-linked 
goat anti-rabbit antibody (Product code: 6154), at a working dilution of 1:1000 for 2 
hours at room temperature. The membrane was washed again as described above 
and the HRP-linked anti-mouse antibody was reacted for 4 minutes before detection 
using enhanced chemiluminescence (ECL kit - 34078, Thermo Fisher Scientific, 
Hemel Hempstead, UK) according to the manufacturer's instructions. The 
membrane image was captured using a G: BOX system (Syngene, Cambridge, UK) 
running the GeneSys software (Syngene, Cambridge, UK). The results were 
analysed with densitometry analysis software, ImageJ, Version 1.48 (Obtained from: 
https://imagej.nih.gov/ij/).  
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2.11 Western Blot Analysis of Nitrated Fibrinogen for STSY- (NO2)-GTG  
Nitrated fibrinogen was blotted for the modifications identified with MS utilizing the 
produced complementary novel anti-serum. This procedure was similar to the anti-3-
nitrotyrosine Western blot, with a modification to the primary antibody used. More 
specifically, anti-STSY- (NO2)-GTGC serum was made to half that used in previous 
ELISAs with the same antibody, 1.5 μg/mL to 0.75 μg/mL, based on multiple 
manufacturers’ recommendations (www.citeab.com) of various other antibodies 
utilized in Western blotting, previously used at higher concentrations in ELISAs. The 
remainder of the assay is the same as for the anti-3-nitrotyrosine Western blot.  
2.12 Preparation of Protein Samples for MS Analysis 
Native, HOCl and SIN-1 treated fibrinogen and HSA protein samples were resolved 
by SDS-PAGE and stained, as previously mentioned, and as described in 
Sambrook and Russell (2006). Briefly, the resolving gel (10%) was made up of 3 mL 
of 40% acrylamide/bis acrylamide, 100 μL of 10% sodium dodecyl sulphate, 90 μL 
of 10% ammonium persulfate (APS) and polymerized with 12% of 14.4M NNN’-N’ 
Tetramethylethylenediamine (TEMED) (BDH Limited, USA). The stacking gel 
consisted of 830 μL of 1 M TRIS-HCl pH 6.8, 440 μL of 40% acrylamide/bis-
acrylamide, 33 μL of 10% SDS, 20 μL of 10% APS and finally, 5 μL of 14.4 M 
TEMED (Sambrook and Russell, 2006). A G: BOX system (Syngene) installed with 
GeneSys© software was then used to capture the images of the gel. 	
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2.13 In-Gel Tryptic Digestion of SDS-PAGE Resolved Proteins 
Fibrinogen α, β and γ chains were visibly stained by coomassie as separate bands. 
These bands were excised with a scalpel and digested with trypsin, essentially, as 
described by Shevchenko et al. (2006). The band fragments were chopped up to aid 
tryptic digestion. The chopped bands were then washed with 50% acetonitrile/ 100 
mM ammonium bicarbonate for 30-60 minutes to remove the stain. The wash 
supernatant was removed, and discarded. Subsequently, 150 μL of 100 mM 
ammonium bicarbonate was used to denature the protein, followed by the addition 
of 10 μL of 45 mM dithiothreitol (DTT) and incubation at 60 °C for 30 minutes to 
allow for the reduction of disulphide bonds. The reduced cysteines were then 
alkylated, to prevent disulphide bonds re-forming, with the addition of 10 μL of 100 
mM iodoacetamide in the dark, to prevent photo-degradation. The gel pieces were 
washed, as before, and acetonitrile added to expel any liquid, shrinking the gel 
pieces. The samples were vacuum centrifuged to dryness. Each gel piece (3.3 μg of 
protein) was tryptically digested with 20 μL of trypsin (2 μg) (Promega, UK) in 20 μL 
of 25 mM ammonium bicarbonate overnight at 37°C. The gel pieces were pelleted in 
the centrifuge at 13,000 RPM for 2 minutes. The supernatant was transferred to 
another 1.5 mL eppendorfs. Gel pieces were further extracted with 20 μL of 5% 
formic acid for 30 minutes, and then with 40 μL of acetonitrile for a further 20 
minutes. The combined extracts were dried using a vacuum centrifuge and stored at 
-20 °C ready for analysis.
66	
2.14 Mass Spectrometry Analysis of Tryptically Digested Proteins  
The samples were analysed on an AB SCIEX TripleTOF® 5600 System (QTOF), 
coupled with a Dionex Ultimate 3000 High Performance Liquid chromatography 
(HPLC) system (Thermo Scientific, UK) with an automatic sampler. The mobile 
phase consisted of eluent A, 98% H2O, 2% acetonitrile and 0.1% formic acid 
(solvent A); eluent B consisted of, 98% acetonitrile, 2% H2O and 0.1% formic acid 
(solvent B) (Sambrook and Russell et al., 2006). The samples were made to a 
volume of 30 µl with solvent A, in screw top auto-sampler glass vials (Chromacol, 
Speck and Burke analytical, UK). Following injection, enrichment and desalting of 
the peptides was achieved using a C18 pre-column (C18 PepMap™, 5 μm, 5 mm × 
0.3 mm i.d. Dionex, Bellefonte, PA, US) washing for 4 minutes with aqueous 2% 
acetonitrile, 0.1% formic acid at 30 μL/min. A C18: 75 μm x 15 cm reversed phase 
column with a pore size of 100 Å and a particle size of 3 μm (Dionex) was used to 
separate the peptides. The flow rate used was 0.2 – 0.3 μL /min, using a gradient 
elution running from 2% to 45% aqueous acetonitrile (0.1% formic acid) over 45 min 
followed by a washing gradient from 45 to 90% aqueous acetonitrile (0.1% formic 
acid) in 1 min. The system was washed with 90% aqueous acetonitrile (0.1% formic 
acid) for 5 minutes and then re-equilibrated to the starting solvent. The 
chromatography was controlled by Chromeleon Xpress© software. Ionization of the 
peptides was achieved with the spray voltage set to 2.4 kV, a source temperature of 
150°C, de-clustering potential of 50 V and a curtain gas setting of 15. Survey scans 
were collected in positive Ion mode in the range of 350 to 1250 Da for 200 ms using 
the high resolution TOF-MS mode. Information-dependent acquisition (IDA) was 
used to collect MS/MS data using the following criteria: the 10 most intense ions 
with 2+ to 5+ charge states and a minimum intensity of 500 counts per second (cps) 
were chosen for analysis, using dynamic exclusion for 30s, 100 ms acquisition and 
a fixed collision energy setting of 50 ± 15 V.  
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2.15 Searching the Obtained MS Data Against the Mascot© Database 
The MS data was converted into the Mascot© (Matrix-Science, UK) data file format 
(.mgf) and searched against the Mascot© database within the Homo sapiens 
taxonomy section of the SwissProt database. The search looked to identify a match 
to the protein, carbamidomethyl fixed modifications and variable modifications. 
Variable modifications were not searched for in one run, rather in multiple 
combinations of the following modifications, nitration of tyrosine (3-nitrotyrosine), 
oxidation of tyrosine (hydroxytyrosine), oxidation of methionine (methionine 
sulfoxide), cysteine trioxidation (Sulfonic Acid), chlorination of tyrosine (3-
chlorotyrosine), and lysine oxidation (allysine). The protease selected was trypsin, 
with a maximum number of missed cleavages of one. The search was set to identify 
peptides by their monoisotopic masses, with 2+, 3+ and 4+ charge states. The 
peptide and MS/MS tolerance was set to ± 0.5 Da.  The Mascot© data was validated 
using PeakView© analysis software, version 1.2 (ABSciex, UK), by de-novo 
sequencing of the peptides and any modifications (IonSource, 2016).  
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2.16 High Performance Liquid Chromatography for Peptide Purification 
The nature of solid phase peptide synthesis means that peptide step-by-step yield 
can be poor. In order to purify out any incomplete sequences of the peptide, a 
Dionex Ultimate 3000 high performance liquid chromatography (HPLC) machine in 
reverse phase with ultra violet (UV) detection at 230 nm for peptide bonds, and 
automated fraction collection was used. The peptide was dissolved in 1mL of 50% 
acetonitrile and 50% water, and then 6mL of 95% water and 5% acetonitrile with 
0.1% TFA. The HPLC machine was run at a flow rate of 4mL/min, with a solvent 
flow of 95% buffer A (Water and 0.1% TFA) and 5% buffer B (acetonitrile and 0.1% 
TFA), changing over time with a pre-programmed gradient, with a total run time of 
12 minutes. The most abundant peaks were chosen by peak area milli absorbance 
units (mAU) at 230 nm, and collected by the auto-sampler based on their retention 
time on the column. Collected fractions were checked with MS, to confirm peptide 
identity.  
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2.17 Mass Spectrometry Analysis to Confirm Synthetic Peptide Identity 
To check the sequence of the synthesised peptide, firstly, the peptide was cleaved 
from the resin. In order to do this, 5 mg of the sample was placed into a 35-mL 
fritted column (Fisher Scientific, UK), a solution of 95% TFA, 2.5% distilled water 
and 2.5% trisopropylsilone (TIPS) (Sigma-Aldrich, UK) was added to the column 
and incubated for 2 hours. This procedure cleaves the peptide from the resin 
support, and removes the protection side groups. The sample was then rinsed with 
100% TFA, poured into a round-bottom flask and dried on a rotary evaporator. Once 
solvents are fully removed, 20 mL of ice-cold diethyl ether was used to precipitate 
out the peptides. The diethyl ether was carefully decanted, and any remaining 
diethyl ether was left to evaporate away for 20 minutes. The dry peptide used for 
MS analysis was then suspended in 50% acetonitrile: distilled water and 0.1% 
formic acid. The sample identity was confirmed by analysis with mass spectrometry 
(Micromass, ZMD) in positive ion mode. Each sample was directly infused in 
volumes of 100 μL, at a flow rate of 30 μL/min, with a source temperature of 100 °C. 
Acquisition involved 1 minute scans within the mass range of 200 – 2000 Da. Any 
unused peptide was frozen on dry ice, and freeze-dried for storage at -20°C. 
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2.18 Keyhole Limpet Haemocyanin Conjugation of Peptides 
The peptides were conjugated to keyhole limpet haemocyanin (KLH) to encourage 
an immune response, according to the protocol recommended by the manufacturer 
(Thermo-Scientific). The carrier protein, KLH, was activated with maleimide and 
reconstituted to 10 mg/mL in distilled water. It was then incubated with an equal 
volume of 10 mM sulfosuccinimidyl-4 -[N-maleimidomethyl] cyclohexane-1-
carboxylate (sulfo-SMCC) at room temperature for 1 hour, with gentle periodic 
mixing. After equilibrating the PD-10 column (Thermo Scientific, UK) with 
conjugation buffer (100 mM ethylenediaminetetraacetic acid, 83 mM sodium 
phosphate, 100 mM sorbitol and 900 mM NaCl, pH 7.2), the excess cross-linker was 
removed by desalting. To ensure efficient conjugation, each peptide was prepared 
in molar excess to KLH, by preparing molecular weight equivalents of the peptides 
and protein. This provided a 32-fold excess of peptides (hapten) to carrier protein 
(KLH). The peptides were reconstituted to 1mg/mL in conjugation buffer, and 
incubated for 2 hours with the collected column eluate. Again, PD-10 columns were 
equilibrated (Thermo Scientific, UK) with conjugation buffer, and conjugated 
peptide-KLH mixture was passed through the column to remove any excess 
unconjugated peptide. The flow through was collected. The KLH conjugated 
peptides were injected into sheep (Orygen Antibodies Ltd, UK), and the anti-serum 
obtained.  Each peptide was injected into its own sheep. The serum was collected, 
pre-immune and once a month for 4 months after the immunization step.  
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2.19 Injection/immunization of Peptide Conjugates into Sheep 
The immunization process was outsourced to specialized companies. KLH 
conjugates were sent to either Orygen (Pentlands Science Park, Bush Loan, 
Penicuik, EH26 0PZ) or the National Services Scotland (Castlelaw Building, 
Pentlands Science Park, Penicuik, EH26 0PZ) at 1 mg/mL of 1mL aliquots, on dry 
ice. Immunization procedures of DYEDQQKQLC peptide series were carried out by 
the National Services Scotland, and Orygen carried out all other peptide 
immunization, including those for the STSYGTGC peptide series. A pre-immune 
(before injection/immunization) bleed for each sheep was collected and sent to 
Aston University for testing. Sheep were then injected with 1mL of peptide-KLH 
conjugate preparations every 28 days, a different peptide for each individual sheep. 
Each bleed collection was performed 7 days after an additional injection of the 1mL 
of peptide-KLH conjugate preparation. These bleeds were then collected and sent to 
Aston University on dry ice for testing. On delivery of sera to Aston University, a 
portion of the stock sera (300 mL) were aliquoted into 30 μL and 1 mL volumes for 
storage at -80°C.   
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2.20 Sheep Anti-Sera Affinity Purification/Enrichment for Antigen  
The peptides were coupled to iodoacetyl gel beads (Product code: 53155, Thermo 
Scientific, UK) in PD-10 columns (Thermo Scientific, UK), by adding 0.75 mg/mL of 
peptide in coupling buffer (50 mM tris and 5 mM ethylenediaminetetraacetic acid pH 
8.5). The coupling solution was gently mixed at 4oC for 20 minutes, and incubated at 
room temperature for 30 minutes. The protein concentration was checked with the 
Bicinchoninic acid assay. The peptide mixture was washed with coupling buffer 
three times. Unbound binding sites were blocked with 50 mM cysteine in coupling 
buffer for 30 minutes at room temperature. The mixture was then washed with 1 M 
NaCl followed by phosphate buffered saline, before storage in phosphate buffered 
saline at 4oC. Anti-sera were purified against bead conjugated peptides with an 
AKTA Purifier (GE Healthcare, Amersham). The serums were first cleaned up with 
0.2 μm syringe filters before purification. A flow rate of 1 mL/ min was used 
throughout. The AKTA columns were first washed with 1 M NaCl (pH 7) to remove 
any non-specific bound material from the column, followed by a PBS (pH 7.4) wash. 
After injecting serum samples onto the column, 0.1 M glycine (pH 2.7) was used to 
elute antibodies bound to the bead conjugated peptides. In order to remove glycine 
from the collected fractions, samples were dialysed with 3.5 kDa snakeskin tubing 
(Product no. 8842, Thermo Scientific, UK) at 4oC in PBS overnight. 
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2.21 Immunoassay Detection of Various Peptides and Proteins  
This in-direct immunoassay was used to test a variety of native, modified and 
treated peptides and proteins against various anti-sera and antibodies. Nunc 
immuno maxi sorp plates were coated with 2.5 μM (100 μL of 2 μg/mL) of 
synthesised peptide (Mologic, UK and Isca Chemicals, UK) or molar equivalents of 
proteins, overnight at room temperature. Plates were then washed three times with 
TBST and blocked with 200 μL 1% BSA TBST, pH 7.5, for 2 hours at room 
temperature. Again, the plates are washed with TBST three times, and then 100 μL 
of sheep anti-sera dilutions (Ranging from 1:100 – 1:128,000), prepared in 1% BSA 
TBST, were incubated on the plate for one hour at room temperature. The plates 
were washed with TBST three times, incubated with 100 μL of 1:25,000 donkey 
anti-sheep alkaline phosphatase antibody (Product code: A5187) in 1% BSA TBST. 
The plates were incubated at room temperature for one hour, and the substrate 
para-nitrophenylphosphate (PNPP) was made to 2.7 mM (1mg/ mL) in 0.1 M glycine 
buffer containing 1 mM MgCl2, 1 mM ZnCl2, pH 10.4 (PNPP buffer). The PNPP 
substrate solution was added to each well (100 μL) and allowed to react at room 
temperature for 15 minutes. The absorbance was measured spectrophotometrically 
at 405 nm with a plate reader (ELx800 plate reader, Bio-Tek, USA). 
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2.22 Testing Translation into Clinical Samples by Immunoassay 
Anti-sera produced and tested in chapter 4 was further tested against clinical 
inflammatory samples. The procedure was similar, utilizing an in-direct ELISA type-
immunoassay. Modifications to the assay include coating the ELISA plates with 
dilutions of plasma, with the constituents as antigens and the use of different 
antibodies. In order to determine appropriate dilution factors, a preliminary 
experiment of healthy volunteers’ plasma was performed. Dilutions of plasma 
ranged from 1:10 – 1:10,000 in 1% BSA TBST. Each plate also had a positive 
control for each anti-serum’s antigen, a positive control where no plasma was added 
and a negative control where plasma was added with to a well with no antigen. The 
plates were incubated overnight at room temperature. Based on the preliminary 
study, 10 healthy patient plasma samples and 10 type II diabetic plasma samples 
were coated to ELISA plates at dilutions of 1:100 in 1% BSA TBST. Primary 
antibodies included the produced anti-sera (Anti- STSYGTGC, Anti- STSY-(Cl)-
GTGC, Anti- STSY-(NO2)-GTGC and Anti- DYEDQQKQLC), which were then 
detected by 1:25,000 donkey anti-sheep alkaline phosphatase antibody (Product 
code: A5187) in 1% BSA TBST, and measured spectrophotometrically at 405 nm 
with a plate reader (ELx800 plate reader, Bio-Tek, USA).  
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Chapter 3 
Detecting Oxidative Modifications to Fibrinogen	
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3.1 Introduction 
3.1.1 Biological Oxidants are Produced During Inflammation 
Organisms are constantly exposed to a number of systems that produce biological 
oxidants, involved in a number of processes that span all biology, from cell signaling 
to immunity. Biological oxidants are not limited to oxygen; other classes include, 
reactive nitrogen species (RNS) and reactive halogen species e.g.  reactive chlorine 
and bromine species (RCS and RBS). These are capable of modifying proteins, 
lipids and nucleic acids that make up our biology (Nathan and Cunningham-Bussel, 
2013, and Stadtman, 2006). Neutrophils are among the most abundant immune 
cells responding to an inflammatory site, and as such are thought to cause most of 
the tissue damage occurring during inflammation. More specifically, phagocytes, 
such as neutrophils, produce the biological oxidants hypochlorous acid, superoxide 
and peroxynitrite to destroy pathogens during inflammation (Pacher, 2007).  
3.1.2 Oxidative Modifications to Fibrinogen in Disease 
Oxidative modifications to fibrinogen have been implicated in the pathology of a 
number of diseases, often involving impaired clot formation and the subsequent 
effects. A study performed by Martinez et al. (2013) highlighted fibrinogen as the 
most oxidized protein in the plasma of smokers, relevant because smokers are the 
sub-population at the greatest risk of lung cancer and thrombosis. Treatment of 
fibrinogen with the inflammatory oxidant hypochlorous acid has been shown to 
modify protein methionine and histidine residues, forming the oxidized products of 
the residues, methionine sulfoxide and oxidized histidine. As a result of these 
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modifications, the rate of clot formation was reduced. Conversely, nitrated fibrinogen 
samples, having formed 3-nitrotyrosine modifications, were shown to have 
increased clot formation (Martinez et al., 2013). Nitrated fibrinogen has been 
specifically identified in a number of diseases, such as, acute respiratory distress 
syndrome (ARD) (Gole et al., 2000), lung cancer (Pignatelli et al., 2001), end-stage 
renal disease (Piroddi et al., 2011), coronary artery disease (Vadseth et al., 2004) 
and patients with venous thromboembolisms (Martinez et al., 2012). More 
specifically, 3-nitrotyrosine modifications to fibrinogen’s β-chain have been detected 
by Western blotting in the plasma of samples taken from patients with ARD (Gole et 
al., 2000).  Elevated levels of fibrinogen, and fibrinogen tyrosine nitration have been 
implicated in various arterial and venous thrombotic diseases. More specifically, a 
study performed by Parastatidis et al., 2008 showed by MS that there were specific 
3-nitrotyrosine modifications to fibrinogen peptides, 284NYCGLPGEY-(NO2)-
WLGNDK298 and 416YYWGGQY-(NO2)-TWDMAK428, in the plasma of smokers 
(Martinez et al., 2013 and Parastatidis et al., 2008).  
3.1.3 Chapter 3 Focus, Aims and Hypothesis 
This chapter focuses on the identification and quantification of in-vitro modification 
sites to human fibrinogen after treatment with similar biological oxidants to those 
produced during inflammatory conditions. The aim was to identify stable 
modifications to the fibrinogen protein that might make good potential markers of 
inflammation, to raise antibodies against. With the hypothesis: a number of 
concentration dependent oxidative modifications, similar to those that might be 
expected during inflammation (Section 3.1.2), to human fibrinogen can be
consistently identified after treatment with SIN-1 and HOCl.   
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3.2 Production of Carbonyl Assay Standards 
In order to measure the level of oxidation to fibrinogen before mass spectrometry 
analysis, the carbonyl assay was performed as described by Carty et al. (2000). To 
enable a comparison of oxidation, standards were produced (Figure 3.1A and 3.1B). 
Bovine serum albumin (BSA) was oxidised with various concentrations of ferrous 
sulphate, and the negative controls were reduced with sodium borohydride to 
remove any basal oxidation. Dinitrophenylhydrazine (DNPH) was used to derivatize 
carbonyl groups, forming dinitrophenylhydrazone adducts, which were quantified by 
spectrophotometry. Standards were treated with sodium borohydride to remove 
basal oxidation and then oxidized with ferrous sulphate. Samples were derivatised 
with 10 mM DNPH in 2 M HCl for 1 hour at room temperature, and read 
spectrophotometrically at 360 nm. The protein concentration of each sample was 
measured using the bicinchoninc acid (BCA) assay, in order to normalise for protein 
content, subsequently, the carbonyl content was calculated as a ratio of each 
samples protein content (Smith et al., 1985). With regard to the standards, a 
concentration dependent increase in carbonyl group formation can be seen per 
milligram of protein present with the increase in ferrous sulphate treatment 
concentration. The standards in figure 3.1A and 3.1B show a small amount of 
variability throughout, more specifically, the 0.5 mM FeSO4 treated sample showed 
the greatest deviation from the concentration dependant increasing carbonyl 
formation trend. In order to check for oxidation of the protein samples that might 
occur during storage at -20oC, freshly prepared reduced BSA and reduced BSA that 
had been stored for several months was compared using the the carbonyl assay. No 
significant differences were seen in the level of carbonyl group formation, hence 
oxidation, between the freshly prepared and stored reduced BSA (Figure 3.1C). 
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Figure 3.1: Spectrophotometric Oxidized BSA Protein Standards. n = 3, error bars are 
standard error of technical replicates. (A) low ferrous sulphate treatment concentration range 
(B) high ferrous sulphate treatment concentration range (C) Comparison of freshly prepared
vs. stored, reduced standards. 
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3.3 Using the Carbonyl Assay to Confirm Oxidation of Fibrinogen 
The carbonyl assay was utilized to quantify carbonyl group formation, hence 
oxidation, of fibrinogen treated with the chlorinating and oxidizing agent NaOCl 
which produces hypochlorous acid (HOCl). The carbonyl assay results of HOCl 
treated fibrinogen, shown in figure 3.2A, show an increase in the level of oxidation in 
the treated samples when compared to the untreated controls. More specifically, a 
concentration dependent exponential increase in carbonyl group formation can be 
seen. However, a considerable amount of variability between replicates can be seen 
with large standard error values. Fibrinogen treated with the peroxynitrite generator 
SIN-1, shown in figure 3.2B, displays a similarly large amount of variability between 
replicates, with very large standard deviation values. The results for SIN-1 treated 
fibrinogen do not follow the expected trend of a concentration dependent increase in 
carbonyl formation. The reactive, sulfur containing, residue methionine was also 
added to quench any excess unreacted oxidant in both the SIN-1 and HOCl treated 
samples, with clear meaningful difference in trend.    
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Figure 3.2: Spectrophotometric Measurement of Treated Fibrinogen Carbonyl Content. 
n = 4, error bars are standard deviation based on technical replicates. (A) HOCl Treated 
Fibrinogen Carbonyl content (B) SIN-1 Treated Fibrinogen Carbonyl content. Samples were 
derivatised with 10 mM DNPH in 2 M HCl for 1 hour at room temperature, and read 
spectrophotometrically at 360 nm. The protein content was measured using the BCA assay, 
and the carbonyl formation calculated based on each samples protein content.  
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3.4 Western Blot Analysis of Nitrated Fibrinogen 
The results from the carbonyl assay confirmed the oxidation of fibrinogen, although 
the effect did not appear to be very linear, and there was substantial variability in the 
assay. The lack of consistency seen with large standard error values suggested the 
need for further testing. Western blot analysis was utilized as another means to 
measure oxidation of fibrinogen before MS analysis. Fibrinogen was nitrated with 
the peroxynitrite generator SIN-1 and run on a reducing SDS-PAGE. Of the two gels 
produced, one was stained with coomassie blue and used to investigate whether the 
oxidative treatments had caused any major structural changes to fibrinogen, such as 
degradation or aggregation. The bands at approximately 45, 55 and  65 kDa (Figure 
3.3A) represent the α, β and γ chains of fibrinogen. A number of fainter bands are 
visible, which are probably due to the contaminants in the human fibrinogen, which 
was only 50- 70% pure. The lanes containing the untreated fibrinogen appeared 
more prominent, suggesting a higher concentration of protein, despite the fact that 
aggregation or fragmentation was not apparent. Densitometry analysis with ImageJ 
software (figure 3.3B) further confirmed these differences between each treatment 
condition, showing a decrease in protein concentration with the increase of SIN-1 
treatment concentration.  In parallel to the SDS-PAGE, another gel of the samples 
was run (figure 3.3C), and treated with DNPH and then anti-DNP antibodies were 
used to detect the carbonyl bound DNP adducts representative of oxidation. The 
Western blot results shown in figure 3.3C show a basal level of binding between 
anti-DNP and fibrinogen’s α, β and γ chains, with prominent binding at 
approximately 45, 55 and 65 kDa. A significant increase in carbonyl formation in the 
1 mM SIN-1 treated sample relative to the negative control was visually apparent, 
whereas little increase between the negative control and the 0.25 mM SIN-1 treated 
was seen. Densitometry was performed with ImageJ software in order to further 
understand the Western blot results. Densitometry confirmed differences between 
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each treatment condition. The 0.25 mM SIN-1 treated fibrinogen showed a very 
similar amount of carbonyl level to the negative control. The 1 mM SIN-1 treated 
fibrinogen showed a 2-fold increase in carbonyl formation relative to the control, 
suggesting that it was oxidized. In addition, it is worth noting that fibrinogen’s α-
chain showed the greatest level of antibody binding across all sample treatments.  
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Figure 3.3: Carbonyl Formation Western Blot to Determine Oxidation. (A) Reducing 
SDS-PAGE of SIN-1 treated fibrinogen (B) Densitometry data (Rectangles show quantified 
areas) of SDS-PAGE (n =1) (C) Reducing Carbonyl Western blot (OxyBlot) of SIN-1 treated 
fibrinogen (D) Densitometry data (Rectangles show quantified areas) of SIN-1 treated 
fibrinogen OxyBlot (n =1). A 10% SDS-PAGE was loaded with 10 μg/ well of protein for 
coomassie staining and 15 μg/ well for Oxyblots. Oxyblots were treated with 10 mM DNPH 
and monoclonal rabbit anti-dnp (D9656) overnight (1:1000), followed by HRP-linked goat 
anti-mouse (6154) (1:1000), for 2 hours. Densitometry was performed with Image J, 1.6.0 
(https://imagej.nih.gov/ij/), with a rectangular selection encompassing all three bands for 
each individual lane.  
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3.5 Western Blot for 3-nitrotyrosine in SIN-1 Treated Fibrinogen 
Identifying carbonyl group formation allowed the confirmation of general oxidation. 
In order to look for modifications more relevant to nitration, a Western blot for 3-
nitrotyrosine was performed. The gels were prepared with a similar procedure to 
before (Section 3.4), in this assay the Western blot membranes were not treated 
with DNPH, rather incubated with anti-3-nitrotyrosine antibody. The coomassie 
stained SDS-PAGE, shown in figure 3.4A appears to show a similar trend to that 
seen in the previous coomassie stained SDS-PAGE, shown in figure 3.4A. The 
densitometry results of each lane confirm these similarities, with a decrease in 
protein concentration after treatment with SIN-1. However, little difference in protein 
concentration was seen between the different SIN-1 treated samples. It is also worth 
noting that protein bands at the bottom of the gel were apparent, potentially 
indicating protein fragmentation. Various other bands can be seen, indicating 
contaminants in the fibrinogen, which was only 70% purity (figure 3.4B). In parallel 
to the coomassie stained SDS-PAGE, a Western blot utilizing 3-nitrotyrosine 
antibodies was performed (figure 3.4C). Bands for 3-nitrotyrosine, corresponding to 
the chains of fibrinogen, were apparent. Densitometry was performed on each 
individual lane, suggesting an increase in anti-3-nitrotyrosine antibody binding with 
the increase in SIN-1 treatment concentration, and therefore, an increase in 3-
nitrotyrosine formation (figure 3.4D).   
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Figure 3.4: 3-nitrotyrosine (3-NT) Western Blot to Determine Nitration. (A) SDS-PAGE 
of SIN-1 treated fibrinogen (B) Densitometry data of SDS-PAGE, rectangle shows quantified 
area (n =1) (C) 3-NT Western blot of SIN-1 treated fibrinogen (D) Densitometry data of SIN-1 
treated fibrinogen 3-NT Western blot, rectangle shows quantified area (n =1). A 10% SDS-
PAGE was loaded with 10 μg/ well of protein for coomassie staining and 15 μg/ well for 
Western blots. Western blots were treated with mouse anti-3-NT (Upstate, clone 1A6) 
overnight (1:4000), followed by HRP-linked goat anti-mouse (6154) (1:1000), for 2 hours. 
Densitometry was performed with Image J, 1.6.0 (https://imagej.nih.gov/ij/), with a 
rectangular selection encompassing each individual lane.  
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3.6 Western Blot Analysis of HOCl Chlorinated Fibrinogen 
Sodium hypochlorite (NaOCl) stock solution concentration was checked 
spectrophotometrically, and diluted as required into phosphate buffer at pH 6.6. This 
solution was used to generate hypochlorous acid (HOCl), for chlorination of 
fibrinogen. The SDS-PAGE produced on analysis of the HOCl treated fibrinogen 
(figure 3.5A) shows bands at approximately 45, 55 and 65 kDa, representing the α, 
β and γ chains of fibrinogen. A number of fainter bands are visible, which are 
probably due to contaminants in the fibrinogen, which was only ~ 70 % purity. The 
higher HOCl treatments of fibrinogen show aggregation in the stacking gel. This 
effect appears to be concentration dependent, with protein aggregation increasing in 
parallel to the increase in HOCl treatment concentration. In addition to visual 
observation, the change in protein concentration was investigated with densitometry 
(figure 3.5B). Although protein aggregation was apparent, the results showed little 
difference in absolute lane staining protein concentration between treatments, 
according to the densitometry analysis. The Western blot analysis (Figure 3.5C) of 
HOCl treated fibrinogen supports the effect seen in figure 3.5A, with the largest part 
of anti-DNP binding in the stacking gel, indicating potential protein aggregation at 
the higher treatment concentrations. In addition, an increase in oxidation at the 
lower treatment concentrations was seen in the fibrinogen samples treated with 1 
mM and 2 mM HOCl.  
88	
Figure 3.5: Carbonyl Formation Western Blot to Determine Oxidation of NaOCl (HOCl). 
(A) SDS-PAGE of NaOCl (HOCl) treated fibrinogen (B) Densitometry data of SDS-PAGE (n
=1) (C) Carbonyl Western blot (OxyBlot) of NaOCl (HOCl) treated fibrinogen (D) 
Densitometry data of NaOCl (HOCl) treated fibrinogen OxyBlot (n =1). A 10% SDS-PAGE 
was loaded with 10 μg/ well of protein for coomassie staining and 15 μg/ well for Oxyblots. 
Oxyblots were treated with 10 mM DNPH and monoclonal rabbit anti-dnp (D9656) overnight 
(1:1000), followed by HRP-linked goat anti-mouse (6154) (1:1000), for 2 hours. Densitometry 
was performed with Image J, 1.6.0 (https://imagej.nih.gov/ij/), with a rectangular selection 
encompassing all three bands for each individual lane. 	
HOClTreatedFibrinogen 0	
mM0	0.06	0.12	0.25	
2	
mM
0.5	1	2	(mM)
HOClTreatedFibrinogen 0	
mM00.060.120.25
2	
mM
0.512(mM)250
130
100
70
55	
25	
15	
10	
35	
HOClTreatedFibrinogen 0	
mM0	0.06	0.12	0.25	
2	
mM
0.5	1	2	(mM)
HOClTreatedFibrinogen 0	
mM00.060.120.25
2	
mM
0.512(mM)250
13
10
70
55
25
15
10
35
A C
NaOCl (mM)	Treated	Fibrinogen	SDS-PAGE	 NaOCl (mM)	Treated	Fibrinogen	OxyBlot
0. 60.120.250.12 2 1 0.5 0.25 0.12 0.06 0kDa
α
β!
0	
2	
4	
6	
0	
0.5	
1	
B D
Fo
ld
	C
ha
ng
e	
in
	P
ro
te
in
	C
on
ce
nt
ra
tio
n
Fo
ld
	C
ha
ng
e	
in
	C
ar
bo
ny
l	F
or
m
at
io
n
Densitometry	of	NaOCl Treated	Fibrinogen	(mM)	
2 1 0.12	0.5	 0.25	 0.06	 0	
Densitometry	of	NaOCl Treated	Fibrinogen	(mM)	
2 1 0.12	0.5	 0.25	 0.06	 0	
89	
3.7 Identifying Modification Sites of Nitrated Fibrinogen With MS 
The coomassie stained counterparts of fibrinogen were identified as modified with 
Western blotting techniques, and in order to further characterize these 
modifications, the bands were excised and tryptically digested ready for MS 
analysis. Several ESI-QTOF MS experimental analyses were carried out in an 
attempt to confirm the identity of the bands excised from the SDS-PAGE shown in 
Figure 3.4A, moreover, to investigate the occurrence of oxPTMs to fibrinogen. All 
MS experiments described throughout were bottom-up MS approaches involving 
protein tryptic digestions (Summarized in table 3.1). With all experiments, the first 
step utilised Mascot© to identify the protein chains of fibrinogen, and potential 
modifications, in all samples. Mascot© searches against the UniProtKB/Swiss-Prot 
database and allocates an ion score to each peptide ion; this is the probability of a 
match between the experimental data and the database in-silico data. The higher 
the ion score value, the lower the probability of the match between the experimental 
and in-silico peptides being a random event. On initial inspection of the Mascot© 
results; peptide ions with ion scores above 30 were selected for manual validation. 
This was seen to be the value at which the sequence coverage was mostly 
complete and the peptide ions could be identified and sequenced in the raw spectra. 
Collectively, the Mascot© results showed an average ion score of 60 to 75, providing 
good confidence in the peptide identification. Mascot was also used to search for a 
number of variable modifications, including: methionine sulfoxide; cysteine tri-
oxidation (sulfonic acid); 3-nitrotyrosine; 3-chlorotyrosine; 3-hydroxytyrosine, 5-
hydroxytryptophan and lysine oxidation (carbonylation). Due to the alkylation of 
cysteine residues during tryptic digestion the fixed modification for carbamidomethyl 
was always selected. For the control samples, containing untreated fibrinogen, no 
modifications were identified by the Mascot© search. In contrast, Mascot© identified 
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a number of 3-nitrotyrosine modifications by the addition of 45 Da for NO2 
substitution of a hydrogen (1 Da) on tyrosine, to samples treated with SIN-1. More 
specifically, various 3-nitrotyrosine modified peptides were identified, summarized in 
table 3.1.  
  These results were manually validated by de-novo sequencing in PeakView© to 
further support the Mascot© results. From the list of peptides identified in Mascot©, 
validated in PeakView©, the peptides containing Y277, Y135 and Y475 occurred most 
frequently. The 3-nitrotyrosine containing peptide 273GGSTSY+45 GTGSETESPR287 
was the most frequently occurring peptide ion identified with MS, showing good 
sequence coverage for both the 0.25 mM and 1 mM SIN-1 treated samples in 
Mascot©. Comparison of the Mascot© spectra (Figure 3.6A) corresponds to the 
PeakView© spectrum (Figure 3.6B), identifying most of the peptide ions that allowed 
the confirmation of the respective sequence. The corresponding amino acid 
additions (peptide ion) for each peak in figure 3.6A are shown in figure 3.6C. The 
majority of the peptide ions are Y ions with the charge residing on the N-terminus.  
As mentioned, the modified peptide was also manually validated in PeakVIew© 
showing a 45 Da mass increase for the addition of NO2 to tyrosine (Y- NO2). The 
increase from 163.05 Da to 208.05 Da supports the presence of a 3-nitrotyrosine 
modification at Y277. The extracted ion chromatogram (XIC) results allowed the 
percentage of modified total peptide ion to be quantified for all peptides. The XIC 
results for 273GGSTSY+45 GTGSETESPR287 (figure 3.6D) showed the modified 
peptide to account for 26%. 
  The second most occurring peptide, 135Y+45 LQEIYNSNNQK146, much like Y277 
showed good sequence coverage for both the 0.25 mM and 1 mM SIN-1 treated 
samples in Mascot©. By comparing figures 3.7A and 3.7B it is clear that the Mascot© 
spectrum (Figure 3.7A), is very similar to the PeakView© spectra (figure 3.7B). 
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Although the peptide ion generally showed good sequence coverage, there was no 
coverage of the actual modification site at Y135. Again, most of the peptide ions were 
Y ions (Figure 3.7C). This was true for both the native and modified versions of the 
peptide. The presence of 3-nitrotyrosine was therefore deduced from the mass of 
the parent peptide and the sequencing of the remainder of the peptide. The XIC 
results for 135Y+45 LQEIYNSNNQK146 (Figure 3.7D) showed the modified peptide to 
account for 2.19%. The peptide 472GSWY+45 SMR478, ranking as the third most 
commonly occurring peptide ion, showed good sequence coverage in the Mascot© 
and PeakView©, despite generally having low ion scores (figure 3.9A and 3.9B). The 
XIC results for 472GSWY+45 SMR478 (figure 3.9D) showed the modified peptide to 
account for 3.08% of the total peptide observed.  
   Table 3.1: Ranked List of the Most Re-Occurring Modified Peptide Ions. (n = 7, error 
bars represent standard deviation of experimental replicates) The sequence confirmed by 
manual validation was shown as highlighted in red. The most abundant ion for each peptide 
was the 2+ charge state. In some samples the 3+ charge state version of the peptide was 
identified. The 3+ peptide was lower in abundance and frequency than the respective 2+ 
peptide ions. The chromatograms for each specific peptide have the same retention times, 
with a small amount of variability between experiments, and a couple of outliers. The native 
peptides were eluted from the chromatography column before the modified versions in all 
chromatograms. 
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Figure 3.6: Mascot© and PeakView© Spectra for 273GGSTSY+45GTGSETESPR287. (n = 7, based on experimental replicates). (A) Mascot© spectrum 
(B) PeakView© spectrum (C) Mascot ion distribution table (D) Extracted ion chromatogram of modified and native peptide ions. See figure 3.9 for 
experimental parameters.  
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Figure 3.7: Mascot© and PeakView© Spectra for 135Y+45LQEIYNSNNQK146. n = 7, based on experimental replicates).(A) Mascot© spectrum (B) 
PeakView© spectrum (C) Mascot ion distribution table (D) Extracted ion chromatogram of modified and native peptide ions. See figure 3.9 for experimental 
parameters. 
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Figure 3.8: Mascot© and PeakView© Spectra for 472GSWY+45SMR478. (n = 7, based on experimental replicates). (A) Mascot© spectrum (B) PeakView© 
spectrum (C) Mascot ion distribution table (D) Extracted ion chromatogram of modified and native peptide ions. See figure 3.9 for experimental parameters. 
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Comparing the data of several experimental replicates (n = 7) showed a large 
amount of variability between biological replicates. The average percentage that 
each peptide was modified showed considerable variation, indicated by large 
standard deviations. This suggests that the percentage of the native peptide that 
was modified did not fall within a narrow range, or, when comparing both treatment 
concentrations (Figures 3.9A and 3.9B), show a clear or expected concentration 
dependent relationship. Modified peptides Y475 and Y589 were shown to make up less 
of the total peptide, with a lower level of modification for each in the 0.25 mM SIN-1 
treated fibrinogen (Figure 3.9A), when compared to the 1 mM SIN-1 (Figure 3.9Bb). 
It is also worth noting that the results for Y475 and Y589 were identified less often, and 
the average and range values, shown in figure 3.9A and 3.9B, are based on a 
smaller n value. The trend shown could as a result be less informative.  
The instances of each modified peptide, and the percentage of which it was shown 
to be modified varied in distribution between each modified peptide ion (Figure 
3.9C), Y277 showed an almost even spread with 1% to 90% shown as modified. The 
higher fibrinogen treatment concentration showed a greater number of instances of 
Y277 modifications, appearing as heavily modified. Whereas the other peptide ions 
with a tyrosine modification appeared to show a large proportion of the 
modifications, both from the 0.25 and 1 mM SIN-1 treatment conditions, in the 1-
10% modified range (Figure 3.9C). With regard to the overall number of 
modifications (Figure 3.9D), the 1mM SIN-1 treated fibrinogen accounted for nearly 
70% (67.4%) of the total modifications, suggesting that the higher treatment 
concentrations produced more modifications. The XIC data for the control samples 
showed intense peaks for the most occurring native peptide ions (Y277, Y135 and 
Y475), with no XIC peaks for the modified versions throughout.	
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Figure 3.9: Analysis of MS XIC Data. (n = 7, error bars represent standard deviation of 
experimental replicates). Average total percentage of native peptide modified at (A) 0.25 mM 
and (B) 1 mM SIN-1 treatment (C) Distribution of specific modified peptides based on 
treatment (0.25 mM or 1 mM SIN-1) and non-treatment (0 mM SIN-1, native fibrinogen) (D) 
Distribution of total modified peptides based on treatment conditions. The following Mascot© 
database search settings were used to search the SwissProt database: homo sapien 
taxonomy, carbamidomethyl fixed modification and three, during any one search, of several 
variable modifications (described in text) were selected. The digesting protease trypsin was 
selected, with a maximum number of 1 miss-cleavages, and 2+, 3+ and 4+ charged peptides 
were allowed based on their monoisotopic masses, with a MS/MS tolerance of ± 0.5 Da. De-
novo data analysis was performed with PeakView© software (ABSciex, UK). The XIC mass 
window was set to 0.05 Da for all experiments, and peaks were Gaussian smoothed for 
clarity to 3. Plotly graphing, version 1 (https://plot.ly) was used to produce the bubble plot (C) 
and pie chart (D).   
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3.8 Identifying OxPTMs to HOCl Treated Fibrinogen with MS  
Several attempts at identifying modifications to HOCl treated fibrinogen were made, 
without success. Multiple in-gel digests, similar to that described in section 3.7, were 
performed. Fibrinogen was treated with HOCl, analysed by a 10% SDS-PAGE gel 
(Figure 3.10), the bands excised and tryptically digested before being run on the 
MS. Because HOCl treated fibrinogen can sometimes aggregate, as seen in the 
SDS-PAGE in figure 3.5, the stacking gel sections were also excised for analysis. 
Data analysis of the subsequent results provided very good protein sequence 
coverage in Mascot©, for all of fibrinogen’s chains, but no modifications other than 
methionine oxidation were seen. In an attempt to avoid any protein aggregation 
limitations of the in-gel digestion procedure, multiple in-solution digests were also 
performed (Table 3.1). All instances of in-solution digestion, including the use of 
Waters Rapigest, much like the in-gel digestion results, provided good sequence 
coverage for the chains of fibrinogen with no modifications other than methionine 
oxidation.  
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Table 3.1: Mascot Database Protein Sequence Coverage Results of NaOH Treated 
Fibrinogen In-Solution Digests.  
Tryptic 
Digestion Exp. 
Alpha Chain  
    Sequence Coverage (%) 
Beta Chain  
Sequence Coverage (%) 
Gamma Chain  
Sequence Coverage (%) 
    NaOH Treatment 
 Solution (Exp. 1) 
   0 mM    0.25 mM   1 mM 0 mM     0.25 mM   1 mM    0 mM     0.25 mM   1 mM 
44 41 37 77 76 73 68 66 72 
 Solution (Exp.  2) 9 24 28 14 43 63 11 42 52 
   Solution (Exp.  3) 49 49 37 77 77 73 63 62 62 
 Solution (Rapigest) 29 32 28 51 42 45 41 41 41 
Figure 3.10: Location of Protein Bands Excised from SDS-Gel. Rectangular boxes 
represent excision area that was digested and run on the MS for analysis, with the red boxes 
highlighting the bands excised from the stacking gel. The alpha (a), beta (b) and gamma (c) 
chains of fibrinogen are also labelled based on their location within the gel.  
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3.9 Literature Peptide 196DYEDQQKQL204 was not found with MS 
The fibrinogen α-chain peptide sequence 196DYEDQQKQL204 was chosen from a 
study performed by Bergt et al. (2004), on the basis that lysine-containing peptides 
juxtaposed to tyrosine residues are more readily chlorinated after exposure to 
activated phagocytes (Bergt et al., 2004). This peptide was selected in order to 
perform an antibody-based proof-of-principle study, discussed further in chapter 4. 
For the purpose of this chapter, MS analysis was performed in an attempt to identify 
whether 196DYEDQQKQL204 was modified after independent in-vitro treatments with 
HOCl and SIN-1. No modifications were identified. However, the native version of 
the peptide was identified (Figure 3.11).  
Figure 3.11: Identification of Native 196DYEDQQKQL204 in the Mascot© Results. The 
Mascot© database Homo sapiens taxonomy was selected in the SwissProt database. 
Carbamidomethyl fixed modifications and three of several variable modifications were 
selected at any one time. Trypsin, with a maximum number 1 miss-cleaves, 2+, 3+ and 4+ 
charged peptides were allowed based on their monoisotopic masses, with a MS/MS 
tolerance of ± 0.5 Da. 
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3.10 Checking Fibrinogen Peptide Sequence Exclusiveness  
In order to determine potential proteins with which the MS identified peptide 
sequences could share similarities with, a Pubmed BLAST search was performed 
against the UniProtKB/Swiss-Prot database, with the taxonomy parameter set to 
Homo sapiens. The Blast search result categories include the identity match, the 
query cover match and the E value (Expect value). The identity match is the 
similarity between the query and the subject sequences, the query cover is the 
percentage of the sequences that overlap, and most importantly the E value is the 
number of positive result returns one can expect to see by chance from the 
database. The lower the E value, the more significant the match is. The Blast search 
results (Tables 3.2 - 3.4) for all peptides, including 273GGSTSY+45GTGSETESPR287, 
135Y+45LQEIYNSNNQK146 and 472GSWY+45SMR478, are not matched to any other 
proteins or peptides other than to those from fibrinogen. The matches to fibrinogen 
show low E values, providing significance to the results. With regard to the 
unmatched returned results, none have both a match to the sequence, and full 
query coverage.  
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 Table 3.2:  Pubmed Blast search results for the peptide 273GGSTSYGTGSETESPR287
(Y-277). 
Record Name Max 
Score 
Total 
Score 
Query 
Cover 
E 
Value 
Identity 
Match 
Fibrinogen alpha chain 23.5	 39	 100%	 0.43	 100%	
Zinc	finger	FYVE	domain	 18.5	 33.9	 85%	 30	 100%	
Contactin	associated	protein	 18.5	 28	 85%	 30	 100%	
Glutamate	receptor	protein	 18.5	 18.5	 91%	 30	 100%	
  Table 3.3: Pubmed Blast search results for the peptide 135YLQEIYNSNNQK146 (Y-135) 
Record Name Max 
Score 
Total 
Score 
Query 
Cover 
E 
Value 
Identity 
Match 
Fibrinogen gamma chain 43.9	 43.9	 100%	 7e-8	 100%	
Ubiquitin	protein	ligase	MGRN1	 27.4	 27.4	 83%	 0.054	 100%	
Protein	POF1B	 26.9	 26.9	 75%	 0.077	 100%	
1-acyl-sn-glycerol	3-phosphate 25.2	 25.2	 71%	 30	 100%	
   Table 3.4: Pubmed Blast search results for the peptide 472GSWYSMR478 (Y-472). 
Record Name Max 
Score 
Total 
Score 
Query 
Cover 
E 
Value 
Identity 
Match 
Fibrinogen beta chain 28.6	 28.6	 100%	 0.07	 100%	
Immunoglobulin	superfamily,	3	 22.7	 42.0	 100%	 0.87	 83%	
Gram	domain-containing	protein	1A	 22.7	 22.7	 71%	 0.87	 100%	
Chromodomain	protein	(CHD1)	 21.0	 21.0	 71%	 3.5	 80%	
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3.11 Determining Predisposition of Fibrinogen Peptides to Modification  
Fibrinogen’s protein crystal structure was mapped using the software Chimera© 
(Pettersen et al., 2004), allowing the illustration of the MS identified modified peptide 
sequences. The crystal structure provided an understanding of fibrinogen’s peptide 
surface exposure, and subsequent susceptibility to modification. Crystal structure 
data was available for the peptides containing Y475, Y71, Y135 and Y197.  However, 
Chimera© shows Y277 as residing within a region of the protein without crystal 
structure coverage. The peptide sequences are shown in green, and the tyrosine 
residues in yellow. The crystal structure (figure 3.12) shows the hydrophobic 
interactions of fibrinogen, and the surface exposure of Y475, Y71 and Y135, further 
supporting the modifications identified in the MS results. The crystal structure for 
Y197 shows this sequence to be buried, and not surface exposed, due to the 
hydrophobic interactions of the tertiary and quaternary structure of fibrinogen, 
further supporting the MS results, in that, Y197 only appears as unmodified in 
Mascot©.  
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Figure 3.12: Crystal Structure of Fibrinogen Showing MS Identified Peptides’ Tertiary Structure Placement. (A) The position of 472GSWYSMR478 with 
the sequence highlighted in green and the tyrosine residue in yellow (B) The position of 54EEAPSLRPAPPPISGGGYR72 with the sequence highlighted in 
green and the tyrosine residue in yellow (C) The position of 135YLQEIYNSNNQK146 with the sequence highlighted in green and the tyrosine residue in yellow. 
The crystal structure data was obtained with Chimera©, version 1.9 (https://www.cgl.ucsf.edu/chimera/). 
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3.12 Chapter 3 Discussion 
The focus of this chapter was on the identification, and quantification of in-vitro 
modification sites to human fibrinogen after treatment with the oxidants SIN-1 and 
HOCl. The aim was to identify stable modifications to fibrinogen peptides that might 
make good potential markers of inflammation. The hypothesis was that a number of 
sequence-specific and concentration dependent oxidative modifications, similar to 
those that might be expected during inflammation, to human fibrinogen can be 
consistently identified after treatment with SIN-1 and HOCl.   
Carbonyl standards were produced in an attempt to measure the level of oxidation 
to fibrinogen before mass spectrometry analysis. The carbonyl content of the 
standards showed a concentration dependent increase up to 20 nmol/ mg of protein, 
and then no further increase. Fibrinogen has a finite number of residues that are 
able to form carbonyl groups, and once all of these have reacted to form carbonyl 
groups, the reaction will have reached its limit. Increasing the oxidant concentration 
beyond this point will have no further effect.  A study performed by Adams et al. 
(2001) supports this, showing a similar effect with HOCl-treated BSA. Carbonyl 
formation on fibrinogen, after treatment with HOCl and SIN-1, was determined with 
the Carty et al., 2000 method. The fibrinogen used was 70% pure, obtained from 
human serum, and as a result contained various other plasma proteins. The 
previously mentioned study performed by Adams et al. (2001) showed how various 
plasma haem-containing proteins, such as haemoglobin, sharing the same 
absorbance wavelength as DNP, increased absorbance values, representative of 
carbonyl content. In addition, a decrease in the level of carbonyl formation, due to 
transition-metal-catalyzed oxidation was shown, concluding substantial variability in 
protein samples containing haem-proteins.    
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Western blotting was successfully used to show protein oxidation and nitration. 
However, HOCl-treated fibrinogen appeared to show a large amount of aggregation. 
This was apparent in the strong protein signal in the stacking gel area of the SDS-
PAGE, and binding of anti-DNP antibodies in the Western blot. A study performed 
by Hazell et al. (1994) showed the mechanism of HOCl-induced protein aggregation 
to relate to modification of the protein lysine residues. Lysine is one of the cleavage 
sites of the protease trypsin used in all MS experiments. A study by Zee et al. 
(2012) describes how modifications to protein lysine residues can cause trypsin 
miscleaveages, and as a result compromise the MS analysis of such proteins. One 
potential possibility, is that, HOCl induced modifications to protein lysine residues, 
which can cause aggregation, also hinder MS analysis. However, this is brought into 
question, as fibrinogen was still successfully identified in several experiments with 
good sequence coverage in Mascot©.  
The peptide ion, 273GGSTSY-(NO2)-GTGSETESPR287, was shown with MS to be the 
most frequently modified fibrinogen peptide. However, no crystal structure data was 
available for this sequence. A study performed by Rasmussen et al. 2007 showed 
how the poor crystal structure of human b2 adrenergic G-protein-coupled receptor 
could be attributed to its inherent structural flexibility, and as such, one potential 
explanation for the lack of crystal structure data for 273GGSTSYGTGSETESPR287, is 
that it displays conformational flexibility. This flexibility may provide some insight into 
the mentioned sequence’s high susceptibility to modification. Comparing the crystal 
structures of the other MS-identified modified peptides, shows a potential correlation 
between how well exposed the peptide sequence is to the surface, and the 
frequency that it occurs as modified in the MS results. More specifically, the 
35YLQEIYNSNNQK146 sequence, shown to be well exposed, is one of the two modified 
peptides that are frequently identified with MS. 
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The literature describes 3-nitrotyrosine residues to account for < 0.1% of total 
protein tyrosine residues (Nuriel et al., 2008). The percentage of the total modified 
peptide in this chapter was determined with XIC, and the modified peptide was 
shown to account for varying amounts of the total peptide, which for the most part 
was well in excess of 0.1%.  
A MS-based study by Parastatidis et al. (2008), of the plasma taken from smokers, 
identified two 3-nitrotyrosine containing peptides of fibrinogen, 284 NYCGLPGEY-
(NO2)-WLGNDK298 and 416YYWGGQY-(NO2)-TWDMAK428. These modified peptides 
were not identified in the discussed study. There are two obvious potential 
explanations: firstly, the oxidative reactions that occur in-vivo differ to those in-vitro, 
and as such, provide different modifications to fibrinogen. In chapter 3 of this study 
the peroxynitrite generator SIN-1 is used as the source of nitration, and 3-
nitrotyosine formation, however, in-vivo peroxynitrite is not the only nitrating agent 
present. Other nitrating agents capable of producing 3-nitrotyrosine include, nitric 
oxide; nitric dioxide; nitrous acid and nitryl chloride, and these are produced via 
various physiological processes. The specific type of nitrating agent could influence 
the selectivity of nitration, and the concentrations of nitrating agents in-vivo may 
differ from those used in-vitro (Abello et al., 2009). A study by Jiao et al. (2001) 
describes that with different ratios of peroxynitrite to human serum albumin, the 
profiles of peptides with 3-nitrotyosine modifications changed. More specifically, the 
chromatography peaks for 3-nitrotyosine on further analysis with MS showed 
several 3-nitrotyosine containing peptides. Whereas, at the lower treatment levels 
the formation of 3-nitrotyrosine was pronounced in two particular peptides. 
Suggesting concentration-specific modifications. In addition, there are a number of 
other factors to consider when comparing in-vivo and in-vitro nitration selectivity, for 
example, conformational changes to proteins and alternative reaction kinetics based 
on the different biological conditions seen in-vivo.  
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Another consideration, should be the software used to perform data analysis. The 
previously mentioned study by Parastatidis et al. (2008) utilized SEQUEST© 
searching algorithm software to identify modified peptides, and this study utilized 
Mascot©, there is potentially a gap in the overlap between search engine peptide ion 
identifications. A comparative study of Mascot© and SEQUEST© search engine 
algorithms by Dorfer et al. (2014) supports this possibility, showing how the two 
search engines have an approximate 20% gap in their overlap (Figure 3.13). A 
review article by McHugh and Arthur (2008) suggests that, because each protein 
search engine software package uses its own search algorithm, that they each have 
their strengths, and weaknesses, and the most accurate approach would be to distill 
the results from various packages.  
Figure 3.13: Venn Diagram Showing the Overlap in Sequence Identification Between 
Different Search Engine Software. Based on four protein data sets, 80% of the peptide 
ions identified by SEQUEST© are also identified by Mascot©, and 83% of the peptide ions 
identified by Mascot©, are also identified by SEQUEST (Dorfer et al., 2014).  
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Ionization efficiency determines how accurately protein peptides are identified with 
MS. Some peptides ionize better than others, and PTM of peptides have been 
shown to alter ionization efficiency (Gao and Wang, 2007). This highlights some 
possible factors affecting the interpretation of the results in this chapter relating to 
poor or altered ionization efficiency, that some of the fibrinogen peptides that were 
shown as modified after treatment with SIN-1 or HOCl, are not detected with MS, 
the frequency of occurring modifications is inaccurate, and the XIC results for the 
amounts of modified peptides are hindered by the ionization efficiency due to PTM.  
3.13 Chapter 3 Conclusions 
Several modifications to fibrinogen were identified with MS after treatment with SIN-
1 and HOCl. Based on the treatment conditions used throughout, no modifications 
were identified as exclusive to the lower or higher oxidative conditions.  The main 
limitations of this study are, how well the nitrated fibrinogen modifications identified 
in-vitro correspond to those seen in clinical samples (in-vivo), potential Mascot© 
false negatives leading to un-identified peptide ions; poor or altered ionization 
efficiency of modified peptides with MS, potentially providing an inaccurate 
representation of the quantitative results. Some aspects of the hypothesis were 
proved, identifying nitrative modifications to fibrinogen. The the study was not able 
to identify modifications to fibrinogen after treatment with HOCl, or determine 
concentration specific modifications. Further work with inflammatory clinical samples 
is required to determine how well the in-vitro modified fibrinogen peptides 
correspond to an in-vivo situation. 
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3.14 Chapter 3 Future Work and Considerations 
In order to identify modifications to HOCl treated fibrinogen, a larger and lower 
treatment concentration range should be used in an attempt to achieve protein 
modifications without aggregation. In order to determine whether the identified 
modified fibrinogen peptides are present in in-vivo, and therefore translate. Analysis 
with MS of various inflammatory clinical samples should be performed. Ideally one 
low level inflammatory condition, such as diabetes, and one highly inflammatory 
condition, such as periodontitis to determine if different modifications and or 
proportions are observed between conditions. More specifically, MS with a MRM 
program selective for STSY-(NO2)-GTG and STSY-(Cl)-GTG peptide ions. A study 
by Tveen-Jensen et al. (2013) describes a MS method utilizing XICs generated from 
high-resolution MS2 data. The use of narrow mass windows allowed for accurate 
quantification of 3-nitrotyrosine and 3-chlorotyrosine. The use of narrow window XIC 
should be considered as supporting alternative method to MRM program 
quantification of modified peptides.  
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Chapter 4 
Developing Antibodies to Specific Peptide 
Sequences of Modified Fibrinogen 	
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4.1 Introduction 
4.1.1 Modifications to Proteins and Their Implications in Disease 
As previously discussed in chapter 3, oxidative modifications to proteins have been 
detected in various diseases involving inflammation and the subsequent oxidative 
pathology. Modifications of tyrosine are generally considered stable, and therefore 
there has been a lot of interest in them as potential biomarkers. The protein 
fibrinogen is highly abundant in the plasma, and as described in chapter 3, was 
shown by Western blotting to be most susceptible to oxidative carbonyl group 
formation (Shacter et al., 1994). A study by Vadseth et al., in 2003 also showed the 
ability of fibrinogen to readily form 3-nitrotyosine modifications.  Throughout chapter 
3, several modifications post in vitro oxidative treatment were identified in fibrinogen 
residues. These modified residues appeared to be the most susceptible to oxidative 
damage, and as such, have potential for translation into an in-vivo system. 
Interestingly, the modifications identified in chapter 3 do not correlate with the 
modifications that have been reported previously by Parastatidis et al. (2008).  
This study identified nitrated fibrinogen peptides in-vivo using MS. The observed 
modified peptides were chosen for further investigation, synthesized, conjugated to 
carrier proteins, immunized into sheep, and the anti-sera tested.  
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4.1.2 Immunoassay methods for Detecting Modified Proteins 
Antibody-based methods are amongst the most common techniques for identifying 
and quantifying oxidative post-translational modifications (oxPTMs) to amino acid 
residues. The most common techniques include ELISA, Western blotting (WB) and 
immunostaining techniques, such as immunohistochemistry (IHC) and 
immunocytochemistry (ICC). The accuracy of these respective techniques rely on 
the specificity of the available antibodies, but not all antibodies are validated for all 
procedures (Houée-Lévin et al., 2015). Issues with the reproducibility of 
immunoassays have been shown to be one of the most critical limitations of such 
techniques.  
A study performed by Ray et al. 2007, identified a series of potential biomarkers of 
Alzheimer’s disease. The antibody produced showed cross reactivity dependent 
variability during detection, and as such, a lack of reproducibility (Ray et al., 2007). 
As stated, not all antibodies are validated for all technical procedures. From 
examining the antibody databases, CiteAb (www.citeab.com) and Biocompare 
(www.biocompare.com), antibody application trends were identified. The majority of 
antibodies for oxPTMs are primarily validated for Western blotting (~75%), with 
smaller numbers suitable for the other techniques such as IHC (~40%) and ELISA 
(~35%), and the use of these antibodies are not necessarily interchangeable.   
As mentioned, the specificity of the available antibodies determines the selectivity 
and sensitivity of immunoassay techniques, and the degree of cross-reactivity 
depends primarily on the antigen that the antibodies are raised against. As the 
antigen becomes smaller, the number of epitope determinants decrease, and the 
probability of cross-reactivity increases (Hennion and Barcelo, 1998). This is 
important when considering small peptides, and modified amino acid residues, as 
they fall into this category. A comprehensive database search of the sites CiteAb 
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and Biocompare suggest there are more than 500 commercially available antibodies 
to modified residues, but on average less than 15% of these have been specifically 
cited in scientific publications. Multiple searches were performed for each amino 
acid oxidative modification type, accounting for differences in nomenclature of the 
same modified amino acid. Some antibodies are more extensively cited than others, 
and each are used in a different variety of techniques, highlighting the critical 
importance of selecting the appropriate one. The degree of accuracy obtained in an 
immunoassay is largely dependent on the specificity of the antibody used, and this 
can vary according to the immunogen used to generate them, including the carrier.  
Cross comparison of the commercially available antibodies on CiteAb and 
Biocompare, shows the most commonly used approach to be conjugation of the 
modified residue to either keyhole limpet hemocyanin (KLH) or bovine serum 
albumin (BSA), but other common methods include immunizing directly with proteins 
treated with oxidants or nitrating agents. An understanding of how antibodies react 
to multiple epitopes of a given antigen highlights limitations in such approaches.  
More specifically, using modified BSA or other proteins will generate antibodies to a 
variety of epitopes on the antigen, which may lead to cross reactivity upon 
translation, especially when considering that most nitrating and chlorinating agents 
are also oxidizing, so a wide range of oxPTMs may result. Even using synthetic 
modified residues conjugated to a carrier protein, there are likely to be several 
antibodies to epitopes that do not include the modification site, so purification is 
required.  
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Thus, the resulting polyclonal sera are semi-specific at best; while monoclonal 
products are better, some cross-reactivity is still possible. For example, limitations of 
antibodies and antibody-dependent assays for methionine sulfoxide have been 
reported (Wehr and Levine, 2012, and Ghesquière and Gevaert, 2014).  
This indicates the importance of understanding the nature of the antibody being 
used in order to interpret results correctly, but unfortunately often little information is 
available from the supplier. It also suggests the benefit of producing better-
characterized antibodies, possibly with known sequence specificity in addition to 
modification specificity.  
4.1.3 Chapter 4 Focus, Aims and Hypothesis 
This chapter focuses on synthesis and purification of fibrinogen peptides identified in 
the literature and by MS, and for the most part, the production and testing of the 
corresponding modified peptide anti-sera. The specific aim of this part of the study 
was to produce anti-sera with antibodies that bind  specifically the modified peptides 
identified in the literature and by MS in chapter 3, exclusively. Chapter 4 is based on 
the hypothesis that antibodies can be produced which differentiate between 
modified and unmodified fibrinogen peptides with sequence context, binding 
exclusively to the specific modified peptide they were produced against.   
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4.2 Synthesis of Preliminary DYEDQQKQLC Peptide Series 
In parallel to MS identification of sites of fibrinogen modifications, a proof-of-principle 
study was undertaken, to show that antibodies could be produced with sequence 
and modification site specificity. The α-chain fibrinogen peptide sequence 
196DYEDQQKQL204 was chosen, as discussed in chapter 3, based on increased 
potential tyrosine chlorination by phagocytes when juxtaposed to lysine residues 
(Bergt et al., 2004). The peptide was also a convenient size with the tyrosine (Y197) 
residue within tryptic cleavage points. A cysteine was added at the C-terminus of the 
peptide to allow subsequent conjugation to KLH for immunization and purification. In 
order to develop specific antibodies to the respective peptide, it was first 
synthesized with purchased FMOC protected/blocked amino acid residues, 
according to well-established methods (Wade, 2007).  
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Figure 4.1: Analysis and Purification of Synthetic Peptides. Synthesized peptides, (A) 
Crude DYEDQQKQLC, (C) Purified DYEDQQKQLC and (D) Purified DY-(Cl)-EDQQKQLC 
were made up into 1mL 50% Acetonitrile, 50% water and then 6ml 95% water, 5% 
Acetonitrile and 0.1% trifluoroacetic acid (TFA). The spectra for the synthesized peptides 
were obtained on a Waters Micromass ZMD mass spectrometer by direct infusion, with a 
flow rate of 30µl/ min at 100°C (A, C and D). Fractionation and purification of all of the 
peptides, (B) Purification of DYEDQQKQLC, were performed on a Dionex ultimate 3000 
HPLC machine with UV detection and automated fraction collection. The HPLC flow rate 
was 4mL/ min, 95% buffer A (100% water and 0.1% TFA) and 5% Buffer B (100% 
Acetonitrile and 0.1% TFA which changed over time with the pre-programmed gradient.  
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On completion of the step-wise procedure for synthesis of the peptides, MS was 
utilized to confirm the correct masses for each of the peptides. The initial MS 
analysis of DYEDQQKQLC shows a larger amount of background peaks (Figure 
4.1A). In order to remove impurities, the peptide was purified using HPLC 
fractionation with peptide elution monitored by the absorbance at 230 nm, 
corresponding to the peptide bonds (Figure 4.1B). The peptide DYEDQQKQLC 
eluted at a retention time of 4 minutes, which was demonstrated by mass 
spectrometry analysis of the eluted fractions.  The mass spectrum of the peak at 4 
minutes was shown in Figure 4.1C, and confirms the presence of DYEDQQKQLC. 
Upon successful confirmation, further fractionation of the remaining respective 
peptide solution was performed, providing a purified solution of DYEDQQKQLC 
which was freeze dried in preparation for later use. Crude and purified products 
were analysed for all synthesized peptides to confirm the syntheses. The 
chlorinated version of the peptide DY-(Cl)-EDQQKQLC was successfully 
synthesized and purified in a similar fashion to the DYEDQQKQLC peptide. The 
addition of chlorine (34 Da) was confirmed in the MS spectrum (Figure 4.1D, with a 
mass increase from 1270 Da (Figure 4.1C) to 1304 Da.  
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4.3 Immunoassay Screening of DYEDQQKQLC Anti-Sera Series  
DYEDQQKQLC and DY-(Cl)-EDQQKQLC peptides were conjugated to keyhole 
limpet haemocyanin (KLH), in order to improve their immunogenicity, and injected 
into separate sheep to generate anti-sera containing antibodies to the respective 
peptide antigens. Four sheep in total were immunized with synthetic peptides, 2 
sheep for each peptide, sheep numbers 1 and 2 were immunized with 
DYEDQQKQLC synthetic peptide, and sheep 3 and 4 with DY-(Cl)-EDQQKQLC 
synthetic peptide. Aliquots of plasma were collected from the sheep on a monthly 
basis, and tested for their ability to recognize the peptides. In order to determine an 
appropriate working dilution, one of the sheep immunized with native peptide (sheep 
2) and one with the chlorinated peptide (sheep 4) were selected for preliminary
testing. The testing of anti- DYEDQQKQLC (sheep 3) and anti- DY-(Cl)-
EDQQKQLC (sheep 3) to their antigens showed increased binding, to their 
respective antigens, over time after immunization (Figures 4.2A and 4.2B), with no 
binding of the pre-immune serum to either of the respective antigens. The sera 
obtained for DYEDQQKQLC (Figure 4.2A) in the later months displayed a reduction 
in absorbance at higher concentrations/lower dilutions. This was thought to be as a 
result of the well-established principle known as the “Hook Effect”, whereby 
agglutination of concentrated anti-sera prevents antibody binding, and as a result a 
drop off in signal is seen. Subsequently, a dilution of 1:2000 was selected to allow 
clear definition between sera bleed months with minimal signal loss. 
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 Figure 4.2: Determining Anti-Sera Optimal Dilution and Anti-Sera Monthly Antibody 
Titre Profile. (n = 3, standard deviation of technical replicates). Nunc maxi-sorp plates 
(Product code: 10098860, Fisher Scientific, UK) were coated with 2 μg/mL of peptide 
antigens. The sera used in A and B was taken from sheep numbers 2 and 3 and used serial 
dilution. The sera used in C – F were diluted to 1:2000 in 1% BSA TBST. The tested anti-
sera were detected with 1:25,000 donkey anti-sheep antibody conjugated to alkaline 
phosphatase (Product code: A5187), and 1 mg/mL phosphate substrate in para-
nitrophenylphosphate (pNPP) buffer, pH 10.4, with an incubation time of 15 minutes at room 
temperature before being read on a plate reader at 405 nm.   
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In order to identify any trends between all of the anti-sera bleed months, each of the 
sheep bleed months were tested against both the native and chlorinated peptides 
(DYEDQQKQLC and DY-(Cl)-EDQQKQLC) for comparison (Figures 4.2C to 4.2F). 
The sera from all sheep collected prior to immunization with synthetic peptides 
showed no significant binding to either antigen (Figures 4.2C - 4.2F). Post-
immunization with the synthetic peptides, an increase in binding of anti-sera to both 
DYEDQQKQLC and DY-(Cl)-EDQQKQLC, corresponding to the months after 
immunization was seen. Cross reactivity between the native and chlorinated 
versions of the peptides were seen for all anti-sera (Figures 4.2C - 4.2F). This cross 
reactivity is most likely due to the polyclonal nature of the anti-sera, made up of 
antibodies for various epitopes of the respective antigens, both including and not 
including the modification site.  
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4.4 Comparing the DYEDQQKQL Antigen Minus the Cysteine Residue 
During peptide synthesis a cysteine residue was included to enable the necessary 
immunization and purification steps. The produced sheep sera were tested against 
two similar peptides, identical except for the presence or absence of a cysteine 
residue (Figure 4.3). This was performed in order to determine if the inclusion of a 
cysteine in the peptide sequence affected the antibody specificity. As figure 4.3 
shows, all sheep sera show binding to both peptides, albeit lower overall binding to 
the peptide without the cysteine residue. This is most likely relating to the polyclonal 
nature of the sera.  
Figure 4.3: Binding Differences of Sera 1 Month After Immunization Vs. Peptides 
Synthesized Either with or without a Cysteine Residue. (n = 3, standard deviation of 
technical replicates). Nunc maxi-sorp plates (Product code: 10098860, Fisher Scientific, UK) 
were coated with 2 μg/mL of peptide antigens.  The tested anti-sera (1:2000 dilution) were 
detected with 1:25,000 donkey anti-sheep antibody conjugated to alkaline phosphatase 
(Product code: A5187), and 1 mg/mL phosphate substrate in pNPP buffer, pH 10.4, with an 
incubation time of 15 minutes at room temperature before being read on a plate reader at 
405 nm.   
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4.5 Reducing DYEDQQKQLC Anti-Sera Series Cross-Reactivity 
In order to obtain more sequence and modification specific anti-sera, affinity 
enrichment described throughout as affinity purification, was performed on sera in 
an attempt to remove some of the cross reactivity. The anti-sera from sheep 
numbers 3 and 4, having been immunized with DY-(Cl)-EDQQKQLC, were initially 
selected for purification. Affinity purification of sera obtained from both sheep was 
carried out, but for illustrative purposes the results for sheep number 3’s serum 
purification are shown (Figures 4.4A and 4.4B). To obtain DY-(Cl)-EDQQKQLC 
specific antibodies, the purification process involved binding DY-(Cl)-EDQQKQLC 
synthetic peptide to silica beads via the cysteine residue. The anti-serum was then 
passed through the column to exclude non-specific antibodies (Fraction eluted with 
PBS, pH 7.4), and collected, figure 4.4A). To elute the bound antibodies, glycine 
buffer at pH 2.7 was used (Shown in Figure 4.4A). This eluent was then passed 
through another column containing beads conjugated with DYEDQQKQLC peptide 
(Figure 4.4b). This time the PBS eluted fraction (Shown in figure 4.4B) contains the 
antibodies specific for DY-(Cl)-EDQQKQLC. Both the PBS and glycine eluted 
fractions were collected for testing.  
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Figure 4.4: Purification and Subsequent Testing of Purified Sera. For affinity purification 
(A and B) (UV λ = 280 nm) the peptides were bound to iodoacetyl gel beads via cysteine 
residues (53155, Thermo Scientific, UK) and unbound binding sites were blocked with 50 
mM cysteine. Utilizing an AKTA Purifier (GE Healthcare) columns were washed with 1 M 
NaCl to remove any non-specific bound material, PBS and 0.1 M glycine (pH 2.7) was used 
to elute antibodies at a flow rate not exceeding 1 mL/ min. The ELISA plates (C and D) (n = 
3, standard deviation of technical replicates) were coated to 2 μg/mL in distilled water, with 
proteins in molar equivalents of peptides antigens, anti -sera concentrations of 1.5 μg / mL. 
Sera was detected with 1:25,000 donkey anti-sheep antibody conjugated to alkaline 
phosphatase (Product code: A5187), and 1 mg/mL phosphate substrate in pNPP buffer, pH 
10.4, with an incubation time of 15 minutes at room temperature before being read on a 
plate reader at 405 nm.  
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Having undergone purification to exclude DYEDQQKQLC antibodies, sheep number 
3’s anti- DY-(Cl)-EDQQKQLC eluate shows no significant binding to the native 
DYEDQQKQLC peptide (figure 4.4C). However, from looking at figure 4.4D, the 
same serum shows a significant amount of binding to its antigen, DY-(Cl)-
EDQQKQLC peptide. Sheep number 4 anti- DY-(Cl)-EDQQKQLC eluate shows a 
similar trend, but with a higher amount of binding/cross-reactivity to the native 
peptide. The purification process also provided anti-sera for the native 
DYEDQQKQLC peptide. The respective sera showed some cross reactivity to DY-
(Cl)-EDQQKQLC (figure 4.4D), which is to be expected between such similar 
antigens, as the sera is made up of antibodies that are potentially specific to multiple 
epitopes of the DYEDQQKQLC peptide. Another factor to consider is that these 
sera will also contain plasma proteins, and a large number of other antibodies for 
various other antigens. The serum collected from sheep number 3 showed strong 
binding to both the native and 3-chlorotyrosine versions of the DYEDQQKQLC 
peptides, and as such, each individual purification fraction was collected for use. 
Sheep number 3, anti- DY-(Cl)-EDQQKQLC eluate, is used throughout and as such 
will now be referred to as affinity purified (AP) anti- DY-(Cl)-EDQQKQLC. In addition 
to testing against DY-(Cl)-EDQQKQLC and DYEDQQKQLC peptides, the specificity 
of AP anti- DY-(Cl)-EDQQKQLC was tested against various other antigens. AP anti- 
DY-(Cl)-EDQQKQLC showed no significant binding to the native, chlorinated or 
nitrated versions of the MS identified peptide STSYGTGC, and neither did it bind to 
whole native fibrinogen (figure 4.5A). A nitrated version of DY-(Cl)-EDQQKQLC 
peptide was synthesized (DY-NO2-EDQKQQLC) and tested against AP anti- DY-
(Cl)-EDQQKQLC to determine the modification site specificity of the anti-serum. AP 
anti- DY-(Cl)-EDQQKQLC displayed strong cross reactivity to DY-(NO2)-
EDQQKQLC (Figure 4.5B).  
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Figure 4.5: Purification and Subsequent Testing of Purified Sera. (n = 3, standard 
deviation of technical replicates)	 The ELISA (A and B) plates were coated to 2 μg/mL, with 
proteins in molar equivalents to peptide antigens. The sera concentration was 1.5 μg/mL, 
detected with 1: 25,000 donkey anti-sheep antibody conjugated to alkaline phosphatase 
(Product code: A5187), and 1 mg/mL phosphate substrate in pNPP buffer, pH 10.4, with an 
incubation time of 15 minutes at room temperature before being read on a plate reader at 
405 nm.   
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4.6 Experimental Variability of AP anti- DY-(Cl)-EDQQKQLC 
It was noted that there was substantial inter plate variability, with regard to the anti-
sera binding values, as can be seen when comparing figures 4.2 and 4.4. In order to 
make comparisons between the responses to different antigens, and investigate 
inter-plate variability, three independent ELISA plates with all antigens on the same 
plate were performed (Figure 4.6). These experimental replicates were performed 
on different days with new reagents and between two different operators to allow 
experimental variability to be determined. The variability was determined by 
calculating the coefficient of variation (CV) of each antigen, based on the results 
from three independent but identical experiments. Expressing the CV of values 
close to zero provides unreliable results, and for this reason only antigens that gave 
absorbance (anti-serum binding) values greater than 0.100 were utilized (Gulhar et 
al., 2012). The CV values based on the three anti- DYEDQQKQLC serum 
experiments (Figure 4.6) had an average CV of 11%. Cross-comparison of the 
absorbance values for AP anti- DY-(Cl)-EDQQKQLC serum ELISAs further supports 
this. Between all experimental work (Figures 4.3 - 4.6) there appears to be large 
anti-serum binding variability, but the overall specificity trend of serum to antigen 
binding is however the same. Specifically, there is very little binding to any non-
DYEDQQKQLC motif series antigens, and a significantly higher amount of binding 
to both the chlorinated and nitrated versions of the DYEDQQKQLC peptide.  The 
reduction in signal seen between anti-DYEDQQKQLC sera series ELISA 
experiments may correspond to the age of the sera. This reduction in signal may be 
due to protein degradation and aggregation following storage at 2-4°C for a 
prolonged period of time, and potentially the presence of plasma proteases. Some 
of the ELISA results were performed 2-3 years after the initial sera were obtained, 
resulting in decreased anti-sera binding over time, and as such inter-assay 
variability. 
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Figure 4.6: Identifying Inter-Experimental Variability and Binding Trends. (n = 3, error bars represent standard deviation of experimental replicates). (ns = P > 
0.05 and * = P ≤ 0.05). Synthesised peptide antigens were coated onto Nunc maxi-sorp plates (Product code: 10098860, Fisher Scientific, UK) at 2 μg/mL. The 
proteins were treated with either SIN-1 or HOCl for 1 hour at 37°C before being coated onto Nunc maxi-sorp plates in molar equivalent amounts to the peptide 
antigens.  The primary anti-serum was made to 1.5 μg/mL. The tested anti-sera were detected with 1:25,000 donkey anti-sheep antibody conjugated to alkaline 
phosphatase (Product code: A5187), and 1 mg/mL phosphate substrate in pNPP buffer, pH 10.4, with an incubation time of 15 minutes at room temperature before 
being read on a plate reader at 405 nm. 
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4.7 Testing DY-(Cl)-EDQQKQLC Serum Vs. Abundant Plasma Proteins 
Extending the approach taken in the previous section (whereby the ability of anti-
serum to recognize native and modified peptides within a protein, was investigated), 
the binding of AP anti- DY-(Cl)-EDQQKQLC to the most abundant plasma proteins, 
(Anderson and Anderson, 2002) was studied. More specifically, in order of 
abundance, native and chlorinated, haemoglobin (Figure 4.7A), human serum 
albumin (HSA) (Figure 4.7B), fibrinogen (Figure 4.7C) and transferrin (Figure 4.7D) 
were tested. The AP anti- DY-(Cl)-EDQQKQLC serum showed no significant binding 
to the chlorinated or native plasma proteins, including fibrinogen (Figures 4.7A- 
4.7D). An extensive Blast® search of the SwissProt database within the human 
taxonomy revealed no proteins, other than fibrinogen, with any similar amino acid 
sequences to DYEDQQKQL, further supporting the lack of binding.   
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Figure 4.7: Binding of AP Anti- DY-(Cl)-EDQQKQLC serum to Most Abundant Plasma 
Proteome Proteins. (n = 3, standard deviation of technical replicates).	 The proteins
described in A to D were treated with hypochlorous acid (HOCl) for 1 hour at 37°C before 
being coated to Nunc maxi-sorp plates (Product code: 10098860, Fisher Scientific, UK) in 
molar equivalent amounts to DYEDQQKQLC peptides. The tested anti-sera were detected 
with 1:25,000 donkey anti-sheep antibody conjugated to alkaline phosphatase (Product 
code: A5187), and 1 mg/mL phosphate substrate in pNPP buffer, pH 10.4, with an 
incubation time of 15 minutes at room temperature before being read on a plate reader at 
405 nm.  
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4.9 Design of Novel 3-nitrotyrosine Peptide for Testing Sera 
In order to test the binding specificity of produced anti-sera, a novel 3-nitrotyrosine-
containing peptide, along with the native and chlorinated versions, were produced. 
Two main factors were considered during the design process, firstly, the solubility of 
the peptide; with tyrosine being a non-polar residue, the addition of polar serine 
residues was selected to encourage better solubility. Finally, the folding of the 
peptide into an α-helix, and how well-distributed the tyrosine residues are for 
antibody binding. The large number of tyrosine resides in the peptide meant that it 
was very non-polar (hydrophobic), and in an attempt to counteract this serine 
residues were added to the sequence. The results returned from the Innovagen 
calculator (Figure 4.8A) showed the SYASYSYC peptide to have poor water 
solubility. However, upon production and use of the peptide, it readily dissolved in 
water. The α-helix projections of the peptide with helical wheel projection software 
showed the tyrosine residues to be evenly distributed (Figure 4.8B). This made the 
peptide ideal for testing antibodies for 3-nitrotyrosine and 3-chlorotyrosine, and 
potentially for generating such specific antibodies. This peptide series was produced 
and used throughout to test antibody specificity.  
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Figure 4.8: Analysis of SYASYSYC Peptide Antigen Properties. (A) The peptide’s 
solubility and charge was determined using Innovagen peptide solubility calculator 
(http://pepcalc.com). (B) Antigenic properties of the peptide were determined by mapping the 
positions of the tyrosine residues within the α-helix with Wheel (version 0.10), helical wheel 
projection software (http://rzlab.ucr.edu/scripts/wheel/wheel.cgi). Each letter represents an 
amino acid, followed by a number representing where it resides in the peptide sequence. 
The connecting lines show the peptides spatial arrangement, in that, the lighter coloured 
lines are further away than the darker lines.  	
A	
B	
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4.10 Details of Synthesis for Designed and Identified Peptides 
As described in chapter 3, the modified fibrinogen peptide 273GSTSY-(NO2)-
GTGSETESPR287 was the most commonly observed modified peptide with a high 
ion score, indicating a strong correlation between the in-silico and experimental 
data, making this peptide a good choice against which to produce antibodies. The 
peptide was shortened in order to improve yield during peptide synthesis, but 
retaining the tyrosine and surrounding amino acid residues. A cysteine residue was 
added at the C-terminus of the peptide to later allow conjugation to KLH for 
immunization, and purification purposes. Native, nitrated and chlorinated versions of 
the peptide were synthesized, STSYGTGC, STSY-(NO2)-GTGC and STSY-(Cl)-
GTGC. In addition to the MS identified peptides, a modified human serum albumin 
(HSA) peptide 287Y-(Cl)-ICENQDSISSK298 identified in a study performed by Tveen-
Jensen et al. (2013), and both a native and nitrated version were synthesized. In 
addition to MS identified peptides, a novel peptide series was designed, discussed 
above. The custom peptides were synthesized and purified, by a commercial 
supplier (Isca Biochemicals, UK), according to the methods described previously. 
The HPLC purification and MS analysis results for the respective peptides can be 
found in the appendix 1- 27.   
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4.11 Immunoassay Screening of STSYGTGC Anti-Sera Series  
None of the pre-immune anti-sera, STSYGTGC, STSY-(NO2)-GTGC or STSY-(Cl)-
GTGC, showed significant binding to any of the STSYGTGC peptides, or DY-(Cl)-
EDQQKQLC (Figures 4.9A – 4.9C). One month after immunization the STSYGTGC 
anti-serum showed strong binding to its corresponding peptide antigen. The serum 
also showed a low level of binding to the nitrated and chlorinated versions of the 
peptide, and no binding to a peptide with a different sequence (DY-(Cl)-
EDQKQQLC) (Figure 4.10A). The anti-STSY-(Cl)-GTGC serum from one month 
after immunization (Figure 4.10B) showed strong binding to STSY-(Cl)-GTGC, and 
some binding to the other STSYGTGC peptides. However, no significant binding to 
the peptide DY-(Cl)-EDQKQQLC, which similarly contains a chlorinated tyrosine 
residue, was apparent. Thus, the anti-STSY-(Cl)-GTGC serum displayed potential 
modification site specificity.  Finally, the serum raised against the modified peptide 
identified in SIN-1-treated fibrinogen by MS, anti-STSY-(NO2)-GTGC, displayed 
specificity to both nitrated and chlorinated versions of STSYGTGC, with greater 
binding to STSY-(NO2)-GTGC. No binding to the DY-(Cl)-EDQQKQLC peptide was 
apparent (Figure 4.10C). Similarly, to the DYEDQQKQLC anti-sera, the STSY-(Cl)-
GTGC and STSY-(NO2)-GTGC anti-sera displayed a prominent “Hook Effect” at 
higher concentrations/lower dilution, presumably due to antibody agglutination 
(Figures 4.10A - 4.10C). For this reason, a dilution of 1:2000 was selected to allow 
clear definition between sera bleed months with minimal agglutination dependent 
signal loss for further ELISA based testing. 
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Figure 4.9: Testing Anti-STSYGTGC Series Sheep Pre-Immune Sera. (n = 3, standard 
deviation of technical replicates).	 (A to C) Pre-immume ELISA results. Nunc maxi-sorp plates
(Product code: 10098860, Fisher Scientific, UK) were coated with 2 μg/mL of peptide 
antigens. The tested anti-sera were serial diluted and detected with 1:25,000 donkey anti-
sheep antibody conjugated to alkaline phosphatase (Product code: A5187), and 1 mg/mL 
phosphate substrate in pNPP buffer, pH 10.4, with an incubation time of 15 minutes at room 
temperature before being read on a plate reader at 405 nm.  
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Figure 4.10: Determining Anti-STSYGTGC Anti-Sera Series Optimal Dilution. (n = 3, 
standard deviation of technical replicates).	 (A to C) 1 month ELISA results. Nunc maxi-sorp
plates (Product code: 10098860, Fisher Scientific, UK) were coated with 2 μg/mL of peptide 
antigens.  The tested anti-sera were serial diluted and detected with 1:25,000 donkey anti-
sheep antibody conjugated to alkaline phosphatase (Product code: A5187), and 1 mg/mL 
phosphate substrate in pNPP buffer, pH 10.4, with an incubation time of 15 minutes at room 
temperature before being read on a plate reader at 405 nm.  
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4.11 Monthly Antibody Titre Profile of Anti-STSYGTGC Sera Series 
With the success of the previous anti-sera production, one sheep for each peptide 
antigen was utilized during immunization. An ELISA of all respective months for 
each sheep, STSYGTGC, STSY-(NO2)-GTGC or STSY-(Cl)-GTGC immunized 
against all STSYGTGC peptide antigens was carried out (Figures 4.11A – 4.11C). 
The anti-STSYGTGC (Figure 4.11A) sera increased in antibody titre for the 
STSYGTGC peptide after immunization, and then plateaued (Figures 4.11A).  The 
anti-STSYGTGC sera also showed cross reactivity for the other STSYGTGC 
peptides, which was not surprising as the polyclonal sera is expected to contain 
antibodies for multiple epitopes of the peptide, both including and excluding the 
modification site. A similar result was seen for anti- STSY - (NO2)-GTGC sera 
(Figure 4.9B), with an increase in binding to the corresponding peptide antigen after 
immunization, but with greater binding to the STSY-(Cl)-GTGC peptide, and little 
binding to the native STSYGTGC peptide. The anti-STSY-(Cl)-GTGC sera (Figure 
4.11C) showed an increase in binding to the corresponding peptide antigen and 
again with cross reactivity to other peptides, with slightly more binding to the 
modified peptide antigens.  
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Figure 4.11: Changes in Anti-Sera Antibody Titre Over Time. (n = 3, standard deviation 
of technical replicates).	 Nunc maxi-sorp plates (Product code: 10098860, Fisher Scientific,
UK) were coated with 2 μg/mL of peptide antigens. The primary anti-sera were diluted to 
1:2000.  The tested anti-sera were detected with 1:25,000 donkey anti-sheep antibody 
conjugated to alkaline phosphatase (Product code: A5187), and 1 mg/mL phosphate 
substrate in pNPP buffer, pH 10.4, with an incubation time of 15 minutes at room 
temperature before being read on a plate reader at 405 nm.  
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4.12 Reducing Anti-STSYGTGC Sera Series Cross-Reactivity 
The anti- STSYGTGC sera series showed some degree of cross reactivity to similar 
antigens, and in order to attempt to reduce the cross reactivity, affinity purification 
was performed, as described previously for DYEDQQKQLC series of sera (Section 
4.5). Affinity purification results for all STSYGTGC sera were produced (Appendix 
29 and 30), for illustrative purposes the results for sheep STSY-(NO2)-GTGC serum 
purification are shown (Figures 4.12A and 4.12B). Enrichment, described as 
purification, for STSY-(NO2)-GTGC specific antibodies, involved binding the STSY-
(NO2)-GTGC synthetic peptide to silica beads via the cysteine residue. The anti-
serum was then passed through the STSY-(NO2)-GTGC column with PBS to 
exclude non-specific antibodies (Figure 4.12A), and the fraction collected. Sodium 
chloride was then used to remove non-specific binding fractions. The pH was 
lowered with glycine (pH 2.7) (shown in Figure 4.12A) and the column bound 
antibody fraction eluted for collection. The described PBS eluted fraction, now 
enriched for STSY-(NO2)-GTGC antibodies, was then passed through another 
column containing beads conjugated with the STSY-(Cl)-GTGC peptide with PBS 
(Figure 4.12B). This PBS eluted fraction (Shown in figure 4.12B) is now excluded of 
STSY-(Cl)-GTGC binding fractions, both the PBS and glycine eluted fractions were 
collected for testing. The results in Figure 4.13 shows the difference in binding 
specificity of the STSY-(NO2)-GTGC anti-serum before (Pre-Cl-Y column pass 
serum) and after (Post-Cl-Y column pass serum) exclusion of STSY-(Cl)-GTGC 
peptide binding fraction. Figure 4.13 result shows how the original serum cross-
reacts, and binds STSY-(Cl)-GTGC, and that after passing the serum through the 
column bound with the STSY-(Cl)-GTGC peptide, although binding to STS-(NO2)-
GTGC is slightly reduced, cross reactivity is abolished. The affinity purified (AP) 
collected STSY-(NO2)-GTGC fraction is now referred to as AP STS -(NO2)-GTGC.   
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Figure 4.12: Affinity Purification Results For STSY - (NO2)- GTGC. (UV λ = 280 nm). 
STSY-(NO2)-GTGC peptide (A) and STSY-(Cl)-GTGC (B) was bound to iodoacetyl gel 
beads via the cysteine residues (Product no. 53155, Thermo Scientific, UK), and unbound 
binding sites were blocked with 50 mM cysteine. Utilizing an AKTA Purifier (GE Healthcare) 
sera was passed through columns at a flow rate not exceeding 1 mL/ min at room 
temperature with PBS (pH 7.4), and fractions collected. Columns were washed with 1 M 
NaCl (pH 7) to remove any non-specific bound material, the fraction collected. Finally, 0.1 M 
glycine (pH 2.7) was used to elute column bound fractions (A and B). The protein 
concentration was measured at UV wavelength 280 nm, and the NaCl concentration via 
conductance.  
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Figure 4.13: Binding Comparison of Serum Fractions Before and After Purification.    
(n = 3, standard deviation of technical replicates) Nunc maxi-sorp plates (Product code: 
10098860, Fisher Scientific, UK) were coated with 2 μg/mL of peptide antigens. The primary 
anti-sera were diluted to 1:2000.  The tested anti-sera were detected with 1:25,000 donkey 
anti-sheep antibody conjugated to alkaline phosphatase (Product code: A5187), and 1 
mg/mL phosphate substrate in pNPP buffer, pH 10.4, with an incubation time of 15 minutes 
at room temperature before being read on a plate reader at 405 nm. 
From looking at figure 4.14A, AP STSY-(NO2)-GTGC shows reduced cross-
reactivity, no longer binding to STSY-(Cl)-GTGC or the native STSYGTGC peptide. 
The serum does however show strong cross reactivity to the DY-(NO2)-EDQKQQLC 
peptide. In order to determine whether cross reactivity was specific to the DY-(NO2)-
EDQKQQLC, 3-nitrotyrosine containing peptide, or to the 3-nitrotyrosine modified 
residue in general, another ELISA of multiple 3-nitrotyrosine containing peptides 
with different amino acid sequences was performed. It can be seen that binding to 
the DY-(NO2)-EDQKQQLC peptide and a model 3-nitrotyrsosine-containing peptide 
(SY-(NO2)-ASY-(NO2)-SYC) occurred with similar affinity (4.14B). The AP antiserum 
was further tested against whole fibrinogen treated with a range of SIN-1 
concentrations, and it can be seen that there was a concentration-dependent 
increase in binding, with no significant binding to the native protein (Figure 4.14C). 
The binding to fibrinogen treated with different HOCl concentrations appeared to be 
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weak, and there was no evidence of a concentration-dependent effect for this 
modification (Figure 4.14D). 
Figure 4.14: Comparing the Binding of AP Anti- STSY - (NO2)- GTGC Serum to Peptide 
and Protein Antigens. (n = 3, standard deviation of technical replicates).  Peptide antigens 
(A and B) were coated onto Nunc maxi-sorp plates (Product code: 10098860, Fisher 
Scientific, UK) at 2 μg/mL. The proteins described in C and D were treated with either (C) 
SIN-1 or (D) HOCl for 1 hour at 37°C before being coated onto Nunc maxi-sorp plates in 
molar equivalent amounts to the peptide antigens.  The primary anti-serum was made to 1.5 
μg/mL. The tested anti-sera were detected with 1:25,000 donkey anti-sheep antibody 
conjugated to alkaline phosphatase (Product code: A5187), and 1 mg/mL phosphate 
substrate in pNPP buffer, pH 10.4, with an incubation time of 15 minutes at room 
temperature before being read on a plate reader at 405 nm. 
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4.13 AP Anti- STSY-(NO2)-GTGC Serum Vs. Other Plasma Proteins 
The most abundant plasma proteins are haemoglobin, human serum albumin 
(HSA), fibrinogen and transferrin (Anderson and Anderson, 2002). Human serum 
albumin contains 585 amino acid residues, 18 of which are tyrosine (3%) (Meloun et 
al.,1975). Transferrin is made up of 678 amino acids, of which 24 are tyrosine 
(3.5%) (MacGillivray et al., 1982). Haemoglobin is made up of 574 amino acids and 
a varying number of tyrosine residues, the average being 2.8 residues (Hill et al., 
1962). The UniProt database amino acid sequences for human haemoglobin (Entry 
code: P68871, P69905 and P69892), human serum albumin (HSA) (Entry code: 
P02768) and human transferrin (Entry code: P02787) were manually selected and a 
Blast search comparison made. None of the mentioned proteins shared similar 
amino acid sequences, or any sequence similar to STSYGTGC.  
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Figure 4.15: Comparing the Binding of AP STSYGTGC Sera and Anti - 3-nitrotyrosine to 
Plasma Proteins. (n = 3, standard deviation of technical replicates). The proteins described in A 
to D were treated with SIN-1 for 1 hour at 37°C before being coated onto Nunc maxi-sorp plates 
(Product code: 10098860, Fisher Scientific, UK) in molar equivalent amounts to STSY-(NO2)-
GTGC 2 μg/mL of peptide antigens. The purified primary serum was made to 1.5 μg / mL. Anti-3-
nitrotyrosine antibody (N0409) was used at a working dilution of 1:1000. The tested anti-sera 
were detected with 1:25,000 donkey anti-sheep antibody conjugated to alkaline phosphatase 
(Product code: A5187), and 1 mg/mL phosphate substrate (S0942) in pNPP buffer, pH 10.4, with 
an incubation time of 15 minutes at room temperature before being read on a plate reader at 405 
nm. 
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The AP STSY-(NO2)-GTGC anti-serum does not show binding to native forms of 
haemoglobin, HSA and transferrin. However, it does show binding to nitrated 
versions of all three of the proteins (Figures 4.15A - 4.15C) to varying degrees. This 
could be explained by the polyclonal nature of the anti-serum showing antibodies 
binding to 3-nitrotyrosine. Although affinity purification removed some of the cross 
reactivity, previous figures support the idea that the serum contains antibodies 
directed to 3-nitrotyrosine- containing antigens. The native serum (STSYGTGC) 
shows no binding to any of the haemoglobin preparations (Figure 4.15A), whereas 
the STSY-(NO2)-GTGC serum shows a concentration dependent increase in binding 
to nitrated haemoglobin (Figure 4.15A). A similar trend is seen for HSA (Figure 
4.15B), with no binding of the native anti-STSYGTGC serum to any of the antigens, 
and a concentration dependent increase in binding to nitrated HSA. A commercial 
anti-3-nitrotyrosine (N0409) showed greater binding than AP anti- STSY-(NO2)-
GTGC serum, which may suggest that the anti-serum contained antibodies selective 
for both 3-nitrotyrosine and STSY-(NO2)-GTGC.	 A similar level of binding of AP 
STSY-(NO2)-GTGC and 3-nitrotyrosine to nitrated transferrin was seen as for 
haemoglobin, and again no binding of the native anti-serum to any of the antigens 
(Figure 4.15C).  
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Figure 4.16: Identifying Experimental Variability and Binding Trends of AP STSY-(NO2)–GTGC Serum. (n = 3, error bars represent standard deviation of 
experimental replicates). (ns = P > 0.05, *** = P ≤ 0.001 and **** = P ≤ 0.0001). Synthesised peptide antigens were coated onto Nunc maxi-sorp plates (Product code: 
10098860, Fisher Scientific, UK) at 2 μg/ mL. The proteins treated with either SIN-1 or HOCl for 1 hour at 37°C before being coated onto Nunc maxi-sorp plates in molar 
equivalent amounts to the peptide antigens.  The primary anti-serum was made to 1.5 μg/mL. The tested anti-sera were detected with 1:25,000 donkey anti-sheep 
antibody conjugated to alkaline phosphatase (Product code: A5187), and 1 mg/mL phosphate substrate in pNPP buffer, pH 10.4, with an incubation time of 15 minutes at 
room temperature before being read on a plate reader at 405 nm. 
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4.14 Experimental Variability of AP STSY-(NO2) –GTGC Serum 
A lot of variability can be seen in the values for anti-sera binding between ELISA 
plates when comparing figures 4.11 to 4.14. In order to make true comparisons 
between antigens under exactly identical conditions, three independent ELISA 
plates with all antigens on the same plate were set up (Figure 4.16). These 
experimental replicates were performed on different days with new reagents, 
between two different operators to allow experimental variability to be determined. 
The variability was determined by expressing the coefficient of variation (CV) of 
each antigen. Expressing the CV of values close to zero provides unreliable results, 
and for this reason only antigens with an absorbance of greater than 0.100 are 
considered (Gulhar et al., 2012). The CV values for the nitrated peptide antigens 
(Figure 4.16) had an average CV of 15%, and the nitrated fibrinogen 25%, 
suggesting a moderate amount of variability between experiments. It is worth noting 
that as the signal reduces and approaches zero, the values for CV will increase. The 
reduction in signal seen between anti-STSYGTGC sera series ELISA experiments 
corresponds to the age of the sera. This is most likely due to protein degradation 
due to storage at 2-4 °C, and potentially the presence of plasma proteases. In 
summary, the STSY-NO2 –GTGC anti- serum showed exclusive binding to antigens 
containing 3-nitrotyrosine, with a concentration dependent increase in binding to 
nitrated whole fibrinogen, and no binding exceeding basal to other antigens (Figure 
4.16).  
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4.15 Testing the Specificity of AP STSY-(Cl)- GTGC Serum 
Although STSY-(Cl)-GTGC was not identified in HOCl-treated fibrinogen by MS, as 
this peptide has been shown to be susceptible to nitration it is possible the same 
site may be susceptible to chlorination also, and for this reason anti-serum was 
produced against this peptide. The affinity purified anti- STSY-(Cl)-GTGC serum, as 
described previously, was produced and affinity purified (enriched) in the same way 
as the AP anti- STSY-(NO2)-GTGC serum. The serum was tested against various 
peptide antigens, and showed cross reactivity for all versions of the STSYGTGC 
peptide (Figure 4.17A). The AP-STSY-(Cl)-GTGC serum was tested against various 
3-chlorotyrosine containing peptides, and showed no more than basal cross
reactivity to any of the other 3-chlorotyrosine-containing samples/preparations 
(Figure 4.17B). When tested against nitrated fibrinogen, substantial cross reactivity 
was seen (Figure 4.17C). The lack of binding to the native protein, and binding to 
SIN-1 treated fibrinogen might suggest that nitration caused conformational changes 
to the protein, exposing the STSYGTGC peptide for binding. Similarly, the anti-
serum for STSY-(Cl)-GTGC showed no specificity to native fibrinogen, but instead 
bound to the HOCl-treated protein, with a concentration-dependent trend (Figure 
4.17D). Reduced binding was seen at the higher HOCl concentrations (Figure 
4.17D), which could be due to aggregation induced by the HOCl treatment. AP 
STSY-(Cl)-GTGC serum was also tested against other abundant plasma proteins, 
haemoglobin, HSA and transferrin, and subsequently showed no binding to any of 
the respective chlorinated or nitrated plasma proteins (See appendix 28).  
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Figure 4.17: Binding of AP STSY-(Cl)-GTGC Serum to Peptide and Protein Antigens. 
(n = 3, standard deviation of technical replicates). Peptide antigens (A and B) were coated 
onto Nunc maxi-sorp plates (Product code: 10098860, Fisher Scientific, UK) at 2 μg/mL. The 
proteins described in C and D were treated with either (C) SIN-1 or (D) HOCl for 1 hour at 
37°C before being coated onto Nunc maxi-sorp plates in molar equivalent amounts to the 
peptide antigens.  The primary anti-serum was made to 1.5 μg/mL. The tested anti-sera 
were detected with 1:25,000 donkey anti-sheep antibody conjugated to alkaline phosphatase 
(Product code: A5187), and 1 mg/mL phosphate substrate in pNPP buffer, pH 10.4, with an 
incubation time of 15 minutes at room temperature before being read on a plate reader at 
405 nm.
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4.16 Experimental Variability of AP STSY-Cl –GTGC Anti-Serum 
Similar experiments to those carried out for anti- STSY AP STSY-(NO2)-GTGC 
serum in Section 4.14. These experimental replicates were performed on different 
days, with new reagents, and between two different operators. The variability was 
determined by expressing the coefficient of variation (CV) of each antigen (n = 3). 
Expressing the CV of values close to zero provides unreliable results, and for this 
reason only antigens with an absorbance of greater than 0.100 were considered 
(Gulhar et al., 2012).  The average CV for the peptide antigens showing above 
basal binding was 4.6%, and for treated whole fibrinogen 3.4%, suggesting a small 
amount of variability between experiments. Experimental work comparing variability 
also showed that AP STSY-(Cl)-GTGC serum displayed some cross reactivity for 
the 3-chlorotyrosine containing peptide, SY-(Cl)-ASY-(Cl)-SY-(Cl)-C (Figure 4.18). It 
also showed a small amount of binding to nitrated fibrinogen, a concentration 
dependent increase in binding to chlorinated fibrinogen, and a lot of cross reactivity 
to the STSYGTGC series peptides. As previously mentioned with AP anti- STSY-
(NO2)-GTGC serum (Section 4.14), a reduction in signal was seen across 
experiments, which could possibly be attributed to protease dependent antibody 
degradation throughout prolonged storage at 2-4°C.   
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Figure 4.18: Identifying Experimental Variability and Binding Trends of AP STSY-Cl–GTGC Serum. (n = 3, error bars represent standard deviation of experimental 
replicates). (ns = P > 0.05, *** = P ≤ 0.001 and **** = P ≤ 0.0001).Synthesised peptide antigens were coated onto Nunc maxi-sorp plates (Product code: 10098860, Fisher 
Scientific, UK) at 2 μg/mL. The proteins treated with either SIN-1 or HOCl for 1 hour at 37°C before being coated onto Nunc maxi-sorp plates in molar equivalent amounts 
to the peptide antigens.  The primary anti-serum was made to 1.5 μg/mL. The tested anti-sera were detected with 1:25,000 donkey anti-sheep antibody conjugated to 
alkaline phosphatase (Product code: A5187), and 1 mg/mL phosphate substrate in pNPP buffer, pH 10.4, with an incubation time of 15 minutes at room temperature 
before being read on a plate reader at 405 nm. 
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4.17 Testing the Specificity of AP STSYGTGC Serum 
AP anti- STSYGTGC Serum was tested against native, chlorinated and nitrated 
STSYGTGC peptides, and another peptide with a different amino acid sequence 
(Figure 4.19A). The serum showed binding specificity for all of the STSYGTGC 
peptides, and no binding exceeding basal level for the DYEDQQKQLC peptide 
series (Figure 4.19A). Because the serum showed affinity for both the nitrated and 
chlorinated versions of the STSYGTGC peptide, and no binding to native 
DYEDQQKQLC, further testing against other modified peptides was performed 
(Figure 4.19B). The serum showed no specificity towards peptides with different 
sequences, both native and modified. The purified serum showed a low level of 
binding to both nitrated and chlorinated fibrinogen protein (Figures 4.19C – 4.19D). 
This binding increased with chlorination and nitration treatment, which may relate to 
conformational changes in the protein encouraged by chlorination/nitration making 
the peptide more readily accessible (Figures 4.19C – 4.19D). At the higher HOCl 
treatment concentrations (Figure 4.19D) there was an abrupt decrease in binding, 
which may be due to protein aggregation blocking antibody binding. The binding of 
this anti-serum the other abundant plasma proteins, haemoglobin, HSA and 
transferrin was tested, and no binding was shown (Appendix 27).   
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				Figure 4.19: Binding of AP STSYGTGC Serum to Peptide and Protein Antigens. (n = 3, 
standard deviation of technical replicates). Peptide antigens (A and B) were coated onto 
Nunc maxi-sorp plates (Product code: 10098860, Fisher Scientific, UK) at 2 μg/mL. The 
proteins described in C and D were treated with either (C) SIN-1 (ONOO-) or (D) NaOCl 
(HOCl) for 1 hour at 37°C before being coated onto Nunc maxi-sorp plates in molar 
equivalent amounts to the peptide antigens.  The primary anti-serum was made to 1.5 
μg/mL. The tested anti-sera were detected with 1:25,000 donkey anti-sheep antibody 
conjugated to alkaline phosphatase (Product code: A5187), and 1 mg/mL phosphate 
substrate in pNPP buffer, pH 10.4, with an incubation time of 15 minutes at room 
temperature before being read on a plate reader at 405 nm. 
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4.18 Experimental Variability of AP STSYGTGC Serum 
Similar to the previously discussed sections looking at inter-experimental variability 
(Sections 4.14 and 4.16), this section looks at the experimental variability seen 
between the day-to-day experiments, users and reagents. In an attempt to make 
trend cross comparisons, three independent ELISA plates with all antigens on the 
same plate were set up (Figure 4.20). As before, experimental replicates were 
performed on different days with new reagents, between two different operators. 
Cross reactivity was shown between native and modified versions of STSYGTGC 
peptides. And, once again, a small amount of binding to nitrated and chlorinated 
fibrinogen was seen, which could have implications in relation to the conformational 
changes seen to fibrinogen after such oxidative treatments, and the accessibility of 
antibodies for binding. The variability was determined by expressing the coefficient 
of variation (CV) of each antigen (n = 3). Expressing the CV of values close to zero 
provides unreliable results, and for this reason only antigens with an absorbance of 
greater than 0.100 were considered (Gulhar et al., 2012). The average CV for the 
STSYGTGC peptide antigens showing above basal binding is 17.8 %, and for 
treated whole fibrinogen it was 33.2%.  The general trend between the three anti-
sera for chlorinated and nitrated fibrinogen is high variability. This could potentially 
be explained by inaccurate CV values, based on low absorbance values.  
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Figure 4.20: Identifying Experimental Variability and Binding Trends of AP STSYGTGC Serum. (For all n = 3). Synthesised peptide antigens were coated onto 
Nunc maxi-sorp plates (Product code: 10098860, Fisher Scientific, UK) at 2 μg/mL. The proteins treated with either SIN-1 or HOCl for 1 hour at 37°C before being 
coated onto Nunc maxi-sorp plates in molar equivalent amounts to the peptide antigens.  The primary anti-serum was made to 1.5 μg/mL. The tested anti-sera were 
detected with 1:25,000 donkey anti-sheep antibody conjugated to alkaline phosphatase (Product code: A5187), and 1 mg/mL phosphate substrate in pNPP buffer, 
pH 10.4, with an incubation time of 15 minutes at room temperature before being read on a plate reader at 405 nm. 
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4.19 Discussion of Chapter 4 Results 
The aim of this part of the study was to produce anti-sera containing antibodies 
which bind exclusively the modified peptides identified in the literature and by MS in 
chapter 3. The hypothesis was that antibodies can be produced to differentiate 
between modified and unmodified fibrinogen peptides with sequence context, 
binding exclusively to the specific modified peptide against which they were 
produced. 
4.19.1 DYEDQQKQLC Series of Anti-Sera 
The study described in this chapter attempted to identify if specific antibodies to 
modified protein antigens could be produced, with both modification site and amino 
acid sequence specificity. As a preliminary study the literature identified fibrinogen 
peptide, 196DYEDQQKQL204, and a chlorinated version DY-(Cl)-EDQQKQL was 
synthesized with the addition of a cysteine residue at the c-terminus preceding 
lysine, and immunized into sheep. The anti-sera against DYEDQQKQLC and DY-
(Cl)-EDQQKQLC showed a month-by-month, time-dependent, increase in 
antibodies for their respective antigens, with a decrease in binding at the much 
lower dilutions of the sera. This is most likely explained by the prozone 
phenomenon/hook effect, whereby the antibody titre is so high that it interferes with 
the antibody-antigen binding capability, due to agglutination (Sidana et al., 2011). 
The crude anti-sera showed cross reactivity for the native and chlorinated versions 
of the peptides. Which is most likely due to the polyclonal nature of the anti-sera, 
made up of antibodies for various epitopes of the respective antigens, both including 
and not including the modification site. A cysteine residue was included in the 
sequence of synthesized peptides in order to allow immunization and purification 
steps. The overall increase in binding of anti-sera to cysteine-containing sequences 
might relate to the inclusion of cysteine within some of the respective 
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complementary antibodies paratope to epitope complexes, meaning absence of this 
residue might preclude some antibodies in the anti-serum from binding to the 
peptide. During affinity purification (affinity enrichment) to remove cross-reactivity, a 
moderate peak for protein content was shown after the pH was changed to elute 
anti- DY-(Cl)-EDQQKQLC antibodies from the DY-(Cl)-EDQQKQLC peptide bound 
column, suggesting successful collection of the fraction. The second purification of 
anti- DYEDQQKQLC serum, provided similar results, suggesting that the anti- 
DYEDQQKQLC antibodies were removed from the fraction.   After this purification 
step, the anti-serum from sheep 4 no longer showed binding to the native peptide, 
suggesting the purification steps were successful. The serum from sheep 3 did 
show a substantial reduction in cross reactivity, with some remaining cross-reactivity 
for the native peptide. However, there was some remaining cross-reactivity between 
chlorinated and nitrated versions of anti- DYEDQQKQLC serum. The specificity of 
the produced antibodies depends on a number of factors, including amino acid 
sequence, conformation and electrostatic charges. The binding of an antibody 
paratope to antigen epitope can be by a combination of ionic, hydrogen and van der 
Waals bonding forces. This bonding involves just few amino acids on the paratope. 
The overall binding strength and specificity is dependent on the conformational fit 
and van der Waals forces (Reverberi and Reverberi, 2007). Peptide antigens are 
known to, for the most part, bind in the cleft between the V regions of the heavy and 
light chains of an antibody, where they make specific contact with some, but not 
necessarily all, of the hypervariable loops that make up the paratope (Charles et al., 
2001). In order to compare the conformational differences between each version of 
the DYEDQQKQLC peptides Marvin sketch version 6.1.7 
(http://www.chemaxon.com) was used to determine the peptides shape, and the 
position of each of the potentially influencing atoms.  
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Figure 4.21: Comparing Conformational Changes Between Modified and Unmodified 
Versions of DYEDQQKQLC. (A) Polar structure of DYEDQQKQLC, (B) Polar structure of 
DY-(Cl)-EDQQKQLC and (C) Polar structure of DY-(NO2)-EDQQKQLC. Chemical structure 
drawing software Marvin Sketch was used to show the hydrophobic interactions and 
conformation of the different versions of the DYEDQQKQLC peptide. The grey balls 
represent carbon atoms, the blue nitrogen, the red hydrogen and the orange chlorine. Marvin 
Sketch 6.1.7, 2014, ChemAxon, (http://www.chemaxon.com).   
A	
DYEDQQKQLC	Polar	Structure	
B	
C	
DY-(Cl)-EDQQKQLC	Polar	Structure	
DY-(NO2)-EDQQKQLC	Polar	Structure	
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Figures 4.21A - 4.21C show similarities in conformation, but also the highlighted 
areas show some differences in both conformation and the available hydrogen 
bonding atoms around the epitope between the native peptide (A), the chlorinated 
(B) and nitrated (C) tyrosine residues. Although peptides are linear epitopes,
whereby the specificity is determined by the sequence of amino acids, maybe it is 
possible that the peptide conformation plays a role in specificity, whereby 
discontinuous amino acid sections make up the antigen. The 3-chlorotyrosine 
containing peptide (Figure 4.21B) shows a protruding tyrosine residue with a 
chlorine atom, which could make the peptide more accessible for antibody binding. 
The 3-nitrotyrosine containing peptide (Figure 4.21B) also shows more polar atoms 
in the epitope region, but with a similar less protruding conformation to the native 
peptide (Figure 4.21A). It is worth noting that transferrin and HSA are negative acute 
phase proteins, decreasing in plasma concentration during inflammation, whereas, 
fibrinogen is a positive acute phase protein, shown to increase in concentration 
during inflammation (Ritchie et al., 1999 and, Page and Schroeder, 1976). None of 
the anti- DYEDQQKQLC series sera showed substantial binding to haemoglobin, 
transferrin, HSA or fibrinogen plasma proteins.  
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The peptide 196DYEDQQKQL204 is a fibrinogen-derived peptide, identified by MS 
chapter 3 as unmodified. The produced AP anti-DY-(Cl)-EDQQKQLC serum 
showed no binding to chlorinated fibrinogen or native fibrinogen. In order to better 
understand why, the crystal structure was examined (Figure 4.22). The tertiary 
structure and hydrophobic interactions of fibrinogen show the DYEDQQKQL 
tyrosine residue to be buried, and not surface exposed, suggesting it to not be 
susceptible to oxidative modification. This agrees with the protein analysis results 
reported in Chapter 3, section 3.9, which demonstrates a lack of susceptibility to 
modification, as only the native peptide was identified. In conclusion, the anti-serum 
to DY-(Cl)-EDQQKQLC appears to show sequence specificity, only binding to 
peptide sequences with the same amino acid motif with a modification. However, 
the anti-serum to DY-(Cl)-EDQQKQLC shows cross-reactivity with DY-(NO2)-
EDQQKQLC, suggesting an inability to differentiate between the 3-cholorotyrosine 
and 3-nitrotyrosine modifications. Future work to produce and test for a specifically 
selective monoclonal antibody might potentially allow this problem to be resolved.    
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Figure 4.22: Understanding Why AP DY-(Cl)-EDQQKQLC Shows no Binding to Treated 
or Native Fibrinogen. Chimera software, version 1.9, 2014, with the crystal structure 
obtained from the Protein Data Bank (http://www.rcsb.org/pdb/home/home.do). The protein 
hydrophobic interactions are shown (tertiary structure). The DYEDQQKQLC sequence was 
highlighted in green and the tyrosine in yellow.  
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4.19.2 STSYGTGC Series of Anti-Sera 
Similarly, the MS identified peptide STSYGTG was synthesized, both a native 
chlorinated and nitrated version, with an added cysteine residue to allow 
immunization and purification steps. The anti-serum for STSYGTGC, STSY-(NO2)-
GTGC and STSY-(Cl)-GTGC showed no binding in the pre-immune sera, and an 
abrupt increase in anti-sera binding for their respective antigens after the first month 
peptides were immunized into sheep. The expected trend of a month-by-month 
linear increase in antibody-titre is not seen. Instead, some variability in the antibody-
titre is apparent, with a general plateau after immunization. This does not correlate 
to the trend seen with anti- DYEDQQKQLC series sera, with a roughly linear 
increase in binding month-by-month. This might be explained by the differences 
sera production, more specifically, the sheep used and or methodology, as the two 
series of sera were produced by different suppliers. Some cross reactivity between 
STSYGTGC anti-serum and modified versions of the peptide was seen. The anti-
serum complementary to the 3-chlorotyrosine peptide (STSY-(Cl)-GTGC) shows a 
similar pattern in cross-reactivity for all versions of the peptide as the native serum, 
suggesting anti-sera are also specific for epitopes that do not include the 
modification site. In contrast, anti- STSY-(NO2)-GTGC anti-serum appeared to be 
specific to modified versions of the peptide, not binding the native, but cross 
reacting to the chlorinated peptide. The binding complex between the paratope and 
epitope is dependent on several electrostatic Coulomb forces, previously described, 
and as such it possible that some antibodies are unable to discriminate between 
similar 3-chlorotyrosine and 3-nitrotyrsoine containing peptides. Another possibility 
is that some of the antibodies in the anti-sera are produced against conformational 
epitopes, rather than linear (sequential) epitopes, and are unable to differentiate 
between the 3-chlorotyorsine and 3-nitrotyrsoine containing peptides.  
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In order to further investigate this, the polar structures of the STSYGTGC series 
peptides were investigated (Figure 4.23). There are clear conformational differences 
between the (A) native, (B) chlorinated and (C) nitrated versions of the STSYGTGC 
peptide, more specifically between the modified and native versions. This supports 
the possibility that some of the differences in specificity of the STSYGTGC series 
anti-sera are dependent on conformational epitopes, whereas others are peptide 
motif specific. This is further supported by a study performed by Forsström et al. 
(2015), where the study showed that although most polyclonal sera for peptide 
antigens are for linear epitopes, a fraction are also complementary to conformational 
epitopes.  
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Figure 4.23: Comparing Conformational Changes Between Modified and Unmodified 
Versions of STSYGTGC. Chemical structure drawing software Marvin Sketch was used to 
show the hydrophobic interactions and conformation of the different versions of the 
STSYGTGC peptide. The grey balls represent carbon atoms, the blue nitrogen, the red 
hydrogen and the orange chlorine., Marvin Sketch 6.1.7, 2014, ChemAxon, 
(http://www.chemaxon.com).   
A	
STSYGTGC	Polar	Structure		
B	
C	
STSY-(Cl)-GTGC	Polar	Structure		
STSY-(NO2)-GTGC	Polar	Structure		
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Affinity purification abolished the cross reactivity for the chlorinated peptide, 
however, some cross-reactivity to other 3-nitrotyosine containing peptide and 
protein antigens were seen. This cross-reactivity is most likely explained by the 
polyclonal nature of the anti-sera, made up of different antibodies for various 
epitopes of the respective antigens, both including and not including the modification 
site. More specifically, the anti-serum may include antibodies specific for just 3-
nitrotyrosine. The affinity purification process is not able to remove cross-reactivity 
to 3-nitrotyrosine, as the peptide epitope also contains 3-nitrotyrosine. In order to 
further check the cross reactivity and determine the involvement of 3-nitrotyorisne 
specific antibodies, the anti-serum was also tested against the other abundant 
plasma proteins, haemoglobin, HSA and transferrin. There was no binding of the 
antiserum to native versions of the proteins, suggesting anti-serum to be somewhat 
sequence specific. However, binding to nitrated versions of the proteins supports 
the presence of 3-nitrotyrosine specific antibodies in the polyclonal serum. 
Noteworthy, is that the number of tyrosine residues in each of the mentioned 
proteins does not correspond to the level of binding from the 3-nitrotyrosine and 
STSY-(NO2)-GTGC antibodies/anti-serums. The higher level of binding of to nitrated 
HSA compared to the other plasma proteins, haemoglobin and transferrin was 
further investigated by comparing the crystal structures (Figure 4.24). The tyrosine 
residues of HSA, haemoglobin and transferrin are shown in figures 4.24A - 4.24C, 
highlighted in yellow.  
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Figure 4.24: Understanding the Level of 3-nitrotyrosine Specific Anti-Sera Binding to 
Plasma Proteins. The crystal structures of human serum albumin (HSA) (A), haemoglobin 
(B) and transferrin (C) were determined using Chimera software, version 1.9, 2014, with the
crystal structure obtained from the Protein Data Bank 
(http://www.rcsb.org/pdb/home/home.do). The protein hydrophobic interactions are shown 
(tertiary structure). The tyrosine residues were highlighted in yellow to show the number of 
surface exposed and hence susceptible residues. 
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Figures 4.24A to 4.24C, shows that HSA (A) has more surface exposed, readily 
accessible, tyrosine residues than haemoglobin (B) and transferrin (B), which, have 
a similar number of tyrosine residues to one another. Explaining the differences in 3-
nitrotyrosine specific anti- STSY-(NO2)-GTGC binding, and because the antigens 
are coated onto ELISA plates in molar equivalents, the binding levels are 
reasonably comparable. The high level of binding of anti-3-nitrotyrosine to nitrated 
HSA, compared to the modest binding of AP anti-STSY-(NO2)-GTGC serum 
suggests, when you consider the high level of binding to the STSY-(NO2)-GTGC its 
positive peptide control, may reflect that the serum not only contains 3-nitrotyrosine 
antibodies, but also STSY-(NO2)-GTGC sequence specific antibodies, and most 
likely some unrelated antibodies also. The AP STSY-(Cl)-GTGC serum showed a 
large amount of cross reactivity to the other STSYGTGC series peptides, and a 
small amount of reactivity to 3-chlorotyrosine and 3-nitrotyrosine containing 
peptides. The polyclonal nature of the serum means it is likely to contain antibodies 
complementary to various regions of the peptide antigen, and some of the peptide 
sequences not only contain 3-chlorotyrosine, but also share some of the same 
amino acid residues to STSYGTGC. The AP-STSY-(Cl)-GTGC serum also showed 
some binding to chlorinated and nitrated fibrinogen, but not native fibrinogen. This 
could potentially be explained by conformational changes induced by oxidation, 
nitration or chlorination, exposing an STSYGTG sequence epitope of fibrinogen to 
the surface, enabling anti-serum binding. The binding to chlorinated fibrinogen was 
shown to decrease at higher HOCl treatment concentrations, which could possibly 
be explained by HOCl induced protein aggregation (Pattison and Davies, 2001). 
After testing the binding of the AP STSY-(Cl)-GTGC serum with plasma proteins, 
haemoglobin, HSA and transferrin, the lack of binding suggests that the serum does 
not contain high levels of non-specific 3-chlorotyrosine antibodies. 
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4.20 Chapter 4 Conclusions 
A number of different peptides have been produced; including those identified in the 
literature as susceptible to modifications, by the MS studies described in chapter 3, 
and designed for testing purposes. These peptides have been used to test the 
various anti-sera produced (figure 4.25). More specifically, anti-sera has been 
produced that can discriminate between native and modified peptides, one of the 
two anti-sera is peptide sequence-specific (DY-(Cl)-EDQQKQLC), whereas, the 
other is modification-site specific (STSY-(NO2)-GTGC). Between the two sera there 
tends to be a lot of cross reactivity between modification sites. The main limitation of 
this study was firstly, the variability seen inter-experimentally, with regard to 
experiments being performed on different ELISA plates, providing large variation. 
And finally, due to the novel nature of this work, no experimental standards were 
available, and for this reason only the trends intra-experimentally could be 
considered. Further work is required to better understand and determine specificity 
of the mentioned anti-sera. This work shows some good potential in proving the 
hypothesis. However, further work and a more comprehensive statistical analysis 
are required to show accurate significance/ non- significance, and therefore support 
or refute the hypothesis. 
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Figure 4.25: Heatmap Overview of Total Anti-Sera Vs. Peptide/Protein Antigens. Results are from multiple ELISA plates performed within a few 
weeks of one another. Peptides were coated onto Nunc maxi-sorp plates (Product code: 10098860, Fisher Scientific, UK) at 2 μg/mL and proteins in 
molar equivalents. The purified primary serum was made to 1.5 μg / mL, crude 1:2000, detected with 1: 25,000 donkey anti-sheep antibody conjugated 
to alkaline phosphatase (Product code: A5187), the substrate was incubated for 15 minutes and read at 405 nm. Plotly graphing, version 1 
(https://plot.ly) was used to produce this heatmap. 
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4.21 Chapter 4 Future Work and Considerations 
With regard to future work, for all anti-sera, in order to understand better the binding 
specificity, monoclonal antibodies should be produced and tested. This will allow 
testing of the individual constituting antibodies, each with specificity to one particular 
epitope, with the possibility of identifying an antibody with exclusive specificity for 
both the modification site and the sequence within which it resides. This might also 
possibly allow for the exclusion of antibodies specific to just the modification site 
E.g.  3-nitrotyrosine. Another possible consideration would be epitope mapping, with
a peptide microarray, potentially allowing for a clear understanding of the epitope to 
paratope complex, and hence antibody specificity. Hydrogen-deuterium exchange 
MS was used in a study by Burkitt et al., 2010 to determine conformational protein 
changes to immunoglobulin G after methionine residues were oxidized to 
methionine sulfoxide. This approach has potential to determine oxidation induced 
conformational changes to the fibrinogen protein, with regard to epitope surface 
exposure and subsequent availability for binding with respective antibodies. In 
addition to binding specificity, the strength of the bond formed by intermolecular 
forces between the epitope and paratope are worth determining. A study performed 
by Englebienne et al., 1998 showed how surface plasmon resonance could be used 
to measure antibody-binding affinity in real time, under various conditions. This 
technique might be useful in investigating the binding affinity of the produced 
antibodies to various peptide and protein antigens (Englebienne et al., 1998). 
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Chapter 5 
Testing Translation into Clinical Samples 
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5.1 Introduction 
As mentioned in chapter 1, it is becoming increasingly apparent that a number of 
inflammatory diseases have an oxidative pathology, whereby the immune cells 
during respiratory burst produce biological oxidants, such as superoxide, to destroy 
pathogens (Guzik et al., 2003, Inoguchi et al., 2003 and Shacter, 2000). Exposure to 
biological oxidants can induce modifications to the amino acid residues that make 
up proteins, and these modifications can act as markers of inflammation. For 
example, the formation of 3-nitrotyrosine and 3-chlorotyrosine are considered 
indicative of oxidative damage during inflammation (Levine, 2002, Mann and 
Jensen, 2003 and Karve and Cheema et al., 2011). Fibrinogen is one of the most 
abundant plasma proteins, shown to be susceptible to oxidative modifications 
(Shacter et al., 1994), and as such, oxidative damage and modifications to 
fibrinogen offer potential as biomarkers of disease (Weigandt et al., 2012). As 
mentioned previously, fibrinogen was shown to be nitrated, specifically in various 
diseases, forming 3-nitrotyrosine modifications (Martinez et al., 2013, Parastatidis et 
al., 2008, and Gole et al., 2000) 
5.1.2 Understanding Protein and Peptide Biomarkers 
Protein and peptide biomarkers could be defined as proteins or peptides that are 
consistently modified or present at abnormal concentrations in specific conditions. A 
biomarker profile is similar, but made up of a combination of multiple protein or 
peptide biomarkers. These markers could be used to determine susceptibility and/or 
progression of disease, as well as the effect of a particular treatment on clinical 
outcomes (Mischak et al., 2010). Mischak et al. (2010) described the validity of a 
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biomarker as based on its ability to predict future clinical outcome. With this in mind, 
important factors to consider when working with protein markers in clinical samples 
include (i) sample size which provide appropriate statistical power, (ii) significant 
effect, (iii) standardization in the experimental design, (iv) continuity between 
investigators (Mischak et al., 2010).  
5.1.3 Pro-Inflammatory Markers 
There are several currently used markers of inflammation, including C-reactive 
protein (CRP). These markers include adhesion molecules, such as intercellular 
adhesion molecule-1 and selectins; cytokines, such as interleukin-1 and the tumor 
necrosis factor; and acute phase reactants, such as fibrinogen, serum amyloid-A 
protein and C-reactive protein. The pathology of cardiovascular disease (CVD) 
involves inflammation, and therefore these markers have sometimes been 
considered as more specific markers of CVD. Translation of which into a clinical 
setting was met with some limitations. The limitations included, standardization of 
assay measurement variability; independence of the markers from established risk 
factors, and as such direct association with CVD. A risk factor is associated with 
disease by its participation in the pathway that leads to the disease, whereas a risk 
marker is statistically associated with the disease, and might not be causally linked. 
The levels of the above-mentioned markers in CVD do not correlate directly with 
atherosclerosis, and are better considered as risk factors for CVD (markers of 
general inflammation), rather than as risk markers of the actual disease (Pearson et 
al., 2003). 
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5.1.4 C-reactive Protein as a Marker of Inflammation 
C-reactive protein (CRP) is an acute phase protein produced by hepatocytes and
adipocytes and regulated by pro-inflammatory cytokines. CRP is a well-established 
sensitive marker of systemic inflammation and tissue damage (Koenig et al., 1999). 
Normal blood concentrations of CRP can increase by 10,000-fold after the 
introduction of an inflammatory stimulus. Generally, the CRP level reflects the level 
of ongoing inflammation and/or tissue damage in a number of diseases, such as 
Crohn’s disease, rheumatoid arthritis, and systemic vasculitis (Jin et al., 2013, and 
Black et al., 2004).    
5.1.5 The Oxidative Pathology of Type II Diabetes 
The main pathophysiological feature of type II diabetes involves impaired insulin 
resistance (Féry and Paquot, 2010). Type II diabetes is an inflammatory disease, 
where inflammation is considered to be a primary cause of obesity-linked insulin 
resistance and hyperglycemia. One of the first indications of a link between obesity 
and inflammation was the identification of overexpression of the pro-inflammatory 
cytokine TNF-α in the adipose and muscle tissue of obese humans. In addition to 
this, obesity has also been characterized as having an accumulation of 
macrophages in the adipose tissue, which is likely to contribute to the production of 
pro-inflammatory mediators and the subsequent oxidative stress. In parallel, the 
increase in glucose delivery to adipose tissue is known to cause an excess 
production of superoxide in the mitochondria. As a result, this inflicts oxidative 
damage, and activates pro-inflammatory cytokines (Giacco and Brownlee, 2010, 
and Wellen and Hotamisligil, 2005).  
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5.1.6 Clinical Sample Biological Variability 
There are a number of variables that must be considered when analyzing clinical 
sample data for potential biomarkers of inflammatory disease. Firstly, biological 
variability, with regard to factors that may affect the proteome, such as other existing 
diseases, gender, age, lifestyle choices (e.g. alcohol consumption and exercise), 
circadian rhythms and food intake (Mischak et al., 2007).  
With regard to oxidative modifications to proteins, it is well established that protein 
oxidation is part of the pathology of a number of diseases, such as diabetes, 
atherosclerosis, rheumatoid arthritis, and neurodegenerative diseases such as 
Alzheimer’s (Griffiths, 2000). The free radical hypothesis of aging suggests a 
senescence-related loss of function due to the increasing and irreversible oxidative 
damage to biomolecules.  Commonly there is a two to threefold age-related 
increase in the abundance of oxidatively-damaged proteins, which is indicated by a 
loss of protein thiol groups, protein carbonylation, and a loss of catalytic activity of 
some enzymes in senescence (Sohal and Weindruch, 1996). A study performed by 
Knez et al. (2006) reported that intermittent bouts of exercise at 40-70% of VO2 max 
significantly reduced plasma malondialdehyde (MDA) levels, a marker of oxidative 
lipid damage, and oxidative stress. On the other hand, as the exercise intensity 
increased so did the levels of plasma MDA, and after prolonged exhaustive 
exercise, such as ultra-endurance exercise, the plasma MDA levels were shown to 
be very high (Knez et al., 2006). Illustrating the importance of understanding patient 
lifestyle choices when examining changes in biomolecules.  
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5.1.7 Chapter 5 Focus, Aims and Hypothesis 
This chapter focuses on testing the translation of anti-serum produced in chapter 4 
to detect the in-vitro modified fibrinogen peptide identified in chapter 3, in-vivo. The 
aim was to test whether anti-serum produced in chapter 4 could be used to detect 
STSY-(NO2)-GTG peptide in type 2 diabetic samples (Ethical consent shown in 
appendix 31). The hypothesis was that anti- STSY-(NO2)-GTGC serum could be 
used to detect the STSY-(NO2)-GTG peptide of fibrinogen in type 2 diabetic 
samples, with increased binding correlating to the increase in CRP level.  
5.1.8 Clinical Sample Ethical Consent and Approval Information 
The type 2 diabetes samples were provided by the Brown research group at Aston 
University. Samples were provided blind, and were made up of 10 healthy and 10 
type 2 diabetic blood plasma samples prepared by the Brown research group 
(ethical approval and informed consent form is shown in appendix 31).    
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5.2 Testing Anti-Sera Vs. Type 2 Diabetic Plasma Samples 
To avoid confusion, the sera containing antibodies produced in sheep will be 
referred to as serum, and the blood samples that might potentially contain modified 
fibrinogen peptide epitopes, are referred to as plasma. As a preliminary experiment, 
a healthy volunteer’s plasma was tested against various anti-sera (Figure 5.1A), 
including a commercial polyclonal anti-fibrinogen antibody, anti-STSYGTGC, anti-
STSY-(NO2)-GTGC, and anti-DY-(Cl)-ED anti-sera, all of which produced and tested 
in chapter 4. The human plasma showed no binding to anti-STSY-(NO2)-GTGC or 
any substantial binding to anti-DY-(Cl)-EDQKQQLC sera (figure 5.1A). However, a 
concentration dependent increase in binding of anti-fibrinogen and anti-STSYGTGC 
to the human plasma can be seen. The binding (absorbance) values from figure 
5.1A were then normalized against their respective fibrinogen concentrations, as the 
most convenient method of standardization (Figure 5.1B). After normalization, the 
binding of anti-sera to human plasma showed a more prominent concentration 
dependent increase in binding of anti-STSYGTGC, and very little binding of the 
other sera (Figure 5.1B).  
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Figure 5.1: Testing Antibody Binding to Human Plasma Samples. (n = 3, standard 
deviation of technical replicates) (A) Serial dilution of human plasma against various anti-
sera (B) Serial dilution of human plasma normalized for fibrinogen content against produced 
anti-sera. Nunc maxi-sorp plates (Product code: 10098860, Fisher Scientific, UK) were 
coated with serial dilutions of plasma samples. Anti-fibrinogen (Product code: F8512) was 
used at a working dilution of 1:10,000, anti-sera was made to 1.5 μg/ mL and detected with 
1: 25,000 donkey anti-sheep antibody conjugated to alkaline phosphatase (Product code: 
A5187), and 1 mg/mL phosphate substrate in pNPP buffer, pH 10.4, with an incubation time 
of 15 minutes at room temperature before being read on a plate reader at 405 nm.   
Based on the preliminary results in figures 5.1A and 5.1B, human plasma dilutions 
of 1:2000 were chosen to investigate samples from type II diabetic patients against 
the anti-STSYGTGC series sera (Figure 5.2). The boxplot representation of the 
clinical data (Figure 5.2A) shows there was little difference in the binding of anti-
STSY-(NO2)-GTGC serum between the healthy and diabetic samples. However, it 
was noted that there were 2 outliers in the diabetic cohort with very high binding 
levels. The outliers of anti-STSY-(NO2)-GTGC serum Vs. diabetic samples 
(Disease) do however suggest some greater binding (figure 5.2A).  
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The plasma samples used in figure 5.2A were then normalized for their fibrinogen 
concentrations, based on the binding of the anti-fibrinogen antibody (Figure 5.2B). 
More specifically, the absorbance values of the produced anti-sera used in figure 
5.2A, representative of binding, were divided by those of anti-fibrinogen, which were 
representative of the plasma sample fibrinogen content. After normalization, the 
trend of binding remained similar to figure 5.2A, with anti-STSYGTGC and anti-
STSY-(Cl)-GTGC binding both healthy and disease samples almost indiscriminately. 
This is not surprising, as it would be expected for anti-STSYGTGC to bind native 
fibrinogen, and anti-STSY-(Cl)-GTGC displayed cross-reactivity for STSYGTGC in 
chapter 4. In addition, Anti-STSY-(NO2)-GTGC bound poorly to both healthy and 
disease samples. However, after normalization for fibrinogen content, the outliers for 
anti-STSY-(NO2)-GTGC seen in figure 5.2A showed greater binding (figure 5.2B). 
The values from figure 5.2B were then plotted against the CRP levels for each of the 
samples (figure 5.3). The healthy plasma samples showed no substantial binding to 
anti-STSY-(NO2)-GTGC serum, and similarly, most of the diabetic samples also 
showed very little binding. With regard to these outliers, two of the diabetic samples 
did show increased binding, compared to the base-line binding seen for the other 
samples, but large standard deviation values suggest sample variability between 
replicates.    
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Figure 5.2: Testing Antibody Binding to Human Diabetic (Disease) and Healthy Plasma 
Samples. (Diabetic, n = 10, healthy, n = 10) (A) Boxplot showing distribution of various anti-
sera and antibodies binding to healthy and type 2 diabetic human plasma samples (B) Anti-
sera binding to healthy and type 2 diabetic human plasma samples normalized to fibrinogen 
content. Nunc maxi-sorp plates (Product code: 10098860, Fisher Scientific, UK) were coated 
with serial dilutions of plasma samples. Anti-fibrinogen (Product code: F8512) was used at a 
working dilution of 1:10,000, anti-sera was made to 1.5 μg/ mL and detected with 1:25,000 
donkey anti-sheep antibody conjugated to alkaline phosphatase (Product code: A5187), and 
1 mg/mL phosphate substrate in pNPP buffer, pH 10.4, with an incubation time of 15 
minutes at room temperature before being read on a plate reader at 405 nm. Clinical 
samples were obtained from the Brown research group at Aston University (Appendix 31). 
Plotly graphing, version 1 (https://plot.ly) was used to produce boxplots (A and B).    
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Figure 5.3: STSY-(NO2)-GTGC Peptide (from figure 5.2) Vs. CRP serum concentration. 
(n = 3, standard deviation of technical replicates). Clinical samples were obtained from the 
Brown research group at Aston University (Appendix 31). Plotly graphing, version 1 
(https://plot.ly) was used to produce this graph. 
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5.3 Chapter 5 Discussion 
The aim of this chapter was to investigate whether anti-serum produced in chapter 4 
could be used to detect STSY-(NO2)-GTG peptide in type 2 diabetic samples, with 
the hypothesis that anti-STSY-(NO2)-GTGC serum could be used to detect the 
STSY-(NO2)-GTG peptide of fibrinogen in type 2 diabetic samples, with increased 
binding correlating to the increase in CRP level.  
Both healthy and diabetic plasma samples, after testing an ELISA type 
immunoassay, showed binding to both anti-fibrinogen and anti-STSYGTGC, in line 
with the fact that fibrinogen is abundant in plasma. The fibrinogen content for each 
sample was measured using a commercial anti fibrinogen antibody, as a way of 
standardizing the fibrinogen protein content between each human plasma sample. 
This is important because fibrinogen is a positive acute phase protein, and 
increases in concentration during inflammation. And, as previously discussed in the 
introduction, many lifestyle factors can induce varying levels of inflammation 
(Mischak et al., 2007). This highlights an important factor worth consideration. We 
must also consider the different binding affinities between antibodies, and for this 
reason, comparisons of antibody binding can only be based on trend profiles, rather 
than absolute values. To understand such values better, future work should include 
utilizing surface plasmon resonance to determine antibody-antigen binding affinities. 
As previously described in chapter 4, surface plasmon resonance has been shown 
to measure antibody binding affinity in real time, under various conditions 
(Englebienne et al., 1998). 
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The anti-STSYGTGC series versus type 2 diabetic and healthy clinical plasma 
samples show little difference between the healthy and diabetic (disease) samples. 
However, two outliers represented as circles above the boxes, suggest greater 
binding in two of the diabetic samples. The presence of 3-nitrotyrosine has 
previously been detected in the plasma of type 2 diabetic patients with ELISA, in a 
study by Ceriello et al., (2001). More specifically, 3-nitrotyrosine was detected in all 
type 2 diabetic plasma samples but none of the healthy controls (Ceriello et al., 
2001). The anti-fibrinogen suggests greater amounts of fibrinogen in the healthy 
samples compared to the disease samples. This contradicts the literature, as 
fibrinogen is a positive acute phase protein, expected to increase in concentration 
during inflammation (Vadseth et al., 2003). The overlap between the error bars and 
median values for both healthy and disease fibrinogen samples do suggest sample 
variability, which suggests better standardization may be required. A comparison of 
the existing fibrinogen antibody discussed and a different anti-fibrinogen antibody, to 
determine the accuracy of the sample fibrinogen content obtained should be 
performed. The binding of anti-STSY-(NO2)-GTGC serum to the clinical plasma 
samples was plotted against plasma CRP concentrations, showing no apparent 
trend in binding profile. The concentration of plasma CRP (indicative of systemic 
inflammation) can vary as a result of several factors, including, body mass index 
(BMI), diabetes, hypertension, cigarette smoking, estrogen replacement therapy, 
cholesterol concentrations, and genetic polymorphisms in the CRP gene (Dhingra et 
al., 2008). Further work is required to compare the other parameters that affect 
plasma CRP levels, and in order to standardize CRP levels based on the discussed 
lifestyle factors. One of the main limitations of this study is the small sample size 
considered, and future work should involve analysis of a larger sample set, in order 
to obtain more representative data.    
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An article by Ioannidis (2005) describes the importance of sample size in studies of 
clinical samples, stating that the smaller a study is, the less likely the research 
findings are to be true. The level of CRP was shown to vary depending on the level 
of inflammation (Henriksen et al., 2008). The level of inflammation is dependent on 
the disease pathology, which means different diseases involve different levels of 
inflammation, and as such different plasma CRP concentrations. The level of 
inflammation seen in type 2 diabetes is considered mild (low-grade), whereas, 
diseases such as rheumatoid arthritis (RA) are defined by high-grade inflammation, 
and high plasma CRP concentrations (Duncan, 2003, Sattar et al., 2003, and 
Gonzalez-Gay et al., 2008). For these reasons we might expect to see a greater 
inflammatory profile in diseases defined by high-grade inflammation, and as such 
future work should include testing anti-STSY-(NO2)-GTGC serum against diseases 
defined by high-grade inflammation.  
5.3.1 Chapter 5 Conclusions and Future Work 
In conclusion, no substantial binding of anti-STSY-(NO2)-GTGC was seen in 
diabetic samples, and no correlation between the sample CRP concentration and 
STSY-(NO2)-GTG could be made. Further work should include analysis of a larger 
sample set, ideally, of clinical samples with a higher inflammatory profile.  
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Chapter 6 
Summary and Conclusions	
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6.1 Summary and Discussion of all Chapters 
Protein oxidation has been reported in a variety of diseases with an inflammatory 
pathology, relating to immune cell activation and the subsequent release of reactive 
oxidants. The oxidative nature of inflammatory pathology also offers potential for 
diagnostic or prognostic markers of disease. The most commonly used translatable 
methods are those involving antibody-based assays, such as ELISA and Western 
blotting; these techniques are popular because of their simplicity, but they are often 
limited by the availability of antibodies with suitable specificity, especially when 
considering oxPTMs, where they might be required to identify both the modification 
site and specific protein.  
Fibrinogen is one of the most abundant plasma proteins, and has been implicated in 
the pathology of various inflammatory diseases. Therefore, the overall aim of the 
research project was to develop new biomaterials for detecting inflammatory protein 
oxidative damage to fibrinogen. More specifically, in order to achieve this, the initial 
goal was to identify stable modifications to fibrinogen as good potential markers of 
oxidative damage by various oxidizing species, and to produce anti-sera that bind 
the modified peptides with sequence and modification site-specificity. The 
hypothesis was that antibodies could be produced for human fibrinogen peptides 
with both sequence and modification site specificity, to a number of oxidative 
modifications, similar to those that might be expected during inflammation. 
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In this work, fibrinogen was treated with SIN-1(peroxynitrite generator) and several 
peptides containing 3-nitrotyrosine were identified by a non-targetted LC-MS2 
approach. The most frequently occurring modified peptides were 273GGSTSY-(NO2)-
GTGSETESPR287, 135Y-(NO2)-LQEIYNSNNQK146 and 472GSWY-(NO2)-SMR478. The 
lack of crystal structure data for 273GGSTSY-(NO2)-GTGSETESPR287 suggested that 
the sequence displayed conformational flexibility, which may support its 
susceptibility to modification (Rasmussen et al., 2007). These fibrinogen 
modifications were different to those identified in the literature (Parastatidis et al., 
2008), which might relate to differences between in-vivo and in-vitro nitration. There 
was no clear trend in the amount or percentage of the peptides that were modified 
between treatment concentrations, and the percentage of modified peptides did not 
correlate to the literature (Nuriel et al., 2008). With regard to chlorinative 
modifications to fibrinogen, with a similar MS approach, HOCl treated fibrinogen 
showed good protein sequence coverage, but no modifications other than 
methionine oxidation were observed. Due to the susceptibility of methionine to 
oxidation, it acts as an oxidative quenching residue, and therefore such 
modifications are not distinctly specific to inflammation (Berlett and Stadtman, 
1997). The lack of chlorinative modifications might be as a result of HOCl treatment 
induced lysine modifications, causing protein aggregation and potentially, tryptic 
miscleaves, hindering the MS analysis, as discussed previously. These results were 
disappointing as a number of previous studies have reported HOCl-induced 
modifications of proteins, including 3-chlorotyrosine formation in HSA (Tveen-
Jensen et al., 2013). The differences in observed modifications might relate to 
conformational differences between fibrinogen and HSA, and the subsequent 
susceptibility to modification, both before and after HOCl induced conformational 
changes. Two peptides were identified from reports in the literature and 
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subsequently synthesized, specifically, a 3-chlorotyrosine modified HSA peptide, 
287Y-(Cl)-ICENQDSISSK298 (Tveen-Jensen et al., 2013), and a fibrinogen peptide, 
196DYEDQQKQL204, which was selected from the literature based on its potential to 
form 3-chlorotyrosine (Bergt et al., 2004). In addition, peptide antigens containing 
either multiple 3-nitrotyrosines or 3-chlorotyrosines were designed, based on the 
exposure of the modification sites as epitopes. Sheep were immunized with either 
the native, chlorinated or nitrated versions of peptide series, STSYGTGC, and, 
native or chlorinated versions of DYEDQQKQLC series. The anti-sera obtained from 
these sheep were tested against all of the synthesized peptides, and several treated 
plasma proteins. Subsequently, the anti-DY-(Cl)-EDQQKQLC serum showed 
sequence specificity with cross-reactivity between modification sites, whereas, anti-
STSY-(NO2)-GTGC serum showed modification site specificity with cross-reactivity 
between peptide sequences (Tables 6.1 and 6.2). 
Table 6.1: Anti-STSY-(NO2)-GTGC Serum Specificity 
Peptide	Sequence	 Binding	
STSYGTGC	 ✗	
STSY-(Cl)-GTGC	 ✗	
STSY-(NO2)-GTGC	 ✓	
DY-(NO2)-EDQQKQLC	 ✓	
SY-(NO2)-ASY-(NO2)-SY-(NO2)	 ✓	
Nitrated	Fibrinogen	 ✓	
Table 6.2: Anti-DY-(Cl)-EDQQKQLC Serum Specificity 
Peptide	Sequence	 Binding	
DYEDQQKQLC	 ✗	
DY-(Cl)-EDQQKQLC			 ✓	
SY-(Cl)-ASY-(Cl)-SY-(Cl)	 ✗
DY-(NO2)-EDQQKQLC	 ✓	
STSY-(Cl)-GTGC	 ✗
STSY-(Cl)-GTGC	
Nitrated	Fibrinogen	
✗
✗	
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The cross reactivity was thought to relate to the polyclonal nature of the obtained 
anti-sera. Translation of the identified peptides and produced anti-sera were tested 
in 10 type 2 diabetic clinical samples and 10 age-matched controls. The modified 
peptide identified in chapter 3, STSY-(NO2)-GTG, was not identified in type 2 
diabetic samples with the produced anti-STSY-(NO2)-GTGC serum, and no 
correlation between STSY-(NO2)-GTG and plasma CRP concentration could be 
made. Future work with clinical samples should include analysis of a larger sample 
set, and ideally should be, of clinical samples with a higher inflammatory profile, 
such as RA. The polyclonal nature of the anti-sera produced means there is no 
certainty which epitopes the antibodies are binding to. Affinity purification was 
performed to reduce cross reactivity to various other antigens. However, there is no 
certainty to how successful this procedure was. The production and testing of 
monoclonal antibodies could potentially allow the specificity of antibodies specific to 
one individual epitope to be tested, with the possibility of identifying an antibody with 
exclusive specificity for both the modification site and amino acid sequence.  
As previously discussed, even with successful production of specific antibodies for 
the peptides identified with MS in chapter 3, it is possible that due to differences 
between in-vitro and in-vivo environments, these modified peptides do not occur in-
vivo. In order to test this, future work should involve an MRM programme and 
narrow window XIC to search for the modified peptides identified in chapter 3 in 
inflammatory clinical samples such as those discussed in chapter 5. Although an 
understanding of binding specificity is important, the nature of antibody and epitope 
interactions also illustrates the importance of understanding binding efficiency. A 
study by Englebienne et al. (1998) utilized surface plasmon resonance (SPR) to 
determine antibody to epitope binding efficiency, and the use of such techniques in 
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future work is recommended. Fibrinogen is known to be an abundant plasma protein 
involved in various inflammatory diseases. However, it is less abundant than HSA. 
 A study performed by Tveen-Jensen et al., 2013 identified a 3-chlorotyrosine 
modification to HSA after treatment with HOCl. Chlorination and nitration of other 
abundant plasma proteins, such as HSA, followed by MS to identify modifications 
should be considered.  
In conclusion, some aspects of the aims were met and the general hypothesis 
described in section 1.11 was to some extent supported. However, some aspects of 
the hypothesis were not supported, and some of the aims were not met. More 
specifically, the modifications identified with MS, although consistent, did not appear 
to be concentration specific. New biomaterials for detecting protein oxidative 
damage were developed, capable of differentiating between native and modified 
peptides of fibrinogen. One of the anti-sera series appeared to show sequence 
specificity, and the other anti-serum showed modification site specificity, but neither 
showed both. As discussed, further work is required to understand anti-sera 
sequence specificity by producing monoclonal antibodies, to determine differences 
in binding efficiency with SPR, and if the in-vitro modifications identified appear in-
vivo with MS analysis of inflammatory clinical samples.  
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Appendix 29: Anti-STSYGTGC Serum Affinity Purification/enrichment. (A) Column: Native 
STSTYGTGC peptide bound to Iodoacetyl gel bead. Serum Loaded: Native STSYGTGC 
(month 3) serum, 1mL was loaded onto the column. (B) Column: Native STSTYGTGC 
peptide bound to Iodoacetyl gel bead Serum Loaded: Native STSYGTGC (month 3) serum, 
2mL was loaded onto the column. 
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Appendix 30: Anti-STSY-(Cl)-GTGC Serum Affinity Purification/enrichment. Column: 
Chlorotyrosine STSTYGTGC peptide bound to Iodoacetyl gel bead. Serum Loaded: 
Chlorotyrosine STSYGTGC (month 3) serum, 2mL was loaded onto the column. 
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Appendix 31: Ethical approval and consent forms for type 2 diabetic samples 
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Appendix 31 (Ctd. II): Ethical approval and consent forms for type 2 diabetic samples 
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Appendix 31 (Ctd. III): Ethical approval and consent forms for type 2 diabetic samples 
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Appendix 31 (Ctd. IV): Ethical approval and consent forms for type 2 diabetic samples 
